CLINICAL DECISION SUPPORT FOR IMMUNIZATION (CDSI):
LOGIC SPECIFICATION FOR ACIP RECOMMENDATIONS

National Center for Immunization and Respiratory Disease (NCIRD)
Informatics and Data Analytics Branch (IDAB)
Version 4.6
December 13, 2024

Logic Specification for ACIP Recommendations v4.6

Page 1 of 151

TABLE OF CONTENTS
1

2

3

4

5

Executive Summary.................................................................................................................................... 7
1.1

Background and Goals ........................................................................................................................ 7

1.2

Approach ............................................................................................................................................. 8

1.3

Scope .................................................................................................................................................. 8

1.4

Products .............................................................................................................................................. 9

Resource Overview .................................................................................................................................. 12
2.1

Chapter Overview.............................................................................................................................. 12

2.2

Resource Design Principles............................................................................................................... 13

2.3

Design and Documentation Strategy ................................................................................................. 13

2.4

Supporting Data ................................................................................................................................ 14

2.5

Logic Definition - Purpose ................................................................................................................. 17

2.6

Logic Definition – Evaluation ............................................................................................................. 17

2.7

Logic Definition – Forecasting ........................................................................................................... 18

2.8

Logic Definition – Select Patient Series ............................................................................................. 18

2.9

Logic Definition – Identify and Evaluate Vaccine Group..................................................................... 19

2.10

Processing Model .............................................................................................................................. 20

2.11

Decision Table Overview ................................................................................................................... 20

Logic Specification Concepts .................................................................................................................... 23
3.1

Target Dose ...................................................................................................................................... 23

3.2

Statuses ............................................................................................................................................ 24

3.3

Selecting Supporting Data ................................................................................................................. 25

3.4

Date Calculations .............................................................................................................................. 27

Processing Model ..................................................................................................................................... 30
4.1

Gather Necessary Data ..................................................................................................................... 31

4.2

Organize Immunization History .......................................................................................................... 32

4.3

Create Relevant Patient Series ......................................................................................................... 34

4.4

Evaluate and Forecast all Relevant Patient Series ............................................................................ 35

4.5

Select Best Patient Series ................................................................................................................. 39

4.6

Identify and Evaluate Vaccine Group................................................................................................. 39

Create Relevant Patient Series................................................................................................................. 41
5.1

6

Select Relevant Patient Series .......................................................................................................... 41

Evaluate Vaccine Dose Administered ....................................................................................................... 45
6.1

Evaluate Dose Administered Condition.............................................................................................. 46

6.2

Evaluate Conditional Skip .................................................................................................................. 47

6.3

Evaluate for Inadvertent Vaccine ....................................................................................................... 52

6.4

Evaluate Age ..................................................................................................................................... 52

6.5

Evaluate Preferable Interval .............................................................................................................. 54

Logic Specification for ACIP Recommendations v4.6

Page 2 of 151

7

8

9

6.6

Evaluate Allowable Interval................................................................................................................ 58

6.7

Evaluate Vaccine Conflict .................................................................................................................. 61

6.8

Evaluate for Preferable Vaccine ........................................................................................................ 63

6.9

Evaluate for Allowable Vaccine ......................................................................................................... 66

6.10

Satisfy Target Dose ........................................................................................................................... 69

Forecast Dates and Reasons ................................................................................................................... 71
7.1

Evaluate Conditional Skip .................................................................................................................. 72

7.2

Determine Evidence of Immunity ....................................................................................................... 73

7.3

Determine Contraindications ............................................................................................................. 74

7.4

Determine Forecast Need ................................................................................................................. 78

7.5

Generate Forecast Dates and Recommended Vaccines ................................................................... 80

7.6

Validate Recommendation................................................................................................................. 83

Select Best Patient Series ........................................................................................................................ 84
8.1

Pre-filter Patient Series ...................................................................................................................... 87

8.2

Identify One Prioritized Patient Series ............................................................................................... 87

8.3

Classify Scorable Patient Series ........................................................................................................ 88

8.4

Complete Patient Series .................................................................................................................... 89

8.5

In-process Patient Series .................................................................................................................. 90

8.6

No Valid Doses.................................................................................................................................. 91

8.7

Select Prioritized Patient Series ........................................................................................................ 91

8.8

Determine Best Patient Series ........................................................................................................... 92

Identify and Evaluate Vaccine Group ........................................................................................................ 93
9.1

Apply General Vaccine Group Rules ................................................................................................. 94

9.2

Single Antigen Vaccine Group ........................................................................................................... 95

9.3

Multiple Antigen Vaccine Group ........................................................................................................ 95

Appendix A: Domain Model and Glossary ....................................................................................................... 97
Domain Model (Concept Model, Vocabulary) Overview ............................................................................... 97
Domain Model Diagrams.............................................................................................................................. 99
Appendix B: Acronyms and Abbreviations ..................................................................................................... 118
Appendix C: Retired Items ............................................................................................................................. 120
Appendix D: Acknowledgements ................................................................................................................... 127
Appendix E: References ................................................................................................................................ 141
Appendix F: Supplemental Material ............................................................................................................... 144
Appendix G: Document Management ............................................................................................................ 145

Logic Specification for ACIP Recommendations v4.6

Page 3 of 151

LIST OF FIGURES AND TABLES
Table 1-1 Vaccine Groups in Scope ....................................................................................................................................... 8
Figure 1-1 CDSi Resources .................................................................................................................................................. 10
Table 2-1 List of Chapters ..................................................................................................................................................... 12
Table 2-2 Descriptions of Components ................................................................................................................................. 13
Table 2-3 Supporting Data Suggested Audience.................................................................................................................. 14
Figure 2-1 Supporting Data ................................................................................................................................................... 16
Table 2-4 Evaluation Suggested Audience ........................................................................................................................... 17
Table 2-5 Forecasting Suggested Audience ......................................................................................................................... 18
Table 2-6 Select Patient Series Suggested Audience .......................................................................................................... 19
Table 2-7 Identify and Evaluate Vaccine Group Suggested Audience ................................................................................. 19
Table 2-8 Processing Model Suggested Audience ............................................................................................................... 20
Table 2-9 Should I Get my Car Washed? ............................................................................................................................. 21
Table 2-10 Explanations of Outcomes .................................................................................................................................. 21
Table 2-11 What Exercise Should I do Today? .................................................................................................................... 21
Figure 3-1 How a Vaccine Dose Administered Satisfies a Target Dose .............................................................................. 24
Table 3-1 Evaluation Statuses .............................................................................................................................................. 24
Table 3-2 Target Dose Statuses ........................................................................................................................................... 25
Table 3-3 Patient Series Statuses ........................................................................................................................................ 25
Figure 3-2 Selecting Supporting Data ................................................................................................................................... 26
Table 3-4 Relevant supporting data Attributes ...................................................................................................................... 26
Table 3-5 Select Relevant supporting data Logical Component element ............................................................................. 26
Figure 3-3 Conditional Skip Context ..................................................................................................................................... 27
Table 3-6 General Date Rules .............................................................................................................................................. 27
Table 3-7 Logical Component Date Rules ............................................................................................................................ 28
Table 4-1 Logic Specification Processing Steps ................................................................................................................... 30
Figure 4-1 Logic Specification Processing Model ................................................................................................................. 30
Figure 4-2 Refinement of Patient Series ............................................................................................................................... 31
Table 4-2 Prior to Organize Immunization History Example ................................................................................................. 32
Table 4-3 After Organize Immunization History Example ..................................................................................................... 32
Figure 4-3 Organize Immunization History Process Model .................................................................................................. 34
Figure 4-4 Create Relevant Patient Series Process Model .................................................................................................. 35
Figure 4-5 Evaluate and Forecast Process Model ................................................................................................................ 36
Figure 4-6 Evaluate Immunization History Process Model ................................................................................................... 37
Figure 4-7 Select Best Series Process Model ...................................................................................................................... 39
Figure 4-8 Identify and Evaluate Vaccine Group Process Model ......................................................................................... 40
Table 5-1 Create Relevant Patient Series Process Steps .................................................................................................... 41
Figure 5-1 Create Relevant Series Process Model............................................................................................................... 41
Figure 5-2 Select Relevant Patient Series Process Model ................................................................................................... 42
Table 5-2 Select Relevant Patient Series Attributes ............................................................................................................. 42
Table 5-3 Select Relevant Patient Business Rules............................................................................................................... 42
Figure 5-3 Assess Indications Process Model ...................................................................................................................... 43
Table 5-4 Does the Indication Apply to the Patient? ............................................................................................................. 43
Table 5-5 Is An Antigen Series a Relevant Patient series for a Patient? ............................................................................. 43
Table 6-1 Evaluation Process Steps ..................................................................................................................................... 45
Figure 6-1 Evaluation Process Model ................................................................................................................................... 46
Figure 6-2 Vaccine Dose Administered Condition Process Model ....................................................................................... 47
Table 6-2 Dose Administered Condition Attributes ............................................................................................................... 47
Table 6-3 Can the Vaccine Dose Administered be Evaluated? ............................................................................................ 47
Figure 6-3 Conditional Skip Process Model .......................................................................................................................... 49
Table 6-4 Conditional Skip Attributes .................................................................................................................................... 49
Logic Specification for ACIP Recommendations v4.6

Page 4 of 151

Table 6-5 Conditional Skip Business Rules .......................................................................................................................... 50
Table 6-6 Conditional Type of Age – Is the Condition Met? ................................................................................................. 50
Table 6-7 Conditional Type of Completed Series – Is the Condition Met? ........................................................................... 50
Table 6-8 Conditional Type of Interval – Is the Condition Met? ............................................................................................ 51
Table 6-9 Conditional Type of Vaccine Count by Age and/or Date – Is the Condition Met? ................................................ 51
Table 6-10 Is the Conditional Skip Set Met? ......................................................................................................................... 51
Figure 6-4 Evaluate for an Inadvertent Vaccine Process Model ........................................................................................... 52
Table 6-12 Inadvertent Vaccine Attributes ............................................................................................................................ 52
Table 6-13 Was the vaccine dose administered an Inadvertent administration for the target dose? ................................... 52
Figure 6-5 Evaluate Age Timeline ......................................................................................................................................... 53
Figure 6-6 Evaluate Age Process Model .............................................................................................................................. 53
Table 6-14 Age Attributes ..................................................................................................................................................... 53
Table 6-15 Was the Vaccine Dose Administered at a Valid Age? ........................................................................................ 53
Table 6-16 Evaluate Age Business Rules ............................................................................................................................. 54
Figure 6-7 Evaluate Interval ‘From Immediate Previous Dose Administered Flag’ Timeline................................................ 55
Figure 6-8 Evaluate Interval 'From Target Dose Number in Series' Timeline....................................................................... 55
Figure 6-9 Evaluate Interval 'From Most Recent Vaccine Type' Timeline ............................................................................ 56
Figure 6-10 Evaluate Interval 'From Relevant Observation Code' Timeline ......................................................................... 56
Figure 6-11 Evaluate Preferable Interval Process Model ..................................................................................................... 57
Table 6-17 Preferable Interval Attributes .............................................................................................................................. 57
Table 6-18 Did the Vaccine Dose Administered Satisfy the preferable Interval for the target dose? ................................... 57
Figure 6-12 Evaluate Allowable Interval 'From Immediate Previous Dose Administered Flag' Timeline ............................. 59
Figure 6-13 Evaluate Allowable Interval 'From Target Dose Number in Series' Timeline .................................................... 59
Figure 6-14 Evaluate Allowable Interval Process Model ...................................................................................................... 60
Table 6-20 Allowable Interval Attributes ............................................................................................................................... 60
Table 6-21 Did the Vaccine Dose Administered Satisfy the Allowable Interval for the target dose? ................................... 60
Table 6-22 Evaluate Allowable Interval Business Rules ....................................................................................................... 61
Figure 6-15 Evaluate Vaccine Conflict Timeline ................................................................................................................... 61
Figure 6-16 Evaluate vaccine Conflict Process Model ......................................................................................................... 62
Table 6-23 Vaccine Conflict Attributes .................................................................................................................................. 62
Table 6-24 Vaccine Conflict Business Rules ........................................................................................................................ 62
Figure 6-17 Patient Received a Preferable Vaccine ............................................................................................................. 64
Figure 6-18 Patient Did Not Receive a Preferable Vaccine .................................................................................................. 64
Figure 6-19 Evaluate for a Preferable Vaccine Process Model ............................................................................................ 65
Table 6-25 Preferable Vaccine Administered Attributes ....................................................................................................... 65
Table 6-26 Was the vaccine dose administered a preferable Vaccine for the target dose? ................................................ 65
Table 6-27 Preferable Vaccine Business Rules.................................................................................................................... 66
Figure 6-20 Patient Received an Allowable Vaccine ............................................................................................................ 67
Figure 6-21 Patient Did Not Receive an Allowable Vaccine ................................................................................................. 67
Figure 6-22 Evaluate for an Allowable Vaccine Process Model ........................................................................................... 68
Table 6-28 Allowable Vaccine Attributes .............................................................................................................................. 68
Table 6-29 Was the vaccine dose admninstered an Allowable Vaccine for the target dose? .............................................. 68
Table 6-30 Allowable Vaccine Business Rules ..................................................................................................................... 69
Figure 6-23 Satisfy Target Dose Process Model .................................................................................................................. 69
Table 6-31 Was the Target Dose Satisfied? ......................................................................................................................... 69
Table 7-1 Forecast Dates and Reasons Process Steps ....................................................................................................... 71
Figure 7-1 Forecast Dates and Reason Process Model ....................................................................................................... 72
Figure 7-2 Evidence of Immunity Process Model ................................................................................................................. 73
Table 7-2 Immunity Attributes ............................................................................................................................................... 73
Table 7-3 Does the Patient have Evidence of Immunity? ..................................................................................................... 73
Figure 7-3 Contraindication Process Model .......................................................................................................................... 74
Table 7-4 Determine Contraindication Attributes .................................................................................................................. 74
Logic Specification for ACIP Recommendations v4.6

Page 5 of 151

Figure 7-4 Antigen Contraindication Process Model............................................................................................................. 75
Table 7-5 Does the Antigen Contraindication Apply to the Patient? ..................................................................................... 75
Figure 7-5 Vaccine Contraindication Process Model ............................................................................................................ 76
Table 7-6 Does the Vaccine Contraindication Apply to the Patient? .................................................................................... 76
Table 7-7 Is the Relevant Patient Series a Contraindicated Patient Series? ....................................................................... 77
Figure 7-6 Determine Forecast Need Process Model .......................................................................................................... 78
Table 7-9 Determine Forecast Need Attributes .................................................................................................................... 78
Table 7-10 Should the Patient Receive Another Target Dose? ............................................................................................ 79
Table 7-11 Determine Forecast Need Business Rules ......................................................................................................... 80
Figure 7-7 Forecast Dates Timeline ...................................................................................................................................... 81
Figure 7-8 Generate Forecast Dates and Recommended Vaccine Process Model ............................................................. 81
Table 7-12 Generate Forecast Date and Recommended Vaccine Attributes ...................................................................... 81
Table 7-13 Generate Forecast Date and Recommended Vaccine Business Rules ............................................................. 82
Figure 7-9 Validate Recommended Dose Process Model .................................................................................................... 83
Table 8-1 Select Best Patient Series Process Steps ............................................................................................................ 84
Figure 8-1 Select Best Patient Series Process Model .......................................................................................................... 85
Figure 8-2 Select Prioritized Patient Series Process Model ................................................................................................. 87
Table 8-2 Pre-Filter Patient Series Business Rules .............................................................................................................. 87
Table 8-3 Is There a single Prioritized Patient Series in a series group? ............................................................................. 87
Table 8-4 Identify one prioritized patient series business rules ............................................................................................ 88
Table 8-5 Which Scorable Patient Series Should be Scored? ............................................................................................. 88
Table 8-6 Classify scorable patient series business rules .................................................................................................... 89
Table 8-7 How Many Points are Awarded to a Scorable Patient Series that is a Complete Patient Series? ....................... 89
Table 8-8 Complete Patient Series Business Rules ............................................................................................................. 90
Table 8-9 How Many Points are Awarded to Scorable Patient Series that is an In-Process Patient Series? ...................... 90
Table 8-10 In-Process Patient Series Business Rules ......................................................................................................... 90
Table 8-11 How Many Points are Awarded to a Scorable Patient Series that has No Valid Doses? ................................... 91
Table 8-12 No Valid Doses Business Rules ......................................................................................................................... 91
Table 8-13 Select Prioritized Patient Series Business Rules ............................................................................................... 92
Table 8-14 Is the prioritized patient series the best patient series for the series group? ..................................................... 92
Table 9-1 Identify and Evaluate Vaccine Group Process Steps ........................................................................................... 93
Figure 9-1 Identify and Evaluate Vaccine Group Process Model ......................................................................................... 93
Table 9-2 GeneraL Vaccine Group Business Rules ............................................................................................................. 94
Table 9-3 Single Antigen Vaccine Group Business Rules .................................................................................................... 95
Table 9-4 What is the Vaccine Group Status of a Vaccine Group forecast for a multiple antigent vaccine group? ............. 95
Table 9-5 Multiple Antigen Vaccine Group Business Rules ................................................................................................. 96
Figure A-1 Neighborhood ...................................................................................................................................................... 98
Table A-1 Domain Model Glossary ....................................................................................................................................... 98
Figure A-2 CDSi Domain Diagram: Patient Neighborhood ................................................................................................... 99
Figure A-3 CDSi Domain Diagram: Schedule Neighborhood ............................................................................................. 101
Figure A-4 CDSi Domain Diagram: Antigen Series Neighborhood ..................................................................................... 103
Figure A-5 CDSi Domain Diagram: Evaluation Neighborhood ........................................................................................... 105
Figure A-6 CDSi Domain Diagram: Forecast Neighborhood .............................................................................................. 106
Table A-7 Glossary ............................................................................................................................................................. 107
Table B-1 Acronyms and Abbreviations .............................................................................................................................. 118
Table C-1 Retired Items ...................................................................................................................................................... 120

Logic Specification for ACIP Recommendations v4.6

Page 6 of 151

1 EXECUTIVE SUMMARY
1.1 BACKGROUND AND GOALS
In 2022, approximately 98% of U.S. children under the age of six participated1 in an Immunization Information
System (IIS), an increase from 82% in 2010.2 Adolescent participation in 2022 was 82%, up from 60% in 2010.
Adult participation in 2022 increased to 94% up from 22% in 2010. Given this widespread IIS participation, it is
important that each patient’s immunization record is consistent and up to date within an IIS.
Health Information Systems (HIS) – which can include Health Information Exchanges (HIEs), IIS, Electronic
Health Records (EHRs), and others – provide healthcare providers with immunization evaluation and forecasting
tools designed to automatically determine the recommended immunizations needed when a patient presents for
vaccination. These recommendations are developed by the Advisory Committee on Immunization Practices
(ACIP). ACIP is a federal advisory committee responsible for providing expert external advice and guidance to
the Director of the Centers for Disease Control and Prevention (CDC) and the Secretary of the U.S. Department
of Health and Human Services (DHHS) on use of vaccines and related agents for control of vaccine-preventable
disease in the United States. Recommendations include but are not limited to age for vaccine dose administered,
number of doses, dosing interval, risk factors, precautions, and contraindications.
After ACIP recommendations are published, technical and clinical subject matter experts (SMEs) work to
interpret and integrate them into their evaluation and forecasting engines. An example of an evaluation and
forecasting engine is a tool an IIS might use to alert a physician that a presenting child is overdue for a Measles,
Mumps, and Rubella (MMR) vaccination. ACIP schedule changes are currently communicated only through
clinical language, in publications like the Morbidity and Mortality Weekly Report (MMWR) and the Epidemiology
and Prevention of Vaccine-Preventable Diseases ("The Pink Book"). The translation of that clinical language into
technical logic that is processed within evaluation and forecasting engines is a time-consuming and complex
process that happens mostly independently within the different HIS. Due to the challenge of interpreting clinically
written ACIP recommendations, clinical decision support (CDS) engine outputs often vary and do not always
match the expectations of clinical SMEs.
To harmonize the outcomes of existing HIS CDS tools, the Informatics and Data Analytics Branch (IDAB) at the
CDC funded the Clinical Decision Support for Immunization (CDSi) Project to develop clinical decision aids 3 for
each vaccine preventable disease in accordance with ACIP recommendations to:
•
•
•
•

Make it easier to develop and maintain immunization evaluation and forecasting products
Ensure a patient’s immunization status is current, accurate, consistent, and readily available
Increase the accuracy and consistency of immunization evaluation and forecasting
Improve the timeliness of accommodating new and changed ACIP recommendations

The ultimate goal of the project is to ensure that patients receive proper immunizations, i.e., “the right
immunization at the right time.”

1 Participation was defined as having at least two recorded vaccinations in an Immunization Information System (IIS).
2 All data derived from the 2018 Immunization Information Systems Annual Report (IISAR). For further information, see: 2018

Immunization Information Systems Annual Report (IISAR).
3 Aids refer to manual support mechanisms and in no way imply that an automated system is being developed or provided. These aids

can, however, be used to refine existing or develop new automated systems.

Logic Specification for ACIP Recommendations v4.6

Page 7 of 151

1.2 APPROACH
As part of this project, an expert panel was formed in April 2011, consisting of SMEs and expert reviewers from:
•
•
•
•
•
•

CDC Public Health Informatics and Technology Program Office (PHITPO)
American Immunization Registry Association (AIRA)
Indian Health Service (IHS)
EHR vendors
IIS programs and vendors
Academic institutions

Please refer to Appendix D for more information regarding the expert panelists.

1.3 SCOPE
The vaccine groups in scope for the current phase of the project are those routinely recommended by ACIP for
healthy individuals from birth through age 65+ years as well as those recommended because of underlying
conditions.
TABLE 1-1 VACCINE GROUPS IN SCOPE

•
•
•
•
•
•
•
•
•

Cholera
Chikungunya
COVID-19
Dengue
DTaP/Tdap/Td
Ebola
Hepatitis A
Hepatitis B
Hib

•
•
•
•
•
•
•
•
•

HPV
Influenza
Japanese Encephalitis
Meningococcal
Meningococcal B
MMR
Orthopoxvirus
Pneumococcal
Polio

•
•
•
•
•
•
•
•

Rabies
Rotavirus
RSV
TBE
Typhoid
Varicella
Yellow Fever
Zoster

Additional items in scope include:
•
•
•
•
•
•
•
•

Current ACIP recommendations with clarifications
Compromised/sub-potent/expired doses
Vaccine recalls
Wrong vaccine formulations
Underlying conditions related to contraindications
Immunities
The 4-day grace period
Catch-up schedule

While not addressed specifically, the CDSi resources were developed to accommodate non-ACIP published
rules (i.e., state law variations, local school schedules, rules published by other organizations, rules published
in other countries). Supporting Data can be adjusted by implementers to cover these variations from the ACIP
recommendations.
Logic Specification for ACIP Recommendations v4.6

Page 8 of 151

Items currently out of scope but candidates for future project phases include the following:
•
•
•
•
•
•

Outbreak recommendations
Immune Globulin (IG)
Route and body site of administration
Non-FDA approved vaccines (i.e., those used in clinical trials)
Precautions
Shared Clinical Decision Making

1.4 PRODUCTS
1.4.1

Resources

The CDSi team has developed the resources which captures ACIP recommendations in an unambiguous
manner and improves both the uniform representation of vaccine decision guidelines as well as the ability to
automate vaccine evaluation and forecasting. The resources provide a single, authoritative, implementationneutral foundation for development and maintenance of clinical decision support engines. It increases the
accuracy and consistency of forecasting and evaluation across the HIS community and improves the timeliness
of HIS accommodation of new and changed rules.
The objectives of the CDSi resources are to:
•
•

•
•

Create a standardized CDS logic representation for ACIP recommendations that allows for broad
implementation and effective usage across IIS and other HIS
Document the logic for applying ACIP business rules in CDS engines in order to improve the clarity,
consistency, and computability of on-going childhood, adolescent, and adult immunization evaluation and
forecasting
Provide testing scenarios to ensure the accurate implementation of the Supporting Data and Logic
Specification by CDS engines
Educate audiences regarding the content and use of the CDSi resources

Logic Specification for ACIP Recommendations v4.6

Page 9 of 151

FIGURE 1-1 CDSI RESOURCES

The CDSi resources were developed to be as technology-neutral as possible to support those currently with or
without complete evaluation and forecasting engines as they:
•
•
•
1.4.2

Refine, extend, or develop their implementation
Clarify their understanding of immunization rules
Troubleshoot and verify correct implementation of immunization rules
Logic Specification

The CDSi team developed a Logic Specification that describes the functionality required to evaluate and forecast
based on the Supporting Data as applied to a patient’s immunization history and patient observations. The Logic
Specification uses defined vocabulary and domain models to build business rules, decision tables and a
processing model which can be implemented by a CDS engine.
The intended audience of the Logic Specification includes business and technical implementers of immunization
CDS engines. These implementers may support any system with an immunization evaluation and forecasting
engine, including but not limited to an IIS.

1.4.3

Supporting Data

Logic Specification for ACIP Recommendations v4.6

Page 10 of 151

The CDSi team developed Supporting Data to describe, by antigen, various factors and their accompanying sets
of values to be considered when implementing ACIP recommendations. Supporting Data can be thought of as a
set of configuration files used as input to a CDS engine. Supporting Data is published both as Excel spreadsheets
and XML.
The intended audience of the Supporting Data includes business and technical implementers of immunization
CDS engines. These implementers may support any system with an immunization evaluation and forecasting
engine, including but not limited to an IIS.
1.4.4

Test Cases

The CDSi team developed a representative set of test cases for use to compare and improve CDS engine actual
results with ACIP recommendations and clarifications.
The intended audience of the Test Cases includes business implementers of immunization CDS engines who
are responsible for ensuring the accuracy of the CDS engine. These implementers may support any system with
an immunization evaluation and forecasting engine, including but not limited to an IIS.
1.4.5

Training Materials

The CDSi team developed training materials to educate audiences interested in knowing more about the CDSi
project and how to implement the accompanying CDSi resources. These materials are also intended to promote
the use of CDSi by a variety of HIS.
The intended audience of the Training Materials includes anyone interested in knowing more about CDSi.

Logic Specification for ACIP Recommendations v4.6

Page 11 of 151

2 RESOURCE OVERVIEW
2.1 CHAPTER OVERVIEW
The Logic Specification provides the rules to determine if the immunizations received meet the requirements
stated by the ACIP. A description of each chapter is presented below:
TABLE 2-1 LIST OF CHAPTERS

Chapter

Title

Description

Chapter 1

Executive Summary Introduces the context, goals, and primary deliverable of the CDSi project.

Chapter 2

Resource Overview

Provides a high-level overview of the key components of the CDSi resources. The
purpose and function are described for each component. In addition, the
instruments used to document each component are also introduced.

Chapter 3

Logic Specification
Concepts

Provides an explanation of target dose, the meanings of statuses used in evaluation
and forecasting, an introduction to Supporting Data, and the business rules for
calculating dates

Chapter 4

Processing Model

Provides the major logical steps involved in the immunization evaluation and
forecasting engine of the CDS process.

Chapter 5

Create Relevant
Patient Series

Provides the rules for selecting series which are relevant for the patient.

Chapter 6

Evaluate Vaccine
Dose Administered

Provides the rules for evaluating a vaccine dose administered. The approach is
documented using a process model, decision tables, and business rules.

Chapter 7

Forecast Dates and
Reasons

Provides the rules for determining forecast dates. The approach is documented
using a process model, decision tables, and business rules.

Chapter 8

Select Patient
Series

Provides the rules for selecting the patient series which best fits based on various
important factors. The approach is documented using a process model, decision
tables, and business rules.

Chapter 9

Identify & Evaluate
Vaccine Group

Provides the rules for combining selected patient series from an antigen-based
forecast into a vaccine group-based forecast. The approach is documented using a
process model, decision tables, and business rules.

Appendix A Domain Model and
Glossary

Provides a domain model that includes diagrams and vocabulary that is pertinent to
the CDSi resources.

Appendix B Acronyms and
Abbreviations

Provides the meanings of acronyms and abbreviations used in the document.

Appendix C Retired Items

Provides a list of concepts that have been previously included in the CDSi
resources but are no longer used.

Appendix D Acknowledgements

Provides biographies of subject matter experts who served as volunteer panelists
for the CDSi project.

Appendix E References

Provides citations of various reference materials that were used to document the
business rules and Supporting Data tables.

Appendix F Supplemental
Material

Provides supplemental material to aid with concepts found in CDSi resources.

Appendix G Document
Management

Provides a table to track key changes and versions of the document.

Logic Specification for ACIP Recommendations v4.6

Page 12 of 151

2.2 RESOURCE DESIGN PRINCIPLES
The following guiding principles (GP) were central to the development and the design of the CDSi resources.
Ultimately, the CDSi resources should:
GP1. Reduce complexity of understanding and implementing ACIP recommendations
GP2. Ensure consistency in interpretation of ACIP recommendations
GP3. Enhance maintainability in response to newly published ACIP recommendations
• Improved timeliness (i.e., turnaround time)
• Reduction in rework
• Minimal impact of changes
GP4. Inform a variety of implementations

2.3 DESIGN AND DOCUMENTATION STRATEGY
Giving the complexity of implementing ACIP recommendations and considering the guiding principles, the design
strategy included two key elements:
•
•

Focusing on three components by setting apart the configuration data, the business rules, and the
processing model that pulls the business rules together
Emphasizing “universal” functionality applicable across HIS instead of implementation-specific
engineering requirements

In addition, a variety of mechanisms were chosen to document the specification in order to provide a concise,
unambiguous, and computable description of the functionality required. Thus, the design of CDSi resources is
divided into three components. The graphic below lists each component, the description, and the documentation
method.
TABLE 2-2 DESCRIPTIONS OF COMPONENTS

Component

Supporting Data

Logic Definition

Description
Describes, by antigen, various factors and
their accompanying sets of values to be
considered when implementing ACIP
recommendations

Documentation Method
Chapter 3:
• Introduction to
Supporting Data
• Rules to select proper
supporting data

Describes the functionality required to
evaluate and forecast based on a
patient’s immunization history and the
Supporting Data.
Logic definitions include:
• Create Relevant Series Logic
• Evaluation Logic
• Forecasting Logic
• Select Patient Series Logic
• Identify and Evaluate Vaccine Group
Logic

Chapters 3, 5, 6, 7, 8 & 9:
• Thin process models
• Decision tables
• Business rules

Logic Specification for ACIP Recommendations v4.6

Page 13 of 151

Component

Processing Model

Description
Describes the technical structure
necessary to pull the details of the Logic
Definition, Supporting Data, and patient
related data together

Documentation Method
Chapter 4:
• Activity diagrams

Together these components describe the functionality to evaluate and forecast based on ACIP recommendations
using a patient’s immunization history.

2.4 SUPPORTING DATA
2.4.1

Purpose

Supporting Data

The Supporting Data describes the attributes (e.g., minimum age, earliest
recommended age, and preferable vaccine type) necessary and specific
values (e.g., schedule-specific, antigen series-specific, and dose-specific)
required to support evaluation and forecasting as described by the Logic
Specification.

……………………… Schedule
……………………. Antigen Series
…………………………………… Doses

Simply put, Supporting Data is akin to configuration data which feeds the system and is able to be modified
separately from the logic. The Supporting Data supplied by the CDSi project represents the ACIP
recommendations and clarifications from Subject Matter Experts at the Health Education and Communication
Branch (HECB).
2.4.2

What problem it helps solve

The Supporting Data was separated from the Logic Specification in order to reduce and ease the maintenance
of the resources as clinical guidance evolves. The Supporting Data values change on a regular basis in
conjunction with new and updated ACIP recommendations. The Logic Specification evolves much more slowly.
When Supporting Data are ultimately implemented as some form of a data store (e.g., database), new and
updated recommendations can be reflected through simple Supporting Data changes. In essence, Supporting
Data can be thought of as configuration parameters and values.
TABLE 2-3 SUPPORTING DATA SUGGESTED AUDIENCE

Role

Perspective

Business Analyst

Understanding and documenting the specific values that describe the relevant
information about antigens, series, doses, etc.

Technical Developer

Implementing the data structures to support storage and access of the
Supporting Data. Understanding the integration of the Supporting Data, Logic
Specification, and processing model.

2.4.3

How and where it is documented

The format of the Supporting Data files is described below and the vocabulary in Appendix A provides definitions
of the concepts and elements used within the CDSi resources. Additional understanding can be obtained by
reviewing the actual Supporting Data. The current standard set of Supporting Data definitions with appropriate
Logic Specification for ACIP Recommendations v4.6

Page 14 of 151

values, based on the ACIP recommendations without modification for any local differences can be found at
http://www.cdc.gov/vaccines/programs/iis/cdsi.html.
The CDSi project provides two Types of Supporting Data:
•
•

Antigen Supporting Data which holds the discrete data describing the ACIP recommendations for each
antigen listed in the scope section of Chapter 1.
Schedule Supporting Data which documents information used across all antigens or between antigens.
Flavors of schedule Supporting Data are:
o A consolidated list of Coded Observations used to identify risk indications, underlying patient
conditions and contraindications in the antigen Supporting Data files
o A CVX to Antigen map which links individual CVX codes to antigen Supporting Data
o A list of Vaccine Groups
o A Vaccine Group to Antigen map to identify the antigens which make up a vaccine group
o A Live Virus Conflict table to identify situations where the timing of administration of a vaccine
may be impacted

Each Type of Supporting Data is available in both XML format as well as in spreadsheet form. The former is
intended to be machine processable while the latter will be more helpful for humans reviewing the Supporting
Data. Should the content of the two formats conflict, the Excel format should be considered the source of truth.
The antigen Supporting Data spreadsheets are split into a number of different Sections organized as different
tabs of the spreadsheets:
•
•
•
•
•
•

The Antigen Series Overview tab provides high level data for the antigen.
The Change History tab documents the evolution of the Supporting Data across multiple releases of the
CDSi resources.
The FAQ tab is home to common questions about the antigen Supporting Data.
The Immunity tab contains discrete data regarding when a patient may have sufficient evidence of
immunity to the disease.
The Contraindication tab identifies discrete patient scenarios which indicate when a dose should not be
administered to a patient.
One or more Series tabs which document different paths to immunity drawn from the ACIP
recommendations.

Note that the Antigen Series Overview, Change History and FAQ tabs are largely intended for human
consumption and the data in these Sections are not represented in the cognate XML file for the antigen.
Each Section (excel tab) is further sub-divided into multiple Logical Components which group sets of related
data Elements. The figure below shows the Logical Components (which are always in Column A of the tab with
a dark orange background) outlined in purple. The Elements of the Logical Component extend across the
spreadsheet (with a light orange background) and are outlined in pink the figure. For a given Logical Component,
there will be zero or more Instances of data (with a yellow background). For example, in the figure below, the
Preferable Vaccine Logical Component contains three different Instances (Preferable Vaccines), each outlined
in a different shade of green.
Furthermore, the Series tabs include a single set of series-level Logical Components which apply to the Series
in general and are outlined in red in the figure below. As well, each Series includes one or more sets of doselevel Logical Components outlined in shades of blue in the figure. While the set of Logical Components is
Logic Specification for ACIP Recommendations v4.6

Page 15 of 151

identical in all doses, the Instance data may be different between doses within a series. For example, the
Preferable Interval for the second dose in the Series may be different than the Preferable Interval for the third
dose in the series.

FIGURE 2-1 SUPPORTING DATA

Logic Specification for ACIP Recommendations v4.6

Page 16 of 151

2.5 LOGIC DEFINITION - PURPOSE
The logic definition describes, in a technology-neutral fashion, the functional steps
necessary to process the patient’s history using the Supporting Data.
The logic definition is composed of four separate, but related functions:
•
•
•
•

Evaluation
Forecasting
Select Patient Series
Identify and Evaluate Vaccine Group

Logic Definition
Evaluation
Forecasting
Select Best Patient Series
Evaluate Vaccine Group

To further reduce complexity, the four logic definitions are divided into logical sub-steps, each of which focuses
on one aspect of the more complex processes of evaluation and forecasting. In addition, the vaccine-specific
values have been abstracted out of the logic and reside in the Supporting Data.

2.6 LOGIC DEFINITION – EVALUATION
2.6.1

Logic Definition

Purpose

The logic definition evaluation describes the process of evaluating a single vaccine
dose administered against a defined target dose to determine if the vaccine dose
administered is valid or not valid for that specific target dose.
2.6.2

Evaluation
Forecasting
Select Best Patient Series
Evaluate Vaccine Group

What problem it helps solve

Focusing only on evaluation of a patient’s immunization history greatly simplifies the complexity of interpreting
ACIP recommendations. It also reduces the breadth of the impact on the logic of future ACIP recommendation
changes.

TABLE 2-4 EVALUATION SUGGESTED AUDIENCE

Role

Perspective

Business Analyst

Understanding and documenting the logical steps of evaluation and the impact
of Supporting Data elements.

Technical Developer

Coding the system to implement the functional processes described in the logic
definition. Understanding the integration of the Supporting Data, Logic
Specification and processing model.

2.6.3

How and where it is documented

Chapter 6 describes the process of evaluation. It is documented using the following:
•
•
•
•

A thin process model that represents the high-level steps to evaluate each of the logical sub-components
which ultimately affect the validity of a vaccine dose administered.
Timelines that graphically represent dates and/or time intervals used in evaluation.
Attribute tables that provide the attribute type, name, and assumed value if empty.
Decision tables that state the conditions and rules which must be assessed for a specific logical subcomponent and the resulting outcomes.

Logic Specification for ACIP Recommendations v4.6

Page 17 of 151

2.7 LOGIC DEFINITION – FORECASTING
2.7.1

Logic Definition

Purpose

The logic definition forecasting describes the process of using a patient’s history
to determine immunization due dates.
2.7.2

What problem it helps solve

Evaluation
Forecasting
Select Best Patient Series
Evaluate Vaccine Group

Focusing only on forecasting immunization due dates, separate from determining
which possible paths to immunity a patient is on, greatly simplifies the complexity of interpreting ACIP
recommendations. It also reduces the breadth of the impact on the logic of future ACIP recommendation
changes. Even though the logic for evaluation and forecasting is separate, sound evaluation simplifies the work
of forecasting; i.e., understanding which target dose has been satisfied simplifies forecasting the next target
dose in the patient series.
TABLE 2-5 FORECASTING SUGGESTED AUDIENCE

Role

Perspective

Business Analyst

Understanding and documenting the logical steps of forecasting and the impact
of Supporting Data elements.

Technical Developer

Coding the system to implement the functional processes described in the logic
definition. Understanding the integration of the Supporting Data, Logic
Specification and processing model.

2.7.3

How and where it is documented

Chapter 7 describes the process of forecasting. It is documented using the following:
•
•
•
•

A thin process model that represents the high-level steps to forecast immunization due dates.
Attribute tables that provide the attribute type, name, and assumed value if empty.
Timelines that graphically represent dates and/or time intervals used to generate or result from the
generated forecasted dates.
Decision tables that represent the combination of conditions and the resulting impact on the need to
generate forecasted dates.

2.8 LOGIC DEFINITION – SELECT PATIENT SERIES
2.8.1

Purpose

The logic definition select patient series describes the process of selecting the
patient series, out of the possible series, which puts the patient on the best path to
immunity based on various important factors.
2.8.2

Logic Definition
Evaluation
Forecasting
Select Best Patient Series
Evaluate Vaccine Group

What problem it helps solve

There is more than one path which can lead a patient to immunity. See Appendix F for representations of multiple
patient series (paths to immunity) for an antigen. Select patient series helps to put a specific patient on the best
path for them through the application of ACIP recommendations given the outcomes of evaluation and
forecasting.
Logic Specification for ACIP Recommendations v4.6

Page 18 of 151

TABLE 2-6 SELECT PATIENT SERIES SUGGESTED AUDIENCE

Role

Perspective

Business Analyst

Understanding and documenting the logical steps of Select Patient Series and
the factors used when scoring patient series.

Technical Developer

Coding the system to implement the functional processes described in the logic
definition. Understanding the integration of the Supporting Data, Logic
Specification, and processing model.

2.8.3

How and where it is documented

Chapter 8 describes the process of selecting best patient series. It is documented using the following:
•
•
•
•

A thin process model that represents the high-level steps to select patient series.
A vocabulary table that provides meanings to terms used strictly in the select patient series logic
definition.
Decision tables that represent the combination of conditions and the resulting impact on classifying and
scoring patient series.
Business rules used to concisely, unambiguously describe what and how various factors affect the score
given to competing patient series.

2.9 LOGIC DEFINITION – IDENTIFY AND EVALUATE VACCINE GROUP
2.9.1

Logic Definition

Purpose

The logic definition identify and evaluate vaccine group describes the process of
combining patient series, described in terms of antigens, into vaccine group-based
forecasts.
2.9.2

Evaluation
Forecasting
Select Best Patient Series
Evaluate Vaccine Group

What problem it helps solve

Performing evaluation and forecasting at the antigen-level provides for an extremely effective and
comprehensive approach. However, clinicians and physicians look at vaccines in a broader grouping known as
vaccine groups. Identify and evaluate vaccine group pulls this notion together to provide a clinical-centric
forecast based on vaccine groups.
TABLE 2-7 IDENTIFY AND EVALUATE VACCINE GROUP SUGGESTED AUDIENCE

Role

Perspective

Business Analyst

Understanding and documenting the logical steps of identifying and evaluating
vaccine groups.

Technical Developer

Coding the system to implement the functional processes described in the logic
definition. Understanding the integration of the Supporting Data, Logic
Specification, and processing model.

2.9.3

How and where it is documented

Logic Specification for ACIP Recommendations v4.6

Page 19 of 151

Chapter 9 describes the process of identifying and evaluating vaccine groups. It is documented using the
following:
•
•
•

A thin process model that represents the high-level steps to identify and evaluate vaccine groups.
Decision tables that represent the combination of conditions which dictate which set of vaccine group
forecasting rules apply.
Business rules used to concisely, unambiguously describe how to apply the proper vaccine group
forecasting rules to determine the appropriate vaccine group-based forecast

2.10 PROCESSING MODEL
2.10.1 Purpose
The logic definitions focus on the functionality necessary to evaluate and forecast
Processing Model
based on one specific target dose and one specific vaccine dose administered.
Eval.
This simplifies the entire process by only focusing on one item at a time. However,
For.
there are many possible paths to immunity which result in many potential target
doses. In addition, a patient’s history often contains multiple vaccine doses
administered. Thus, the processing model describes, in a technology-neutral fashion, the algorithms necessary
to merge multiple executions and results of the logic definitions for evaluation and forecasting.
2.10.2 What problem it helps solve
Separating the functionality of evaluation from forecasting and the algorithmic details of handling multiple
iterations of evaluation and forecasting greatly simplifies the complexity of implementing ACIP recommendations.
It also reduces the breadth of the impact on the logic of future ACIP recommendation changes
TABLE 2-8 PROCESSING MODEL SUGGESTED AUDIENCE

Role

Perspective

Technical Developer

Coding the system to implement the functional processes described in the logic
definition. Understanding the integration of the patient related data, Supporting
Data, and Logic Specification.

2.10.3 How and where it is documented
Chapter 4 describes the more detailed algorithms represented in the Logic Specification Processing Model.
These algorithms are documented using activity diagrams, which represent the detailed looping necessary to
evaluate a patient’s full immunization history against multiple potential vaccination series resulting in multiple
candidate forecasted immunization due dates.

2.11 DECISION TABLE OVERVIEW
A decision table documents the way that a system responds to various combinations of input conditions. It
describes business rules where the required response depends on a number of factors that must all be
considered at the same time. Decision tables are useful when trying to clearly define a set of conditions, how
they work in combination, and what actions should be taken on encountering a given set of conditions.

Logic Specification for ACIP Recommendations v4.6

Page 20 of 151

There are various ways of documenting decision tables. The Logic Specification uses two different styles. Both
start with a simple business question as the title or subject of the decision table.
The majority of decision tables in the Logic Specification use a condition/outcome style formatting. In this
approach, the top half lists conditions based on the business question. The bottom half of the decision table
states the outcome after the rules have been applied to the condition.
In order to familiarize the reader with the use of decision tables in the Logic Specification, an example is provided
below using a real-world scenario that is unrelated to immunizations.
TABLE 2-9 SHOULD I GET MY CAR WASHED?
CONDITIONS
Is the car wash open?

No

RULES
-

-

Is my car dirty?
Do I have enough money?

-

No
-

No

No. My car is not dirty.

No. I cannot afford it.

OUTCOMES
Default: Yes. I should get
my car washed.

No. The car wash is
closed.

The following table provides explanations of how the various outcomes were determined.
TABLE 2-10 EXPLANATIONS OF OUTCOMES
Outcome
No. The car wash is
closed.

Explanations
The answer “No” to the first condition means the car wash was not open. The other
conditions (Is my car dirty? or Do I have enough money?) do not matter.

No. My car is not
dirty.
No. I cannot afford it.

The answer “No” to the second condition means my car is not dirty. The other
conditions (Is the car wash open? Or Do I have enough money?) do not matter.
The answer “No” to the third condition means I do not have enough money. The other
conditions (Is the car wash open? Or Is my car dirty?) do not matter.

Default: Yes. I should
get my car washed.

The default outcome is to wash the car. When nothing is preventing the car from being
washed, the decision is to always wash the car.

In the second style, the outcome is the intersection of a row and column where the row and column heading are
the conditions. The example below illustrates exercise based on the day of the week and the weather outside.
For example, the exercise on Saturday when it is raining outside is a Yoga Class.
TABLE 2-11 WHAT EXERCISE SHOULD I DO TODAY?

Monday
Tuesday
Wednesday
Thursday
Friday

Dry
Trail Run
No Exercise
Trail Run
Trail Run
No Exercise

Weather
Raining
Treadmill
No Exercise
Treadmill
Treadmill
No Exercise

Logic Specification for ACIP Recommendations v4.6

Snowing
Cross Country Ski
No Exercise
Cross Country Ski
Cross Country Ski
No Exercise
Page 21 of 151

Saturday
Sunday

Golf
Golf

Weather
Yoga Class
Yoga Class

Downhill Ski
Downhill Ski

A decision table is helpful when decision-based rules have to be applied in combination. As illustrated above,
the Logic Specification refers to key components of a decision table as (1) Conditions, (2) Rules, and (3)
Outcomes. These components function together in the following manner: Conditions + Answers = Rules; Rules
determine Outcomes.
Logical reasoning used to determine the outcome in the example decision tables above is similar to the decision
tables used in the Logic Specification. The goal of a decision table is to answer a business question while
providing the correct technical outcome.

Logic Specification for ACIP Recommendations v4.6

Page 22 of 151

3 LOGIC SPECIFICATION CONCEPTS
The information contained in this chapter will be useful in understanding the business rules, decision tables, and
process models that are used in the Logic Specification. The first section provides a basic understanding of
target dose and how it is used throughout the document. Next, relevant meanings of statuses used during
evaluation and forecasting are provided for clarity. Then, rules for selecting the correct Supporting Data is
provided. Business rules used when calculating dates for evaluation and forecasting are provided next.

3.1 TARGET DOSE
Target dose is a term used often in the Logic Specification document. A target dose is a patient-specific dose
required to satisfy the recommendations of ACIP. Until a target dose is satisfied, the patient is not allowed to
move to the next target dose in the patient series. The patient remains on the “unsatisfied” target dose until the
patient has a “valid” vaccine dose administered that satisfies the target dose. A target dose is also allowed to
be skipped. This situation isn’t the common path and not immediately discussed here. Details on skipping target
doses can be found in Chapters 6 and 7.
This concept can be seen graphically below in Figure 3-1. For simplicity in this hypothetical patient series, the
target doses are defined only by the minimum age. The target doses have minimum ages of 0 days, 2 months,
and 6 months. These are the minimum ages allowed by this patient series. The patient must have vaccine
doses administered on or after these minimum ages to be considered valid. A valid vaccine dose administered
will satisfy a target dose and allow movement to the next target dose. A vaccine dose administered which is
anything but valid does not satisfy a target dose and does not allow movement to the next target dose.
This can be seen in Figure 3-1 by looking at target dose 2 and vaccine doses administered dose 2 and dose 3.
Dose 2 was administered too early and resulted in the evaluation status “not valid.” A not valid vaccine dose
administered means the target dose was not satisfied and must be repeated. Dose 3 was given at an appropriate
age which resulted in the evaluation status “valid” and satisfied the goals of target dose 2. This allows movement
to target dose 3 which is subsequently satisfied by vaccine dose administered dose 4.
While not shown on this graphic, there is also a status which tracks the patient’s progress towards completion of
a patient series. In this example, the patient series status is “not complete” for the first three vaccine doses
administered. The patient series status is changed to “complete” once the fourth vaccine dose administered
satisfies the third target dose which completes the patient series.

Logic Specification for ACIP Recommendations v4.6

Page 23 of 151

FIGURE 3-1 HOW A VACCINE DOSE ADMINISTERED SATISFIES A TARGET DOSE

3.2 STATUSES
The Logic Specification uses different statuses to denote the state of evaluation, target dose, and patient series.
The following tables provide the meanings of statuses used in Logic Specification business rules and decision
tables.
TABLE 3-1 EVALUATION STATUSES
Status

Meaning

Extraneous

An evaluation status that indicates the vaccine dose administered was not administered according to ACIP
recommendations, but the dose does not need to be repeated (including maximum age and extra doses)

Not Valid

An evaluation status that indicates the vaccine dose administered was not administered according to ACIP
recommendations and must be repeated at an appropriate time in the future

Sub-standard

An evaluation status that indicates the vaccine dose administered has a known dose condition (e.g., expired,
sub-potent, and recall) which requires the dose to be repeated at an appropriate time in the future

Valid

An evaluation status that indicates the vaccine dose administered was administered according to ACIP
recommendations

Logic Specification for ACIP Recommendations v4.6

Page 24 of 151

TABLE 3-2 TARGET DOSE STATUSES
Status

Meaning

Not Satisfied

A target dose status that indicates no vaccine dose administered has met the goals of the target dose

Satisfied

A target dose status that indicates a vaccine dose administered has met the goals of the target dose

Skipped

A target dose status that indicates no vaccine dose administered has met the goals of the target dose. Due
to the patient's age and/or interval from a previous dose, the target dose does not need to be satisfied.

TABLE 3-3 PATIENT SERIES STATUSES
Status

Meaning

Aged Out

A patient series status that indicates the patient exceeded the maximum age prior to completing the patient
series

Complete

A patient series status that indicates the patient has met all of the ACIP recommendations for the patient
series

Contraindicated

A patient series status that indicates no further vaccines should be administered at this time for the patient
series

Immune

A patient series status that indicates the patient has evidence of immunity indicating no further vaccines
are needed for the patient series

Not Complete

A patient series status that indicates the patient has not yet met all of the ACIP recommendations for the
patient series

Not Recommended

A patient series status that indicates the patient's immunization history provides sufficient protection
against a target disease and there's no recommended action at this time

3.3 SELECTING SUPPORTING DATA
When a clinical recommendation is changed, it is typically applied to patient evaluation and forecasting
retroactively but, depending on the nature of the change, the evaluation status of administered doses may or
may not change. For example, if a recommendation changed the minimum interval from 6 months to 4 months,
previously administered doses that met the 6 month interval requirement are still considered valid when the new
4 month interval is applied. For this reason, many recommendations changes are instituted in new published
versions of the Supporting Data simply as a new value with no indication of the previous value.
However, some recommendation changes are not applied retroactively, and historical Supporting Data must be
retained and selectively applied during the evaluation and forecasting processes. For example, prior to the ACIP
HPV recommendation published 12/16/2016, the absolute minimum interval between Doses 1 and 3 was 16
weeks but the recommendation increased the absolute minimum interval to 5 months minus 4 days. However,
the change was not applied retroactively. Therefore, a third dose administered prior to 12/16/2016 need only
meet the 16-week interval while a third dose (for a different patient) administered on or after 12/16/2016 would
need to meet the longer 5 month interval. In the figure below, these differential requirements are represented,
highlighted in blue, in the Supporting Data using Effective and Cessation Dates which indicate a date range that
the Supporting Data component was in effect.
Only a subset of the Supporting Data Logical Components use Effective and Cessation Dates elements (e.g.
Age, Preferable Interval, Allowable Interval and Conditional Skip). When a Logical Component does not include
Logic Specification for ACIP Recommendations v4.6

Page 25 of 151

Effective and Cessation Dates elements (e.g. Preferable Vaccine, Allowable Vaccine, Inadvertent Vaccine,
Recurring Dose and Seasonal Recommendation), the Instances of supporting data in that Logical Component
must be selected for evaluation and forecasting purposes.
In order to determine if a Supporting Data Logical Component Instance is relevant, the anchor date (the
administration date in the case of an evaluation or the assessment date in the case of a forecast) must fall
between the Effective and Cessation Dates (see decision table below) for the Supporting Data. This selection
process must be applied any time either the Effective Date or Cessation Date is valued other than “n/a” in the
Supporting Data as highlighted in red below. Data Instances where both valued “n/a” must be always be applied
during the evaluation and forecasting process.

FIGURE 3-2 SELECTING SUPPORTING DATA

TABLE 3-4 RELEVANT SUPPORTING DATA ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Vaccine dose administered

Date Administered

-

Runtime data

Assessment Date

current date

Supporting Data (Effective Date)

Effective Date

01/01/1900

Supporting Data (Cessation Date)

Cessation Date

12/31/2999

TABLE 3-5 SELECT RELEVANT SUPPORTING DATA LOGICAL COMPONENT ELEMENT
Business Rule ID

Business Rule

RELEVANT-1

A logical component instance must be used in evaluation if one of the following is true:
• the effective date and cessation date are both 'n/a'
• the date administered is on or after the effective date and on or before the cessation date.

RELEVANT-2

A logical component instance must be used in forecasting or selecting the best patient series if one of the
following is true:
• the effective date and cessation date are both 'n/a'
• the assessment date is on or after the effective date and on or before the cessation date.

In addition to Supporting Data selection by Effective and Cessation Dates, relevant Conditional Skip Logic
Component Instances must be selected on the basis of context. In some scenarios, the rationale for skipping a
dose in a series differs depending on whether a retrospective evaluation or a prospective forecast is being
performed. In the Supporting Data, 4 contexts are possible:
•
•
•
•

Evaluation – applicable when a dose is being evaluated (see section 6.2)
Forecast – applicable when a dose is being forecasted (see section 7.1)
Both – applicable when a dose is being either evaluated or forecasted (see sections 6.2 and 7.1)
n/a – there are no conditions that can result in a dose being skipped during either evaluation or forecast

Logic Specification for ACIP Recommendations v4.6

Page 26 of 151

FIGURE 3-3 CONDITIONAL SKIP CONTEXT

3.4 DATE CALCULATIONS
Business rules that are specific to calculating dates are provided in this section. A calculated date is a date that
is mathematically derived from one or more terms. The first table provides rules for calculating dates in general.
The second table provides rules for calculating dates by logical component.
TABLE 3-6 GENERAL DATE RULES
Business Rule ID

Business Rule

Example

CALCDT-1

The computed date of adding any number of years to an existing
date must be calculated by incrementing the date-year while
holding the date-month and date-day constant.

01/01/2000 + 3 years = 01/01/2003

CALCDT-2

The computed date of adding any number of months to an existing 01/01/2000 + 6 months = 07/01/2000
date must be calculated by incrementing the date-month (and date- 11/01/2000 + 6 months = 05/01/2001
year, if necessary) while holding the date-day constant.

CALCDT-3

The computed date of adding any number of weeks or days to an
existing date must be calculated by adding the total days to the
existing date.

01/01/2000 + 3 days = 01/04/2000
01/01/2000 + 3 weeks = 01/22/2000
02/01/2000 + 5 weeks = 03/07/2000
(leap year)
02/01/2001 + 5 weeks = 03/08/2001
(not a leap year)

CALCDT-4

The computed date of subtracting any number of days from an
existing date must be calculated by subtracting the total days from
the existing date.

01/15/2000 – 4 days = 01/11/2000

CALCDT-5

A computed date which is not a real date must be moved forward
to first day of the next month.

03/31/2000 + 6 months = 10/01/2000
(September 31 does not exist)
08/31/20010 + 6 months =
03/01/2001 (February 31 does not
exist)

CALCDT-6

A computed date must be calculated by first adjusting the years,
followed by the months, and finally the weeks and/or days.

01/31/2000 + 6 months – 4 days =
07/27/2000

Logic Specification for ACIP Recommendations v4.6

Page 27 of 151

TABLE 3-7 LOGICAL COMPONENT DATE RULES
Business Rule ID

Business Rule

CALCDTAGE-1

A patient's maximum age date must be calculated as the patient's date of birth plus the maximum age.

CALCDTAGE-2

A patient's latest recommended age date must be calculated as the patient's date of birth plus the latest
recommended age.

CALCDTAGE-3

A patient's earliest recommended age date must be calculated as the patient's date of birth plus the earliest
recommended age.

CALCDTAGE-4

A patient's minimum age date must be calculated as the patient's date of birth plus the minimum age.

CALCDTAGE-5

A patient's absolute minimum age date must be calculated as the patient's date of birth plus the absolute
minimum age.

CALCDTALLOW-1

A patient's allowable vaccine type begin age date must be calculated as the patient's date of birth plus the
vaccine type begin age of an allowable vaccine.

CALCDTALLOW-2

A patient's allowable vaccine type end age date must be calculated as the patient's date of birth plus the
vaccine type end age of an allowable vaccine.

CALCDTCI-1

A patient's contraindication begin age date must be calculated as the patient's date of birth plus the
contraindication begin age of a contraindication.

CALCDTCI-2

A patient's contraindication end age date must be calculated as the patient's date of birth plus the
contraindication end age of a contraindication.

CALCDTCONFLICT-1

The conflict begin interval date for a previous vaccine dose administered must be calculated as the date
administered of the previous vaccine dose administered plus the conflict begin interval of a vaccine type
conflict where all the following are true:
• The vaccine type of the current vaccine dose administered is an impacted vaccine type.
• The vaccine type of the previous vaccine dose administered is a conflicting vaccine type for the
impacted vaccine type.

CALCDTCONFLICT-2

The conflict end interval date for a previous vaccine dose administered must be calculated as one of the
following:
• the date administered of the previous vaccine dose administered plus the minimum conflict end
interval of a vaccine type conflict if all the following are true:
o The vaccine type of the current vaccine dose administered is an impacted vaccine type.
o The vaccine type of the previous vaccine dose administered is a conflicting vaccine type
for the impacted vaccine type.
o The previous vaccine dose administered has one of the following:
▪ an evaluation status of 'Valid'
▪ no evaluation status.
• the date administered of the previous vaccine dose administered plus the conflict end interval of a
vaccine type conflict if all the following are true:
o The vaccine type of the current vaccine dose administered is an impacted vaccine type.
o The vaccine type of the previous vaccine dose administered is a conflicting vaccine type
for the impacted vaccine type.
o The previous vaccine dose administered has an evaluation status.
o The previous vaccine dose administered does not have an evaluation status of 'Valid'.

CALCDTCONFLICT-3

The forecast conflict end date of a vaccine type conflict that impacts a next target dose must be calculated
as the date administered of a vaccine dose administered plus the conflict end interval of the vaccine type
conflict if all the following are true:
• The next target dose is tracked by a series dose that includes a preferable vaccine that is
classified by an impacted vaccine type.
• The vaccine type of the vaccine dose administered is a conflicting vaccine type for the impacted
vaccine type.

Logic Specification for ACIP Recommendations v4.6

Page 28 of 151

Business Rule ID

Business Rule

CALCDTIND-1

A patient's indication begin age date must be calculated as the patient's date of birth plus the indication begin
age of an indication.

CALCDTIND-2

A patient's indication end age date must be calculated as the patient's date of birth plus the indication end
age of an indication.

CALCDTINT-1

A patient's reference dose date for an interval must be calculated as the date administered of the most
immediate previous vaccine dose administered if all the following are true:
• The interval has a from immediate previous dose administered flag of 'Y'
• The vaccine dose administered has an evaluation status of 'Valid' or 'Not Valid'
• The vaccine dose administered is not an inadvertent administration.

CALCDTINT-2

A patient's reference dose date for an interval must be calculated as the date administered of the vaccine
dose administered that satisfies the target dose with the same target dose number as the from target dose
number in series if all the following are true for the interval:
• From immediate previous dose administered flag is 'N'
• From target dose number in series is not 'n/a'

CALCDTINT-3

A patient's absolute minimum interval date must be calculated as the patient's reference dose date plus the
absolute minimum interval.

CALCDTINT-4

A patient's minimum interval date must be calculated as the patient's reference dose date plus the minimum
interval.

CALCDTINT-5

A patient's earliest recommended interval date must be calculated as the patient's reference dose date plus
the earliest recommended interval.

CALCDTINT-6

A patient's latest recommended interval date must be calculated as the patient's reference dose date plus
the latest recommended interval.

CALCDTINT-8

A patient's reference dose date for an interval must be calculated as the date administered of the most recent
vaccine dose administered that is the same vaccine type as the from most recent vaccine type if all the
following are true for the interval:
• From immediate previous dose administered flag is 'N'
• From most recent vaccine type is not 'n/a'
• The vaccine dose administered is not an inadvertent administration.

CALCDTINT-9

A patient's reference dose date for an interval must be calculated as the observation date of the most recent
active patient observation if all the following are true for the interval:
• From immediate previous dose administered flag is 'N'
• From relevant observation code is not 'n/a'

CALCDTLOTEXP-1

The lot number expiration date must be one of the following:
• Lot number expiration date if the month, day, and year are all known.
• Last day of the month if only the month and year are known.

CALCDTPREF-1

A patient's preferable vaccine type begin age date must be calculated as the patient's date of birth plus the
vaccine type begin age of a preferable vaccine.

CALCDTPREF-2

A patient's preferable vaccine type end age date must be calculated as the patient's date of birth plus the
vaccine type end age of a preferable vaccine.

CALCDTSKIP-3

A patient's conditional skip begin age date must be calculated as the patient's date of birth plus the
conditional skip begin age of a conditional skip.

CALCDTSKIP-4

A patient's conditional skip end age date must be calculated as the patient's date of birth plus the conditional
skip end age of a conditional skip.

CALCDTSKIP-5

A patient's conditional skip interval date must be calculated as the vaccine date administered from the
immediate previous vaccine dose administered plus the Interval of the conditional skip condition.

Logic Specification for ACIP Recommendations v4.6

Page 29 of 151

4 PROCESSING MODEL
At a very simple level, the major logical steps involved in the immunization evaluation and forecasting engine
can be described in two parts. The first part is very mechanical in nature and focuses on gathering and prepping
all of the required data. The second part uses the data gathered earlier to generate the evaluation and forecast.
The following table lists the major steps of the processing model.
TABLE 4-1 LOGIC SPECIFICATION PROCESSING STEPS
Section

Activity

Goal

4.1

Gather Necessary Data

The goal of this step is to gather all pertinent information which will be used in
subsequent steps in the process.

4.2

Organize Immunization History

The goal of this step is to break apart vaccine doses administered into their
antigen parts.

4.3

Create Relevant Patient Series

The goal of this step is to instantiate (Chapter 5) antigen series into relevant
patient series for this patient.

4.4

Evaluate and Forecast All Patient The goal of this step is to evaluate (Chapter 6) each antigen administered and
Series
create a forecast for each relevant patient series (Chapter 7).

4.5

Select Best Patient Series

The goal of this step is to select one or more best patient series (Chapter 8) for
the patient based on their evaluated history and forecast.

4.6

Identify and Evaluate Vaccine Group

The goal of this step is to merge together patient series forecasts into a vaccine
group forecast (Chapter 9).

Figure 4-1 provides the high-level process of the major steps of the processing model.

FIGURE 4-1 LOGIC SPECIFICATION PROCESSING MODEL

Logic Specification for ACIP Recommendations v4.6

Page 30 of 151

As illustrated in Figure 4-2, as the process model progresses, the set of patient series continually becomes more
restricted as:
•
•
•
•

Relevant Patient Series are selected from the total list of Antigen Series based on standard
recommendations, patient gender, and patient observations.
Scorable Patient Series are selected from the evaluated and forecasted Relevant Patient Series.
A Prioritized Patient Series is selected per Series Group (provided the Series Group had at least one
Relevant Patient Series.
One or more non-redundant Best Patient Series are selected from the Prioritized Patient Series

FIGURE 4-2 REFINEMENT OF PATIENT SERIES

4.1 GATHER NECESSARY DATA
Gathering all the necessary data is a generic step which could technically be performed in several different ways.
While this step is important, it is outside of the purview of this document and is only noted as a generic step in
the process.
The required data fall into two categories (1) Patient-related data and (2) Evaluation and forecasting data. The
lists below provide class level data needed. Further details on these classes can be found in Appendix A.
Patient-related data needed:
•
•
•
•
•
•

Patient
Vaccine Dose Administered
Vaccine
Immunization History
Adverse Reaction
Patient Observations

Evaluation and forecasting data needed:
•

Schedule

Logic Specification for ACIP Recommendations v4.6

Page 31 of 151

•
•
•
•
•

Antigen Series
Series Dose
Vaccine Group
Antigen
Vaccine

Finally, the term “gather” is not meant to imply a fetch, get, or retrieve operation to accumulate this data.
Depending upon the implementation, some of this data may be passed by an external entity; other data may
already be known; and still other data may arrive at different points in the process on an as needed basis. It is
an acknowledgement of the minimal data needed in the evaluation and forecasting processes.

4.2 ORGANIZE IMMUNIZATION HISTORY
The second step in the process is to look at the patient’s immunization history and prepare those records for
evaluation and forecasting by breaking them into their antigen parts. This allows the evaluation and forecasting
engine to be as granular and specific as possible for both evaluation and forecasting purposes. Later in the
process, these antigens are assembled into commonly known vaccine groups (vaccine families) for vaccine
group forecasts.
To provide some specifics to this step, the following tables are provided as a high-level example of the work
organize immunization history performs.
TABLE 4-2 PRIOR TO ORGANIZE IMMUNIZATION HISTORY EXAMPLE
Product (CVX/MVX) – Description

Date

Engerix B-Peds (08/SKB) – HepB

01/01/2011

Pediarix (110/SKB) – DTaP-HepB-IPV

03/01/2011

ActHIB (48/PMC) – Hib

03/01/2011

Prevnar 13 (133/WAL) – PCV13

03/01/2011

Pediarix (110/SKB) – DTaP-HepB-IPV

06/01/2011

ActHIB (48/PMC) – Hib

06/01/2011

Prevnar 13 (133/WAL) – PCV13

06/01/2011

ProQuad (94/MSD) – MMRV

01/01/2012

TABLE 4-3 AFTER ORGANIZE IMMUNIZATION HISTORY EXAMPLE
Product (CVX/MVX) – Description

Date

Antigen*

Pediarix (110/SKB) – DTaP-HepB-IPV

03/01/2011

Diphtheria

Pediarix (110/SKB) – DTaP-HepB-IPV

06/01/2011

Diphtheria

Engerix B-Peds (08/SKB) – HepB

01/01/2011

HepB

Pediarix (110/SKB) – DTaP-HepB-IPV

03/01/2011

HepB

Pediarix (110/SKB) – DTaP-HepB-IPV

06/01/2011

HepB

ActHIB (48/PMC) – Hib

03/01/2011

Hib

ActHIB (48/PMC) – Hib

06/01/2011

Hib

Logic Specification for ACIP Recommendations v4.6

Page 32 of 151

Product (CVX/MVX) – Description

Date

Antigen*

ProQuad (94/MSD) – MMRV

01/01/2012

Measles

ProQuad (94/MSD) – MMRV

01/01/2012

Mumps

Prevnar 13 (133/Wal) – PCV13

03/01/2011

PCV

Prevnar 13 (133/Wal) – PCV13

06/01/2011

PCV

Pediarix (110/SKB) – DTaP-HepB-IPV

03/01/2011

Pertussis

Pediarix (110/SKB) – DTaP-HepB-IPV

06/01/2011

Pertussis

Pediarix (110/SKB) – DTaP-HepB-IPV

03/01/2011

Polio

Pediarix (110/SKB) – DTaP-HepB-IPV

06/01/2011

Polio

ProQuad (94/MSD) – MMRV

01/01/2012

Rubella

Pediarix (110/SKB) – DTaP-HepB-IPV

03/01/2011

Tetanus

Pediarix (110/SKB) – DTaP-HepB-IPV

06/01/2011

Tetanus

ProQuad (94/MSD) – MMRV

01/01/2012

Varicella

*Sorted by antigen and then by date

The figure below illustrates how an immunization history of vaccine doses administered can be converted into
antigen administered records.

Logic Specification for ACIP Recommendations v4.6

Page 33 of 151

FIGURE 4-3 ORGANIZE IMMUNIZATION HISTORY PROCESS MODEL

The process of breaking apart vaccine doses administered into their antigen parts is a fairly simple iterative
process.
1. For each vaccine dose administered in the patient’s immunization history, the vaccine dose administered is
interrogated for the antigens contained within.
2. For each antigen within a vaccine dose administered, an antigen administered record is created. The activity
diagram above provides the basic data elements used in evaluation and forecasting. The following notes
should be considered:
a. The CVX to Antigen Supporting Data includes Association Begin Age and Association End Age
attributes to properly associate the administered vaccine with the proper antigen based on the
age of patient at the time of administration (e.g., a Zoster vaccine administered below 50 years
should be associated with Varicella).
b. The activity diagram above provides the basic data elements used in evaluation and forecasting.
It is entirely possible different implementations may use more or less attributes from this list.
3. After all vaccine doses administered have been turned into antigen administered records, the final step in
the activity diagram is to sort the antigen administered records by antigen and then by ascending date order
within each antigen. Sorting these now will allow for consistent and accurate results in remainder of the
steps.
A Supporting Data table mapping CVX codes to antigens to aid in this process can be found at the following
location: http://www.cdc.gov/vaccines/programs/iis/cdsi.html

4.3 CREATE RELEVANT PATIENT SERIES
An antigen series is one way to reach perceived immunity against a disease. An antigen series can be thought
of as a “path to immunity” and is described in relative terms. In many cases, a single antigen may have more
than one successful path to immunity and as such may have more than one antigen series. Antigen series are
defined through Supporting Data spreadsheets defined in Chapters 2 and 3. Some series, classified here as
“Standard” series, are based on recommendations for all patients based on age. Other series, classified as “Risk”
series, are based on recommendations for patients with specific characteristics or underlying conditions which
put them at increased risk. Finally, some series are strictly for the purpose of “Evaluation Only” and should not
be recommended for completion, but if already complete can be used as proof of series completion.
Similar to gathering necessary data (section 4.1), create relevant patient series will likely vary from system to
system based on design details and technologies used. The important aspect of this step is to instantiate each
antigen series as a relevant patient series provided it meets necessary requirements as defined by the logic in
Chapter 5.
The process model below shows the iterative steps to create relevant patient series. At the end of this step, each
antigen series relevant for the patient is turned into a relevant patient series. The set of relevant patient series
for a given patient are used in subsequent chapters. Those not relevant for the patient are excluded from further
processing.

Logic Specification for ACIP Recommendations v4.6

Page 34 of 151

FIGURE 4-4 CREATE RELEVANT PATIENT SERIES PROCESS MODEL

4.4 EVALUATE AND FORECAST ALL RELEVANT PATIENT SERIES
This step is the core of the business logic and decision points many people think of when describing evaluation
and forecasting. In the Logic Specification, this step contains all of the clinical business rules and decision logic
in the form of business rules and decision tables.
At the end of this step, each relevant patient series will have an evaluated history and a forecast.
The iterative nature of this step is best described with two activity diagrams. First, Figure 4-5 shows the highlevel iterative process of looping through all relevant patient series. Next, Figure 4-6 specifically deals with the
details of evaluation. A description of the activity diagram follows each figure.

Logic Specification for ACIP Recommendations v4.6

Page 35 of 151

FIGURE 4-5 EVALUATE AND FORECAST PROCESS MODEL

At the highest level of this step, as illustrated in the figure above, a simple iterative process is used to walk
through each relevant patient series and apply the logic defined in the evaluation and forecasting chapters.
For each relevant patient series created in the create relevant patient series step (Chapter 5), the following steps
are performed:
1. Evaluate the immunization history. See the evaluate immunization history activity diagram below for further
details.
2. Create forecast dates and/or reasons for the next target dose to be administered. Process models and
detailed decision logic on forecasting are in Chapter 7.

Logic Specification for ACIP Recommendations v4.6

Page 36 of 151

FIGURE 4-6 EVALUATE IMMUNIZATION HISTORY PROCESS MODEL

Figure 4-6 illustrates the iterative nature of evaluate immunization history in greater detail. There are two
collections (e.g., arrays, lists, etc.) which must be traversed. The first collection is the relevant patient series
consisting of one or more target doses. The second collection is the antigen administered records. At any point
in the iterative process either collection could be the trigger to end our evaluation process. Specifically, whichever
collection is exhausted first will be the trigger for ending the evaluation process.
It is important to note the contents of antigen administered records at this point in the process. Antigen
administered records are only those which could potentially satisfy the goals of the relevant patient series. For
example, if the patient series is a path to immunity for HepB, then the antigen administered records will only
contain HepB records in ascending date order.
Logic Specification for ACIP Recommendations v4.6

Page 37 of 151

It should also be noted that when multiple relevant patient series have been created (Chapter 5), all antigen
administered records for the patient should be evaluated against each relevant patient series, and a status (e.g.,
valid, not valid, etc.) should be assigned per dose per relevant patient series. An administered dose that is “valid”
for one relevant patient series may be “not valid” for a different relevant patient series for the same patient.
The evaluate immunization history process is as follows:
1. The process begins by getting the first target dose from the relevant patient series collection. The current
target dose is an important concept as the process moves from evaluation into forecasting. The evaluation
process will inform the forecasting process which target dose needs to be forecasted.
2. If the antigen administered collection has elements in it, the process gets the first antigen administered and
continues to step 3.
a. If the antigen administered collection is empty, the evaluation process for this relevant patient series
ends.
3. The step described as “evaluate the antigen administered record against the target dose” is a reference to
Chapter 6 which contains process models and detailed decision logic that must be followed prior to moving
on to step 4.
4. After the antigen administered record was evaluated against the target dose, the next step is to determine
which collections to iterate based on the results of the evaluation.
a. If the target dose status is satisfied, proceed to step 5.
i. The antigen administered was valid. The target dose is satisfied. The evaluation process can
push forward to the next target dose if one exists.
b. If the target dose status is not satisfied, proceed to step 7.
i. The antigen administered did not meet the goals of the target dose. The evaluation process
cannot move onto the next target dose.
5. This step determines if the current target dose is a recurring dose. This is a semi-rare condition (e.g., Td
boosters, yearly Flu, COVID-19, certain risk series). A recurring dose may recur based on a time interval
from the previous dose (i.e. a tetanus recurring dose every 10 years for adults) or based on a patient
observation (i.e. a pertussis recurring dose with every pregnancy).
a. If the target dose is defined to be a recurring dose, initialize a new target dose identical to the current
target dose. The newly created target dose must now be the next element in the collection (e.g.,
immediately following the current target dose just satisfied). Any subsequent target dose elements
will be moved down by one and will occur after the recurring dose. Finally, iterate the collection to
get this newly created target dose and proceed to step 7.
b. If the target dose is not defined to be a recurring dose, proceed to step 6.
6. This step determines if there are more target doses in the relevant patient series collection.
a. If the relevant patient series collection has been exhausted, the evaluation process for this relevant
patient series ends. Any remaining antigen administered records should have their evaluation
statuses set to “extraneous.”.
b. If the relevant patient series collection contains another target dose, get the next target dose and
proceed to step 7.
7. This step determines if there are any more antigen administered records to evaluate.
a. If the antigen administered collection has been exhausted, the evaluation process for this relevant
patient series ends.
b. If the antigen administered collection contains another record, get the next antigen administered
record and return back to step 3.

Logic Specification for ACIP Recommendations v4.6

Page 38 of 151

i. Repeat steps 3 – 7 until the evaluation process for this relevant patient series ends. At this
point the process can end in one of two ways: (1) No more target doses (step 6.b) or (2) No
more antigen administered records (step 7a).

4.5 SELECT BEST PATIENT SERIES
The goal of select patient series is to determine the best path(s) to immunity for the patient based on the
evaluated immunization history, forecast, and any patient observations. A best patient series will be selected for
each Series Group, however, some antigen series define Equivalent Series Groups which allow a single best
series to be selected from across multiple Series Groups. Depending upon the ACIP recommendations, it is
possible to select a single best patient series across the entire antigen(e.g., across all Series Groups). In other
cases, multiple best patient series may be selected for a patient. For example, a patient may need to complete
a risk series in the short term to address an underlying risk condition but still need to complete a standard series
later in life.
The process of selecting the best patient series at the highest level is a simple iterative process which loops
through each antigen and applies the business rules found in Chapter 8 to each antigen. A sample iterative
process model is shown below to detail the looping structure.

FIGURE 4-7 SELECT BEST SERIES PROCESS MODEL

4.6 IDENTIFY AND EVALUATE VACCINE GROUP
The goal of identify and evaluate vaccine group is to merge together antigen-based forecasts into vaccine group
forecasts. This is especially important in MMR and DTaP/Tdap/Td vaccine groups which each contain more
Logic Specification for ACIP Recommendations v4.6

Page 39 of 151

than one antigen in their respective vaccine groups. In these cases, it is important to provide a forecast
consistent with the vaccine group rather than the individual antigen. The business rules to create vaccine group
forecasts are defined in Chapter 9. For vaccine groups which contain non-equivalent series groups, it is important
to only blend best patient series of the same series type (e.g., risk with risk and standard with standard).
The process of identifying and evaluating a vaccine group at the highest level is a simple iterative process which
loops through each vaccine group and applies the business rules defined in Chapter 9 to each vaccine group.
Figure 4-8 is a sample iterative process model that shows the looping structure.

FIGURE 4-8 IDENTIFY AND EVALUATE VACCINE GROUP PROCESS MODEL

Logic Specification for ACIP Recommendations v4.6

Page 40 of 151

5 CREATE RELEVANT PATIENT SERIES
The antigen Supporting Data defines one or more antigen series for each antigen. Before beginning the
evaluation process for a given patient, a set of relevant patient series must first be selected and created for the
patient. Not all antigen series will be relevant for a given patient and only antigen series appropriate for the
patient should be evaluated, forecasted, and considered for best patient series selection. The appropriateness
of an antigen series is based on criteria such as patient gender, age, and underlying conditions.
TABLE 5-1 CREATE RELEVANT PATIENT SERIES PROCESS STEPS
Section

Activity

Goal

5.1

Select Relevant Patient Series

The goal of this step is to identify the antigen series which are appropriate for the
patient.

FIGURE 5-1 CREATE RELEVANT SERIES PROCESS MODEL

5.1 SELECT RELEVANT PATIENT SERIES
Select relevant patient series determines which series defined by the Supporting Data are appropriate to
evaluate for the patient. Antigen series with a Series Type of “Standard” or “Evaluation Only” are relevant for all
patients of the appropriate gender. Not all antigen series with a Series Type of “Risk” will be appropriate for a
given patient.
Given the complex nature of indications, it may not always be possible to conclusively determine if an indication
applies to a patient. To minimize false positive forecasts, in the case where a Risk Series cannot be definitively
determined to be relevant for a patient (that is some or all indications are inconclusive and none unambiguously
apply to the patient) the series will not be evaluated or forecast, but a notification should be available to a clinician
alerting them to the presence of the indication(s) which could not be resolved.

Logic Specification for ACIP Recommendations v4.6

Page 41 of 151

FIGURE 5-2 SELECT RELEVANT PATIENT SERIES PROCESS MODEL

TABLE 5-2 SELECT RELEVANT PATIENT SERIES ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Patient

Gender

Unknown

Patient

Date of Birth

-

Patient history

Active Patient Observation(s)

-

Supporting Data (Gender)

Required Gender

Gender of the patient

Supporting Data (Series Type)

Series type

-

Supporting Data (Indication)

Observation Code

-

Runtime data

Assessment Date

current date

Calculated date (CALCDTIND-1)

Indication Begin Age Date

01/01/1900

Calculated date (CALCDTIND-2)

Indication End Age Date

12/31/2999

TABLE 5-3 SELECT RELEVANT PATIENT BUSINESS RULES
Business Rule ID

Business Rule

CALCDTIND-1

A patient's indication begin age date must be calculated as the patient's date of birth plus the indication begin
age of an indication.

CALCDTIND-2

A patient's indication end age date must be calculated as the patient's date of birth plus the indication end
age of an indication.

Logic Specification for ACIP Recommendations v4.6

Page 42 of 151

FIGURE 5-3 ASSESS INDICATIONS PROCESS MODEL

TABLE 5-4 DOES THE INDICATION APPLY TO THE PATIENT?
CONDITIONS

RULES

Does the indication describe
any active patient
observations?

Yes

No

Unknown

-

Is the indication begin age
date ≤ assessment date <
indication end age date?

Yes

Yes

Yes

No

No. The
Indication does
not apply to the
patient.

No. The Indication does not apply to the
patient; however, the Indication Text
Description should be made available to the
clinician for manual determination.

No. The
indication does
not apply to the
patient.

OUTCOMES

Yes. The
Indication
applies to the
patient.

TABLE 5-5 IS AN ANTIGEN SERIES A RELEVANT PATIENT SERIES FOR A PATIENT?
CONDITIONS

RULES

Is the patient gender one of the
required genders of the antigen
series?

Yes

No

Yes

Yes

Is the series type of the antigen
series 'Standard' or 'Evaluation
Only'?

Yes

-

No

No

Does at least one indication that
drives the need for the antigen
series apply to the patient?

-

-

Yes

No

Logic Specification for ACIP Recommendations v4.6

Page 43 of 151

CONDITIONS
OUTCOMES

RULES
Yes. The antigen
series is a relevant
patient series for the
patient.

Logic Specification for ACIP Recommendations v4.6

No. The antigen series Yes. The antigen
is not a relevant patient series is a relevant
series for the patient.
patient series for the
patient.

No. The antigen series is
not relevant patient
series for the patient.

Page 44 of 151

6 EVALUATE VACCINE DOSE ADMINISTERED
The core of a CDS engine is the process of evaluating a single vaccine dose administered against a defined
target dose within a relevant patient series to determine if the vaccine dose administered is “valid” or “not valid”
for the relevant patient series. The results will ultimately determine if all requirements of the target dose are
satisfied. This can be accomplished by breaking the evaluation process into simple logical components. After
processing each logical component, the results of those logical components are used to determine if the vaccine
dose administered satisfies the goals of the target dose.
Each logical component has its own set of business rules that are used to determine if a target dose is “satisfied.”
These business rules are documented using business rules and decision tables. (See section 2.11 to review an
example of a decision table using a real-world scenario.) The decision table describes the way that the CDS
engine responds to various combinations of conditions. The implementer can clearly see the set of conditions,
how they work in combination, and what actions should be taken on a given set of conditions.
Specific attributes and decision tables are provided for each step of the evaluation process.
TABLE 6-1 EVALUATION PROCESS STEPS
Section

Activity

Goal

6.1

Evaluate Dose Administered Condition The goal of this step is to determine if a vaccine dose administered can be
evaluated.

6.2

Evaluate Conditional Skip

The goal of this step is to determine if the target dose can be skipped due to a
patient’s age or immunization history.

6.3

Evaluate For Inadvertent Vaccine

The goal of this step is to determine if the vaccine dose administered was an
inadvertent administration due to the vaccine type that was administered.

6.4

Evaluate Age

The goal of this step is to determine if the vaccine dose administered was given
at an appropriate age.

6.5

Evaluate Preferable Interval

The goal of this step is to determine if the vaccine dose administered was given
at an appropriate interval.

6.6

Evaluate Allowable Interval

The goal of this step is to determine if the vaccine dose administered was given
at an allowable interval.

6.7

Evaluate Vaccine Conflict

The goal of this step is to determine if the vaccine dose administered was in
conflict with any other vaccines.

6.8

Evaluate For Preferable Vaccine

The goal of this step is to determine if the vaccine dose administered was one
of the preferable vaccines.

6.9

Evaluate For Allowable Vaccine

The goal of this step is to determine if the vaccine dose administered was one
of the allowable vaccines.

6.10

Satisfy Target Dose

The goal of this step is to determine if the target dose is satisfied.

Logic Specification for ACIP Recommendations v4.6

Page 45 of 151

FIGURE 6-1 EVALUATION PROCESS MODEL

6.1 EVALUATE DOSE ADMINISTERED CONDITION
Logic Specification for ACIP Recommendations v4.6

Page 46 of 151

Evaluate Dose Administered Condition checks the dose administered to see if the target dose must be repeated
regardless of the other evaluation rules.
Relationship to ACIP recommendations:
•
•

Doses which were administered after the lot expiration date or which contain a condition do not need to
be evaluated.
Examples of conditions which would prevent evaluation of a vaccine dose administered range from
misadministration to recalls to cold chain breaks.

The following processing model, attribute table and decision table are used to determine if dose administered
can be evaluated.

FIGURE 6-2 VACCINE DOSE ADMINISTERED CONDITION PROCESS MODEL

TABLE 6-2 DOSE ADMINISTERED CONDITION ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Vaccine dose administered

Date Administered

-

Vaccine dose administered

Dose Condition Flag

-

Calculated date (CALCDTLOTEXP-1)

Lot Expiration Date

12/31/2999

TABLE 6-3 CAN THE VACCINE DOSE ADMINISTERED BE EVALUATED?
CONDITIONS

RULES

Date administered > lot
number expiration
date?

Yes

No

No

Is the dose condition
flag 'Y'?

-

Yes

No

OUTCOMES

No. The vaccine dose administered No. The vaccine dose administered cannot
Yes. The vaccine dose
cannot be evaluated. Target dose be evaluated. Target dose status is 'not
administered can be
status is 'not satisfied.'
satisfied.' Evaluation status is 'sub-standard.' evaluated.
Evaluation status is 'sub-standard.'

6.2 EVALUATE CONDITIONAL SKIP
Logic Specification for ACIP Recommendations v4.6

Page 47 of 151

Evaluate Conditional Skip addresses times when a target dose can be skipped. A dose should be considered
necessary unless it is determined that it can be skipped. The most common scenarios for skipping a dose are:
•
•
•

Catch-up doses where the patient is current with their administrations and does not need to catch-up
The patient is behind schedule and the total number of doses needed to complete the relevant patient
series can be reduced
The previously administered dose(s) negates the need for the current target dose

Only Conditional Skip Instances with a context of Evaluation or Both should be used. In cases where a target
dose does not specify Conditional Skip attributes, the target dose cannot be skipped.
A dose may be skipped based on whether or not one or more conditions evaluates to true. Conditions are
classified as one of a number of types, each with one or more parameters in the Supporting Data. Conditions
are contained within sets. Each set contains one or more conditions to be evaluated. Within a set, one or more
conditions must be met for the set to be met. In the case where a set contains multiple conditions, whether all
conditions or just one condition must be met is specified by the Condition Logic (e.g., AND vs. OR). Similarly, a
dose may contain multiple sets. In the case where a dose contains multiple sets, whether all sets or just one set
must be met is specified by the Set Logic.
Finally, in an effort to reduce page size and eliminate duplicate logic which could result in typographical and
consistency errors, this section of logic is defined here once, but used in both Evaluation and Forecasting. The
forecasting chapter refers the reader back to this section for appropriate logic.
The following process model, attribute table, and decision table are used to determine if the target dose can be
skipped.

Logic Specification for ACIP Recommendations v4.6

Page 48 of 151

FIGURE 6-3 CONDITIONAL SKIP PROCESS MODEL

TABLE 6-4 CONDITIONAL SKIP ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Vaccine dose administered

Date Administered

-

Patient Immunization History

Administered Dose Count

-

Supporting Data (Conditional Skip)

Conditional Skip elements

-

Logic Specification for ACIP Recommendations v4.6

Page 49 of 151

Attribute Type

Attribute Name

Assumed Value if Empty

Runtime data

Assessment Date

current date

Runtime data

Earliest Date

-

Supporting Data (Conditional Skip)

Start Date

01/01/1900

Supporting Data (Conditional Skip)

End Date

12/31/2999

Calculated date (CALCDTSKIP-3)

Conditional Skip Begin Age Date

01/01/1900

Calculated date (CALCDTSKIP-4)

Conditional Skip End Age Date

12/31/2999

Calculated date (CALCDTSKIP-5)

Conditional Skip Interval Date

-

TABLE 6-5 CONDITIONAL SKIP BUSINESS RULES
Business Rule ID

Business Rule

CALCDTSKIP-3

A patient's conditional skip begin age date must be calculated as the patient's date of birth plus the
conditional skip begin age of a conditional skip.

CALCDTSKIP-4

A patient's conditional skip end age date must be calculated as the patient's date of birth plus the
conditional skip end age of a conditional skip.

CALCDTSKIP-5

A patient's conditional skip interval date must be calculated as the vaccine date administered from the
immediate previous vaccine dose administered plus the Interval of the conditional skip condition.

CONDSKIP-1

The Number of Conditional Doses Administered must be calculated as the count of vaccine doses
administered where all the following are true:
• The vaccine type of the vaccine dose administered is one of the conditional skip vaccine
types.
• The date administered is on or after the conditional skip begin age date and before the
conditional skip end age date.
• The date administered is on or after the conditional skip start date and before conditional skip
end date.
• The Evaluation Status must be one of the following:
• 'Valid' when the conditional skip dose type is 'Valid'.
• Any status when the conditional skip dose type is 'Total'.

CONDSKIP-2

The Conditional Skip Reference Date must be one of the following:
• The Date Administered of the vaccine dose administered when evaluating a vaccine dose
administered.
• The Assessment Date when determining a forecast.
• The Earliest Date when validating a forecast.

TABLE 6-6 CONDITIONAL TYPE OF AGE – IS THE CONDITION MET?
CONDITIONS
Is the Conditional Skip End Age Date > Conditional Skip Reference Date
≥ Conditional Skip Begin Age Date?

OUTCOMES

RULES
Yes

No

Yes. The condition is met.

No. The condition is not met.

TABLE 6-7 CONDITIONAL TYPE OF COMPLETED SERIES – IS THE CONDITION MET?
Logic Specification for ACIP Recommendations v4.6

Page 50 of 151

CONDITIONS

RULES

Does the Does the Conditional Skip Series Group identify a Series Group with at least one
relevant patient series with a patient series status of ‘Complete’?

OUTCOMES

Yes

No

Yes. The condition No. The condition is
is met.
not met.

TABLE 6-8 CONDITIONAL TYPE OF INTERVAL – IS THE CONDITION MET?
CONDITIONS

RULES

Has at least one dose been administered to the patient?

Yes

Yes

No

Is the Conditional Skip Reference Date ≥ Conditional Skip
Interval Date?

Yes

No

-

OUTCOMES

Yes. The condition is No. The condition is not No. The condition is not
met.
met.
met.

TABLE 6-9 CONDITIONAL TYPE OF VACCINE COUNT BY AGE AND/OR DATE – IS THE CONDITION MET?
Number of conditional doses administered
(BR: CONDSKIP-1) / Dose Count Logic

Greater than Conditional
Skip Dose Count

Equal to Conditional
Skip Dose Count

Less than Conditional
Skip Dose Count

Greater Than

Yes. The condition is met.

No. The condition is not
met.

No. The condition is not
met.

Equal

No. The condition is not
met.

Yes. The condition is
met.

No. The condition is not
met.

Less Than

No. The condition is not
met.

No. The condition is not
met.

Yes. The condition is met.

TABLE 6-10 IS THE CONDITIONAL SKIP SET MET?
How many conditions were met? /
Condition Logic Type

All

At least one, but not all

None

AND

Yes. The set is met.

No. The set is not met.

No. The set is not met.

OR

Yes. The set is met.

Yes. The set is met.

No. The set is not met.

TABLE 6-11 CAN THE TARGET DOSE BE SKIPPED?
How many sets
were met?/
Set Logic Type

All

At least one, but not all

None

AND

Yes. The target dose can be skipped. The
target dose status is 'Skipped'.

No. The target dose cannot be skipped.

No. The target dose
cannot be skipped.

Logic Specification for ACIP Recommendations v4.6

Page 51 of 151

How many sets
were met?/
Set Logic Type

All

At least one, but not all

None

OR

Yes. The target dose can be skipped. The
target dose status is 'Skipped'.

Yes. The target dose can be skipped. The
target dose status is 'Skipped'.

No. The target dose
cannot be skipped.

6.3 EVALUATE FOR INADVERTENT VACCINE
Evaluate for inadvertent vaccine determines if the vaccine type of a vaccine dose administered was an
inadvertent administration due to the vaccine type that was administered.
The following process model, attribute table, Business Rule table and decision table, are used to evaluate for an
unallowable vaccine.

FIGURE 6-4 EVALUATE FOR AN INADVERTENT VACCINE PROCESS MODEL

TABLE 6-12 INADVERTENT VACCINE ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Vaccine dose administered

Vaccine Type

-

Supporting Data (inadvertent Vaccine)

Vaccine Type

-

TABLE 6-13 WAS THE VACCINE DOSE ADMINISTERED AN INADVERTENT ADMINISTRATION FOR THE TARGET
DOSE?
CONDITIONS

RULES

Is the vaccine type of the vaccine dose
administered one of the vaccine types
of an inadvertent vaccine for the target
dose?

OUTCOMES

Yes

No

Yes. The vaccine dose administered was an inadvertent
administration for the target dose. Target Dose Status is
'Not Satisfied'. Evaluation Status is 'Not Valid'. Evaluation
Reason is 'Inadvertent Administration'.

No. The vaccine dose
administered was not an
inadvertent administration for
the target dose.

6.4 EVALUATE AGE
Logic Specification for ACIP Recommendations v4.6

Page 52 of 151

Evaluate age validates the age at administration of a vaccine dose administered against a defined age range of
a target dose. In cases where a target dose does not specify age attributes, the age at administration is
considered “valid.”

FIGURE 6-5 EVALUATE AGE TIMELINE

The following process model, attribute table and decision table are used to evaluate age at administration.

FIGURE 6-6 EVALUATE AGE PROCESS MODEL

TABLE 6-14 AGE ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Patient

Date of Birth

-

Vaccine dose administered

Date Administered

-

Calculated date (CALCDTAGE-1)

Maximum Age Date

12/31/2999

Calculated date (CALCDTAGE-4)

Minimum Age Date

01/01/1900

Calculated date (CALCDTAGE-5)

Absolute Minimum Age Date

01/01/1900

TABLE 6-15 WAS THE VACCINE DOSE ADMINISTERED AT A VALID AGE?

Logic Specification for ACIP Recommendations v4.6

Page 53 of 151

CONDITIONS

RULES

Is the date
administered <
absolute minimum
age date?

Yes

No

No

No

Is the absolute
minimum age date ≤
date administered <
minimum age date?

No

Yes

No

No

Is the minimum age
date ≤ date
administered <
maximum age date?

No

No

Yes

No

Is the date
administered ≥
maximum age date?

No

No

No

Yes

No. The vaccine dose
administered was not
administered at a valid age
for the target dose.
Evaluation reason is 'Too
young'.

Yes. The vaccine dose
administered was
administered at a valid age
for the target dose.
Evaluation reason is
'Grace period'.

OUTCOMES

Yes. The vaccine
No. The vaccine dose
dose administered
administered was not
was administered at a administered at a valid age
valid age for the target for the target dose. It is
dose.
extraneous. Evaluation
reason is 'Too old'.

TABLE 6-16 EVALUATE AGE BUSINESS RULES
Business Rule ID

Business Rule

CALCDTAGE-1

A patient's maximum age date must be calculated as the patient's date of birth plus the maximum age.

CALCDTAGE-4

A patient's minimum age date must be calculated as the patient's date of birth plus the minimum age.

CALCDTAGE-5

A patient's absolute minimum age date must be calculated as the patient's date of birth plus the absolute
minimum age.

6.5 EVALUATE PREFERABLE INTERVAL
Evaluate preferable interval validates the date administered of a vaccine dose administered against defined
preferable interval(s) from previous vaccine dose(s) administered or other events. In cases where a target dose
does not specify preferable interval attributes, the interval is considered “valid.”
Preferable intervals can be measures in four different ways:
•
•
•

“From Immediate Previous Dose Administered Flag” requires the interval to be evaluated from the
immediate previous vaccine dose administered and is used in the majority of cases.
“From Target Dose # in Series” requires the interval to be evaluated from the date of the specified dose.
“From Most Recent Vaccine Type” requires the interval to be evaluated from the date of the most recently
administered dose of any of the specific vaccine types listed (e.g., this is used in Pneumococcal to ensure
proper spacing between the different intervals between PCV13 and PPSV23).

Logic Specification for ACIP Recommendations v4.6

Page 54 of 151

•

“From Relevant Observation Code” requires the interval to be evaluated from the date of a particular
patient observation (e.g. the interval for a dose of Pertussis vaccine is measured from the date of the
onset of pregnancy).

It is possible for a given dose to use multiple preferable interval types. For example, dose 3 of HepB and dose 3
of HPV, each have two preferable intervals. The first interval is from the immediate previous vaccine dose
administered. The second interval is from satisfied target dose 1 in each respective antigen series. Note that if
multiple intervals are specified, then all intervals must be satisfied in order for the dose to satisfy the interval
requirements.
Figure 6-7 provides the evaluation interval timeline used to define adjacent intervals by using from immediate
previous dose administered flag as the reference point.

FIGURE 6-7 EVALUATE INTERVAL ‘FROM IMMEDIATE PREVIOUS DOSE ADMINISTERED FLAG’ TIMELINE

Figure 6-8 illustrates the evaluation interval timeline used to define non-adjacent intervals by using from target
dose number in series as the reference point. This timeline is used only when from immediate previous dose
administered flag is “N”.

FIGURE 6-8 EVALUATE INTERVAL 'FROM TARGET DOSE NUMBER IN SERIES' TIMELINE
Logic Specification for ACIP Recommendations v4.6

Page 55 of 151

Figure 6-9 illustrates the evaluation interval timeline used to define most recent vaccine intervals by using from
most recent vaccine type as the reference point.

FIGURE 6-9 EVALUATE INTERVAL 'FROM MOST RECENT VACCINE TYPE' TIMELINE

Figure 6-10 illustrates the evaluation interval timeline used to define most recent vaccine intervals by using from
relevant observation code as the reference point.

FIGURE 6-10 EVALUATE INTERVAL 'FROM RELEVANT OBSERVATION CODE' TIMELINE

The following process model, attribute table, decision table, and business rule table are used to evaluate
preferable interval of a vaccine dose administered.

Logic Specification for ACIP Recommendations v4.6

Page 56 of 151

FIGURE 6-11 EVALUATE PREFERABLE INTERVAL PROCESS MODEL

TABLE 6-17 PREFERABLE INTERVAL ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Vaccine dose administered

Date Administered

-

Supporting Data

Preferable Interval elements

-

Calculated date (CALCDTINT-3)

Absolute Minimum Interval Date

01/01/1900

Calculated date (CALCDTINT-4)

Minimum Interval Date

01/01/1900

TABLE 6-18 DID THE VACCINE DOSE ADMINISTERED SATISFY THE PREFERABLE INTERVAL FOR THE TARGET
DOSE?
CONDITIONS

RULES

Is the date administered
< absolute minimum
interval date?

Yes

No

No

Is the absolute minimum
interval date ≤ date
administered < minimum
interval date?

No

Yes

No

Logic Specification for ACIP Recommendations v4.6

Page 57 of 151

CONDITIONS
Is the minimum interval
date ≤ date
administered?

OUTCOMES

RULES
No

No

Yes

No. The vaccine dose
administered did not satisfy the
preferable interval for the target
dose. Evaluation reason is 'Too
soon'.

Yes. The vaccine dose
administered satisfied the preferable
interval for the target dose. Evaluation
reason is 'Grace period'.

Yes. The vaccine dose
administered satisfied the
preferable interval for the target
dose.

Table 6-19 Evaluate Preferable Interval Business Rules
Business Rule ID

Business Rule

CALCDTINT-1

A patient's reference dose date for an interval must be calculated as the date administered of the most
immediate previous vaccine dose administered if all the following are true:
• the interval has a from immediate previous dose administered flag of 'Y'
• the vaccine dose administered has an evaluation status of 'Valid' or 'Not Valid'
• the vaccine dose administered is not an inadvertent administration.

CALCDTINT-2

A patient's reference dose date for an interval must be calculated as the date administered of the vaccine
dose administered that satisfies the target dose with the same target dose number as the from target dose
number in series if all the following are true for the interval:
• from immediate previous dose administered flag is 'N'
• from target dose number in series is not 'N/A'.

CALCDTINT-3

A patient's absolute minimum interval date must be calculated as the patient's reference dose date plus the
absolute minimum interval.

CALCDTINT-4

A patient's minimum interval date must be calculated as the patient's reference dose date plus the minimum
interval.

CALCDTINT-8

A patient's reference dose date for an interval must be calculated as the date administered of the most recent
vaccine dose administered that is the same vaccine type as the from most recent vaccine type if all the
following are true for the interval:
• from immediate previous dose administered flag is 'N'
• from most recent vaccine type is not 'N/A'
• the vaccine dose administered is not an inadvertent administration.

CALCDTINT-9

A patient's reference dose date for an interval must be calculated as the observation date of the most recent
active patient observation if all the following are true for the interval:
• from immediate previous dose administered flag is 'N'
• from relevant observation code is not 'N/A'.

6.6 EVALUATE ALLOWABLE INTERVAL
Evaluate allowable interval validates the date administered of a vaccine dose administered against defined
allowable interval(s) from previous vaccine dose(s) administered. In rare cases, intervals can be applied which
are either abnormally early – usually specified in ACIP footnotes or subsequent clarifications – or intervals which
differ following a not valid administration.

Logic Specification for ACIP Recommendations v4.6

Page 58 of 151

In cases where a target dose does not specify allowable interval attributes, evaluate allowable interval cannot
be used to validate a vaccine dose administered. To avoid a false validation, the allowable interval should be
considered “not valid” in these cases.
The figure below provides evaluate allowable interval timeline used to define all adjacent intervals by using from
immediate previous dose administered flag as the reference dose.

FIGURE 6-12 EVALUATE ALLOWABLE INTERVAL 'FROM IMMEDIATE PREVIOUS DOSE ADMINISTERED FLAG'
TIMELINE

The figure below illustrates evaluate allowable interval timeline used to define all non-adjacent intervals by using
from target dose number in series as the reference dose.

FIGURE 6-13 EVALUATE ALLOWABLE INTERVAL 'FROM TARGET DOSE NUMBER IN SERIES' TIMELINE

The following process model, attribute table, decision table, and business rule table are used to evaluate interval
of a vaccine dose administered.

Logic Specification for ACIP Recommendations v4.6

Page 59 of 151

FIGURE 6-14 EVALUATE ALLOWABLE INTERVAL PROCESS MODEL

TABLE 6-20 ALLOWABLE INTERVAL ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Vaccine dose administered

Date Administered

-

Supporting Data

Allowable Interval elements

-

Calculated date (CALCDTINT-3)

Absolute Minimum Interval Date

01/01/1900

TABLE 6-21 DID THE VACCINE DOSE ADMINISTERED SATISFY THE ALLOWABLE INTERVAL FOR THE TARGET
DOSE?
CONDITIONS

RULES

Is the date administered <
absolute minimum interval
date?

OUTCOMES

Yes

No

No. The vaccine dose administered did not satisfy the Yes. The vaccine dose administered satisfied
allowable interval for the target dose. Evaluation
the allowable interval for the target dose.
Reason is 'Too soon'.

Logic Specification for ACIP Recommendations v4.6

Page 60 of 151

TABLE 6-22 EVALUATE ALLOWABLE INTERVAL BUSINESS RULES
Business Rule ID

Business Rule

CALCDTINT-1

A patient's reference dose date for an interval must be calculated as the date administered of the most
immediate previous vaccine dose administered if all the following are true:
• The interval has a from immediate previous dose administered flag of 'Y'
• The vaccine dose administered has an evaluation status of 'Valid' or 'Not Valid'
• The vaccine dose administered is not an inadvertent administration.

CALCDTINT-2

A patient's reference dose date for an interval must be calculated as the date administered of the vaccine
dose administered that satisfies the target dose with the same target dose number as the from target dose
number in series if all the following are true for the interval:
• From immediate previous dose administered flag is 'N'
• From target dose number in series is not 'n/a'

CALCDTINT-3

A patient's absolute minimum interval date must be calculated as the patient's reference dose date plus the
absolute minimum interval.

6.7 EVALUATE VACCINE CONFLICT
Evaluate vaccine conflict validates the date administered of a vaccine dose administered against previous
administered vaccines to ensure proper spacing between administrations. This covers live virus vaccine conflicts
as well as non-live virus vaccine conflicts. Many vaccines do not have any conflict with each other. Therefore, if
no vaccine Supporting Data exists for the vaccine type of the vaccine dose administered being evaluated, the
vaccine dose administered is not in conflict with any other vaccine dose administered.

FIGURE 6-15 EVALUATE VACCINE CONFLICT TIMELINE

The following process model, attribute table, decision tables, and business rule table are used to evaluate for a
vaccine conflict.

Logic Specification for ACIP Recommendations v4.6

Page 61 of 151

FIGURE 6-16 EVALUATE VACCINE CONFLICT PROCESS MODEL

TABLE 6-23 VACCINE CONFLICT ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Vaccine dose administered

Date Administered

-

Vaccine dose administered

Vaccine Type

-

Supporting Data

Live Virus Conflicts

-

Calculated date (CALCDTCONFLICT-1)

Conflict Begin Interval Date

-

Calculated date (CALCDTCONFLICT-2)

Conflict End Interval Date

-

Implementer Note
This section of the logic specification has been considerable refined in version 4.4 to be less process driven and more
business rule based. The outcome should be functionally equivalent to previous versions of the logic specification. One
important note is in the terminology used in the logic specification and the supporting data. In an effort to not break
existing implementations who auto-consume the supporting data, we have not updated headings or XML tags. These will
be migrated in 5.0 to use the same terms across the logic specification and the supporting data.
In the meantime, here are the terms in this version of the logic specification mapped to existing supporting data terms.
Logic Specification Term
Conflicting Vaccine Type
Impacted Vaccine Type

Supporting Data Term
Previous Vaccine Type
Current Vaccine Type

TABLE 6-24 VACCINE CONFLICT BUSINESS RULES

Logic Specification for ACIP Recommendations v4.6

Page 62 of 151

Business Rule ID

Business Rule

CALCDTCONFLICT-1

The conflict begin interval date for a previous vaccine dose administered must be calculated as the date
administered of the previous vaccine dose administered plus the conflict begin interval of a vaccine type
conflict where all the following are true:

•
•
CALCDTCONFLICT-2

The conflict end interval date for a previous vaccine dose administered must be calculated as one of the
following:

•

•

CONFLICT-3

The vaccine type of the current vaccine dose administered is an impacted vaccine type.
The vaccine type of the previous vaccine dose administered is a conflicting vaccine type for the
impacted vaccine type.

the date administered of the previous vaccine dose administered plus the minimum conflict end
interval of a vaccine type conflict if all the following are true:
o The vaccine type of the current vaccine dose administered is an impacted vaccine type.
o The vaccine type of the previous vaccine dose administered is a conflicting vaccine type
for the impacted vaccine type.
o The previous vaccine dose administered has one of the following:
▪ an evaluation status of 'Valid'
▪ no evaluation status.
the date administered of the previous vaccine dose administered plus the conflict end interval of a
vaccine type conflict if all the following are true:
o The vaccine type of the current vaccine dose administered is an impacted vaccine type.
o The vaccine type of the previous vaccine dose administered is a conflicting vaccine type
for the impacted vaccine type.
o The previous vaccine dose administered has an evaluation status.
o The previous vaccine dose administered does not have an evaluation status of 'Valid'.

A current vaccine dose administered must be considered an impacted vaccine dose administered if all the
following are true for the date administered of the current vaccine dose administered:

•
•

It is on or after the conflict begin interval date.
It is before the conflict end interval date.

6.8 EVALUATE FOR PREFERABLE VACCINE
Evaluate for preferable vaccine validates the vaccine of a vaccine dose administered against the list of preferable
vaccines.
Figure 6-17 depicts a patient who received a preferable vaccine while Figure 6-18 depicts a patient who did not
receive a preferable vaccine.

Logic Specification for ACIP Recommendations v4.6

Page 63 of 151

FIGURE 6-17 PATIENT RECEIVED A PREFERABLE VACCINE

FIGURE 6-18 PATIENT DID NOT RECEIVE A PREFERABLE VACCINE

It should be noted that volume is sparsely populated and tracked differently in most systems. Therefore, volume
will not be used to evaluate the validity of a vaccine dose administered. However, it will be provided as an
evaluation reason that less than sufficient volume was administered.
The following process model, attribute table, decision table, and business rule table are used to evaluate for a
preferable vaccine.
Logic Specification for ACIP Recommendations v4.6

Page 64 of 151

FIGURE 6-19 EVALUATE FOR A PREFERABLE VACCINE PROCESS MODEL

TABLE 6-25 PREFERABLE VACCINE ADMINISTERED ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Vaccine dose administered

Date Administered

-

Vaccine dose administered

Volume

-

Vaccine dose administered

Trade Name

-

Supporting Data

Preferable Vaccine elements

-

Calculated date (CALCDTPREF-1)

Preferable Vaccine Type Begin Age Date

01/01/1900

Calculated date (CALCDTPREF-2)

Preferable Vaccine Type End Age Date

12/31/2999

TABLE 6-26 WAS THE VACCINE DOSE ADMINISTERED A PREFERABLE VACCINE FOR THE TARGET DOSE?
CONDITIONS
Is the vaccine type of
the vaccine dose
administered the
same as the vaccine
type of a preferable
vaccine for the target
dose?

RULES
Yes

Yes

Logic Specification for ACIP Recommendations v4.6

No

Yes

Yes

Page 65 of 151

CONDITIONS

RULES

Is the preferable
vaccine type begin
age date ≤ date
administered <
preferable vaccine
type end age date?

Yes

Yes

-

No

Yes

Is the trade name of
the vaccine dose
administered the
same as the trade
name of the
preferable vaccine for
the target dose?

Yes

Yes

-

-

No

Is the volume of the
vaccine dose
administered ≥ the
volume of the
preferable vaccine for
the target dose?

Yes

No

-

-

-

No. The vaccine
dose
administered was
not a preferable
vaccine for the
target dose.

No. The vaccine dose
administered was not a
preferable vaccine for
the target dose. It was
administered out of the
recommended age
range for the preferable
vaccine.

No. The vaccine
dose administered
was not a
preferable vaccine
for the target dose.
The trade name of
the vaccine dose
administered is not
the same as the
trade name of the
preferable vaccine.

OUTCOMES

Yes. The vaccine Yes. The vaccine dose
dose
administered was a
administered was preferable vaccine for
a preferable
the target dose.
vaccine for the
Evaluation Reason is
target dose.
'Volume administered is
less than recommended
volume'.

TABLE 6-27 PREFERABLE VACCINE BUSINESS RULES
Business Rule ID

Business Rule

CALCDTPREF-1

A patient's preferable vaccine type begin age date must be calculated as the patient's date of birth plus the
vaccine type begin age of a preferable vaccine.

CALCDTPREF-2

A patient's preferable vaccine type end age date must be calculated as the patient's date of birth plus the
vaccine type end age of a preferable vaccine.

6.9 EVALUATE FOR ALLOWABLE VACCINE
Evaluate for allowable vaccine validates the vaccine of a vaccine dose administered against the list of allowable
vaccines.
Figure 6-20 depicts a patient who received an allowable vaccine while Figure 6-21 depicts a patient who did not
receive an allowable vaccine.
Logic Specification for ACIP Recommendations v4.6

Page 66 of 151

FIGURE 6-20 PATIENT RECEIVED AN ALLOWABLE VACCINE

FIGURE 6-21 PATIENT DID NOT RECEIVE AN ALLOWABLE VACCINE

The following process model, attribute table, decision table, and business rule table are used to evaluate for an
allowable vaccine.

Logic Specification for ACIP Recommendations v4.6

Page 67 of 151

FIGURE 6-22 EVALUATE FOR AN ALLOWABLE VACCINE PROCESS MODEL

TABLE 6-28 ALLOWABLE VACCINE ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Vaccine dose administered

Date Administered

-

Vaccine dose administered

Vaccine Type

-

Supporting data

Allowable Vaccine elements

-

Calculated date (CALCDTALLOW-1)

Allowable Vaccine Type Begin Age Date

01/01/1900

Calculated date (CALCDTALLOW-2)

Allowable Vaccine Type End Age Date

12/31/2999

TABLE 6-29 WAS THE VACCINE DOSE ADMNINSTERED AN ALLOWABLE VACCINE FOR THE TARGET DOSE?
CONDITIONS

RULES

Is the vaccine type of the vaccine
dose administered the same as
the vaccine type of an allowable
vaccine for the target dose?

Yes

No

Yes

Is the allowable vaccine type begin
age date ≤ date administered <
allowable vaccine type end age
date?

Yes

-

No

Logic Specification for ACIP Recommendations v4.6

Page 68 of 151

CONDITIONS

RULES

OUTCOMES

Yes. The vaccine dose
administered was an
allowable vaccine for the
target dose.

No. The vaccine dose
administered was not an
allowable vaccine for the
target dose.

No. The vaccine dose administered was
not an allowable vaccine for the target
dose. It was administered out of the
recommended age range for the allowable
vaccine.

TABLE 6-30 ALLOWABLE VACCINE BUSINESS RULES
Business Rule ID

Business Rule

CALCDTALLOW-1

A patient's allowable vaccine type begin age date must be calculated as the patient's date of birth plus the
vaccine type begin age of an allowable vaccine.

CALCDTALLOW-2

A patient's allowable vaccine type end age date must be calculated as the patient's date of birth plus the
vaccine type end age of an allowable vaccine.

6.10 SATISFY TARGET DOSE
Satisfy target dose uses the results from the previous evaluation sections as conditions to determine if the target
dose is satisfied.
The following processing model and decision table are used to determine if the target dose was satisfied.

FIGURE 6-23 SATISFY TARGET DOSE PROCESS MODEL

TABLE 6-31 WAS THE TARGET DOSE SATISFIED?
CONDITIONS

RULES

Was the vaccine
dose administered at
a valid age for the
target dose?

Yes

Extraneous

No

-

-

-

Did the vaccine dose
administered satisfy
all preferable
intervals or all
allowable intervals
for the target dose?

Yes

-

-

No

-

-

Logic Specification for ACIP Recommendations v4.6

Page 69 of 151

CONDITIONS

RULES

Is the current
vaccine dose
administered an
impacted vaccine
dose administered?

No

-

-

-

Yes

-

Was the vaccine
dose administered a
preferable vaccine or
an allowable vaccine
for the target dose?

Yes

-

-

-

-

No

Yes. The target
dose status is
'Satisfied'.
Evaluation
status is 'Valid'
with evaluation
reasons.

No. The target
dose status is 'Not
Satisfied'.
Evaluation status
is 'Extraneous'
with evaluation
reasons.

No. The target
dose status is
'Not Satisfied'.
Evaluation
status is 'Not
Valid' with
evaluation
reasons.

No. The target
dose status is
'Not Satisfied'.
Evaluation
status is 'Not
Valid' with
evaluation
reasons.

No. The target
dose status is
'Not Satisfied'.
Evaluation
status is 'Not
Valid' with
evaluation
reasons.

No. The target
dose status is
'Not Satisfied'.
Evaluation
status is 'Not
Valid' with
evaluation
reasons.

OUTCOMES

Logic Specification for ACIP Recommendations v4.6

Page 70 of 151

7 FORECAST DATES AND REASONS
A CDS engine uses a patient’s medical and vaccine history to forecast immunization due dates for a relevant
patient series. It is also possible the patient would not be recommended additional doses. In that case, the
outcome of the forecast will be an appropriate status (e.g., complete, immune, contraindicated) and no dates will
be generated. This chapter identifies specific business rules that are used by a CDS engine to forecast the next
target dose. The major steps involved in this process are listed in the table below.
TABLE 7-1 FORECAST DATES AND REASONS PROCESS STEPS
Section

Activity

Goal

7.1

Evaluate Conditional Skip

The goal of this step is to determine if the target dose can be skipped due to a
patient’s age at assessment or immunization history.

7.2

Determine Evidence Of Immunity

The goal of this step is to determine if the patient has evidence of immunity.

7.3

Determine Contraindications

The goal of this step is to determine if any patient series are contraindicated.

7.4

Determine Forecast Need

The goal of this step is to determine if the patient should receive another dose.

7.5

Generate Forecast Dates And
Recommended Vaccines

The goal of this step is to generate forecast dates for the next target dose.

7.6

Validate Recommendation

The goal of this step is to ensure the generated forecast will be logical when the
patient arrives for their next visit (e.g., will they no longer need the dose).

The next figure provides an illustration of the forecast dates and reasons process.

Logic Specification for ACIP Recommendations v4.6

Page 71 of 151

FIGURE 7-1 FORECAST DATES AND REASON PROCESS MODEL

7.1 EVALUATE CONDITIONAL SKIP
Evaluate Conditional Skip addresses times when a target dose can be skipped. A dose should be considered
necessary unless it is determined that it can be skipped. The most common scenarios for skipping a dose are:
•
•
•

Catch-up doses where the patient is current with their administrations and does not need to catch-up
The patient is behind schedule and the total number of doses needed to satisfy the patient series can be
reduced
The previously administered dose(s) negates the need for the current target dose

Logic Specification for ACIP Recommendations v4.6

Page 72 of 151

Only Conditional Skip Instances with a context of Forecast or Both should be used. In cases where a target dose
does not specify Conditional Skip attributes, the target dose cannot be skipped.
The process model, attribute table, business rules, and decision tables are used to determine if the target dose
can be skipped is the same as described in Chapter 6.2.

7.2 DETERMINE EVIDENCE OF IMMUNITY
Determine evidence of immunity assesses the patient’s profile to determine if the patient is already potentially
immune to the target disease, negating the need for additional doses. A patient may be considered immune due
to their clinical history or if they were born before a defined date for the given target disease. For example, for
measles, a patient is considered immune if they have a clinical finding of “Measles immune” or if they were born
before 01/01/1957. Additional patient attributes, such as occupation or pregnancy status, may supersede the
birth date logic.

FIGURE 7-2 EVIDENCE OF IMMUNITY PROCESS MODEL

TABLE 7-2 IMMUNITY ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Patient

Date of Birth

-

Patient

Country of Birth

-

Patient

Evidence of Immunity

Supporting Data

Immunity elements

-

TABLE 7-3 DOES THE PATIENT HAVE EVIDENCE OF IMMUNITY?
CONDITIONS

RULES

Does the patient history
contain one of the immunity
guidelines?

Yes

No

No

No

No

Is the patient's date of birth
< the immunity birth date?

-

Yes

Yes

Yes

No

Does this patient have an
immunity exclusion
condition?

-

Yes

No

No

-

Is the patient's country of
birth the same as the
immunity country of birth?

-

-

Yes

No

Logic Specification for ACIP Recommendations v4.6

-

Page 73 of 151

CONDITIONS

OUTCOMES

RULES

Yes. The patient
has evidence of
immunity.

No. The patient
does not have
evidence of
immunity.

Yes. The patient
has evidence of
immunity.

No. The patient
does not have
evidence of
immunity.

No. The patient
does not have
evidence of
immunity.

7.3 DETERMINE CONTRAINDICATIONS
Determine contraindications assesses if any or all series for an antigen are contraindicated for the patient.
Contraindications may be applied at either the antigen or vaccine level.
Given the complex nature of contraindications, it may not always be possible to conclusively determine if a
contraindication applies to a patient. To minimize missed doses, in the case where a contraindication cannot be
definitively determined to be relevant for a patient, the contraindication will not be applied, but a notification
should be made to a clinician alerting them to the presence of the possible contraindication which could not be
resolved.
The following process model is used to assess contraindications.

FIGURE 7-3 CONTRAINDICATION PROCESS MODEL

TABLE 7-4 DETERMINE CONTRAINDICATION ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Patient

Active Patient Observations

-

Patient

Adverse Reactions

-

Supporting Data

Contraindication elements

-

Processing data

Assessment Date

current date

Calculated date (CALCDTCI-1)

Contraindication Begin Age Date

01/01/1900

Calculated date (CALCDTCI-2)

Contraindication End Age Date

12/31/2999

An antigen contraindication prevents all relevant patient series for that antigen from recommending further
vaccination for the patient. That is, no relevant patient series for the antigen should forecast dates for the patient.
The patient series status will be contraindicated for each relevant patient series.

Logic Specification for ACIP Recommendations v4.6

Page 74 of 151

FIGURE 7-4 ANTIGEN CONTRAINDICATION PROCESS MODEL

TABLE 7-5 DOES THE ANTIGEN CONTRAINDICATION APPLY TO THE PATIENT?
CONDITIONS

RULES

Does the antigen
contraindication
describe any active
patient
observations?

Yes

No

No

Unknown

-

Does the antigen
contraindication
describe any
adverse reactions?

No

Yes

No

Unknown

-

Is the
contraindication
begin age date ≤
assessment date <
contraindication end
age date?

Yes

Yes

Yes

Yes

No

Logic Specification for ACIP Recommendations v4.6

Page 75 of 151

CONDITIONS
OUTCOMES

RULES
Yes. The antigen
contraindication
applies to the
patient.

Yes. The antigen
contraindication
applies to the
patient.

No. The antigen
contraindication
does not apply to
the patient.

No. It could not be
determined if the antigen
contraindication applies to
the patient; however, the
Contraindication Text
Description should be made
available to the clinician for
manual determination.

No. The antigen
contraindication
does not apply to
the patient.

A vaccine contraindication eliminates a specific vaccine from being forecast for the patient.

FIGURE 7-5 VACCINE CONTRAINDICATION PROCESS MODEL

TABLE 7-6 DOES THE VACCINE CONTRAINDICATION APPLY TO THE PATIENT?
Logic Specification for ACIP Recommendations v4.6

Page 76 of 151

CONDITIONS

RULES

Does the vaccine
contraindication
describe any active
patient observations?

Yes

Yes

No

No

No

-

Unknown

Does the vaccine
contraindication
describe any adverse
reactions?

No

No

Yes

Yes

No

-

Unknown

Is the
contraindication
begin age date ≤
assessment date <
contraindication end
age date?

Yes

Yes

Yes

Yes

-

No

Yes

Is the vaccine type of
the preferable
vaccine one of the
contraindicated vacci
ne types for the
contraindication?

Yes

No

Yes

No

-

-

Yes

Yes. The
vaccine
contraindicati
on applies to
the patient.

No. The
vaccine
contraindicati
on does not
apply to the
patient.

Yes. The
vaccine
contraindicati
on applies to
the patient.

No. The
vaccine
contraindicati
on does not
apply to the
patient.

No. The
vaccine
contraindicati
on does not
apply to the
patient.

No. The
vaccine
contraindicati
on does not
apply to the
patient.

No. It could
not be
determined if
the vaccine
contraindicatio
n applies to
the patient;
however, the
Contraindicati
on Text
Description
should be
made
available to
the clinician
for manual
determination.

OUTCOMES

A relevant patient series should not be forecast if either an antigen contraindication exists, or if all preferable
vaccines are contraindicated.
TABLE 7-7 IS THE RELEVANT PATIENT SERIES A CONTRAINDICATED PATIENT SERIES?
CONDITIONS
Are there any antigen contraindication that
apply to the patient?

Logic Specification for ACIP Recommendations v4.6

RULES
Yes

No

No

Page 77 of 151

CONDITIONS

RULES

Do all preferable vaccines for the relevant
patient series have at least one vaccine
contraindication that applies to the patient?

OUTCOMES

-

Yes

No

Yes. The relevant patient
series is a contraindicated
patient series.

Yes. The relevant patient
series is a contraindicated
patient series.

No. The relevant patient
series is not a
contraindicated patient
series.

TABLE 7-8 DETERMINE CONTRAINDICATION BUSINESS RULES
Business Rule ID

Business Rule

CALCDTCI-1

A patient's contraindication begin age date must be calculated as the patient's date of birth plus the
contraindication begin age of a contraindication.

CALCDTCI-2

A patient's contraindication end age date must be calculated as the patient's date of birth plus the
contraindication end age of a contraindication.

7.4 DETERMINE FORECAST NEED
Determine forecast need determines if there is a need to forecast dates. This involves reviewing patient data,
antigen administered records, and patient series. This is a prerequisite before a CDS engine can produce
forecast dates and reasons.
The following process model, attribute table, and decision table are used to determine the need to generate
forecast dates.

FIGURE 7-6 DETERMINE FORECAST NEED PROCESS MODEL

TABLE 7-9 DETERMINE FORECAST NEED ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Immunization history

Vaccine Dose(s) Administered

-

Relevant Patient series

Target Dose Statuses

-

Supporting Data (Seasonal Recommendation)

Seasonal Recommendation End Date

12/31/2999

Section 7.2 Outcome

Evidence of Immunity

No evidence of immunity

Section 7.3 Outcome

Contraindicated Patient Series

The relevant patient series is
NOT a contraindicated patient
series.

Logic Specification for ACIP Recommendations v4.6

Page 78 of 151

Attribute Type

Attribute Name

Assumed Value if Empty

Runtime data

Assessment Date

current date

Calculated date (CALCDTAGE-1)

Maximum Age Date

12/31/2999

Calculated date (FORECASTDTCAN-1)

Candidate Earliest Date

12/31/2999

TABLE 7-10 SHOULD THE PATIENT RECEIVE ANOTHER TARGET DOSE?
CONDITIONS

RULES

Does the patient
have at least one
target dose with
a target dose
status of 'Not
Satisfied'?

Yes

No

No

-

-

-

-

-

Does the patient
have at least one
target dose with
a target dose
status of
'Satisfied'?

-

Yes

No

-

-

-

-

-

Does the patient
have evidence of
immunity?

No

-

-

Yes

-

-

-

-

Is the relevant
patient series a
contraindicated
patient series?

No

-

-

-

Yes

-

-

-

Is the
assessment date
≤ the seasonal
recommendation
end date?

Yes

-

-

-

-

No

-

-

Is the
assessment date
< the maximum
age date?

Yes

-

-

-

-

-

No

-

Is the candidate
earliest date <
the maximum
age date?

Yes

-

-

-

-

-

-

No

Logic Specification for ACIP Recommendations v4.6

Page 79 of 151

CONDITIONS
OUTCOMES

RULES
Yes. The
patient
should
receive
another
dose.

No. The
patient
should not
receive
another
dose.

No. The patient
should not
receive another
dose.

Patient
Series
Status is
'Not
Complete'

Patient
Series
Status is
Forecast reason
'Complete' is 'Not
recommended
Forecast
at this time due
reason is to past
'Patient
immunization
series is
history'
complete'.

Patient series
status is 'Not
Recommended'

No. The
patient
should not
receive
another
dose.
Patient
Series
Status is
'Immune'

No. The patient
should not
receive another
dose.

No. The patient
should not
receive another
dose.

Patient Series
Patient Series
Status is
Status is 'Not
'Contraindicated' Recommended'

No. The
patient
should
not
receive
another
dose.

No. The
patient
should not
receive
another
dose.
Patient
Series
Status is
'Aged Out'

Patient
Forecast reason Forecast reason Series
is 'Patient has a is 'Past seasonal Status is
contraindication'. recommendation 'Aged Out' Forecast
Forecast
end date'.
reason is
reason is
Forecast 'Patient is
'Patient
reason is unable to
has
'Patient
finish the
evidence
has
series
of
exceeded prior to
immunity'.
the
the
maximum maximum
age'
age'.

TABLE 7-11 DETERMINE FORECAST NEED BUSINESS RULES
Business Rule ID

Business Rule

CALCDTAGE-1

A patient's maximum age date must be calculated as the patient's date of birth plus the maximum age.

FORECASTDTCAN-1

The candidate earliest date of a patient series forecast must be the latest of the following dates:
• Minimum age date
• Latest of all minimum interval dates
• Latest of all forecast conflict end dates
• Seasonal recommendation start date
• Latest of all dates administered of any inadvertent administration being evaluated against a target
dose that is part of a patient series that is the basis of the patient series forecast
• Date administered of the most recent vaccine dose administered being evaluated against a target
dose that is part of a patient series that is the basis of the patient series forecast.

7.5 GENERATE FORECAST DATES AND RECOMMENDED VACCINES
Generate forecast dates and recommend vaccines determines the forecast dates for the next target dose and
identifies one or more recommended vaccines if the target dose warrants specific vaccine recommendations.
Additional detail, such as administrative guidance for providers may also be included. The forecast dates are
generated based on the patient’s immunization history. If the patient has not adhered to the preferred schedule,
then the forecast dates are adjusted to provide the best dates for the next target dose. Figure 7-7 below provides
an illustration of how forecast dates appear on the timeline.

Logic Specification for ACIP Recommendations v4.6

Page 80 of 151

FIGURE 7-7 FORECAST DATES TIMELINE

The following process model, attribute table, and business rule table are used to generate forecast dates. If an
attribute value is empty, then the date calculations will remain empty. No assumptions will be made for the
attribute.

FIGURE 7-8 GENERATE FORECAST DATES AND RECOMMENDED VACCINE PROCESS MODEL

TABLE 7-12 GENERATE FORECAST DATE AND RECOMMENDED VACCINE ATTRIBUTES
Attribute Type

Attribute Name

Assumed Value if Empty

Calculated date (CALCDTAGE-4)

Minimum Age Date

-

Calculated date (CALCDTAGE-3)

Earliest Recommended Age Date

-

Calculated date (CALCDTAGE-2)

Latest Recommended Age Date

-

Calculated date (CALCDTAGE-1)

Maximum Age Date

-

Calculated date (CALCDTINT-4)

Minimum Interval Date(s)

-

Calculated date (CALCDTINT-5)

Earliest Recommended Interval Date(s)

-

Calculated date (CALCDTINT-6)

Latest Recommended Interval Date(s)

-

Calculated date (CALCDTLIVE-4)

Latest Conflict End Interval Date

-

Supporting Data (Seasonal
Recommendation)

Seasonal Recommendation Start Date

01/01/1900

Supporting Data (Preferable Vaccine)

Vaccine Type (CVX)

-

Supporting Data (Preferable Vaccine)

Forecast Vaccine Type Flag

N

Logic Specification for ACIP Recommendations v4.6

Page 81 of 151

TABLE 7-13 GENERATE FORECAST DATE AND RECOMMENDED VACCINE BUSINESS RULES
Business Rule ID

Business Rule

FORECASTDT-1

The earliest date of a patient series forecast made from a relevant patient series must be the candidate
earliest date.

FORECASTDT-2

The unadjusted recommended date of a patient series forecast must be one of the following:
• The earliest recommended age date.
• The latest of all earliest recommended interval dates if there is no earliest recommended age
date.
• The earliest date of the patient series forecast if there is no earliest recommended age date or
earliest recommended interval date.

FORECASTDT-3

The unadjusted past due date of a patient series forecast must be one of the following:
• The latest recommended age date minus 1 day.
• The latest of all latest recommended interval dates minus 1 day if there is no latest recommended
age date.
• Blank if there is no latest recommended age date or latest recommended interval date.

FORECASTDT-4

The latest date of a patient series forecast must be one of the following:
• The maximum age date minus 1 day if there is a maximum age date.
• Blank if there is no maximum age date.

FORECASTDT-5

The adjusted recommended date of a patient series forecast must be one of the following:
• The earliest date of the patient series forecast.
• The unadjusted recommended date of the patient series forecast if it is after the earliest date.

FORECASTDT-6

The adjusted past due date of a patient series forecast must be one of the following:
• The later of the earliest date of the patient series forecast and the unadjusted past due date of the
patient series forecast if there is an unadjusted past due date.
• Blank if there is no unadjusted past due date.

FORECASTGUIDANCE- Administrative guidance included in a forecast made for a patient must include all the following:
1
• Administrative guidance pertaining to any antigen series that defines the regimen for a
recommended antigen.
• Administrative guidance pertaining to any indication for which there is an active patient
observation for the patient.
• Administrative guidance pertaining to any contraindication for which there is an active patient
observation for the patient.
FORECASTRECVAC-1

A series dose vaccine must be considered a recommended series dose vaccine for a patient series forecast
if all the following are true:
• The series dose vaccine is a preferable vaccine.
• The forecast vaccine type flag of the series dose vaccine is 'Y'
• There is no vaccine contraindication involving the vaccine type that is used for the series dose
vaccine.
• At least one of the following is true:
o The earliest date of the patient series forecast is on or after the preferable vaccine type
begin age date and before the preferable vaccine type end age date of the series dose
vaccine.
o The adjusted recommended date of the patient series forecast is on or after the
preferable vaccine type begin age date and before the preferable vaccine type end age
date of the series dose vaccine.

Logic Specification for ACIP Recommendations v4.6

Page 82 of 151

Business Rule ID

Business Rule

FORECASTDN-1

The forecast dose number for a patient series forecast must be calculated as one of the following:
• The count of all target doses plus 1 where all the following are true:
o The target dose is part of the relevant patient series.
o The target dose has a target dose status of 'Satisfied.'
o There is no seasonal recommendation start date for the series dose that is tracked by
the target dose.
• The count of all target doses plus 1 where all the following are true:
o The target dose is part of the relevant patient series.
o The target dose has a target dose status of 'Satisfied.'
o There is a seasonal recommendation start date for the series dose that is tracked by the
target dose.
o The date administered of the vaccine dose administered evaluated by the target dose is
on or after the seasonal recommendation start date.

7.6 VALIDATE RECOMMENDATION
Validation Recommendation interrogates the forecasted earliest date to ensure the forecast makes logical sense.
Conditional Skip is used to determine if a forecast is illogical and thus in need of a complete re-forecasting.
The forecasted dates are beyond the conditional skip requirements of the target dose being forecasted
resulting in a different forecast when the patient returns for vaccination. To prevent erroneous
recommendations, this section prospectively ensures the recommendation remains valid at the earliest date. If
the recommendation is found to be invalid, re-forecasting for the next target dose is required.
• For example, a patient is behind on Hib and has just received a first dose at 11 months and 1 week of
age. The patient is then recommended for a catch-up dose in four weeks, shortly after the 12-month
mark. However, upon returning to the provider office four weeks later, the freshly updated forecast skips
the previously forecasted target dose and now forecasts the patient return 8 weeks after the previous
dose.

FIGURE 7-9 VALIDATE RECOMMENDED DOSE PROCESS MODEL

7.6.1

Conditional Skip

The process model, attribute table, and decision table are used to determine if the target dose can be skipped
is the same as described in Chapter 6.2. Only Conditional Skip Instances with a context of Forecast or Both
should be used. In cases where a target dose does not specify Conditional Skip attributes, the target dose cannot
be skipped. In CONDSKIP-2, the Earliest Date is used.

Logic Specification for ACIP Recommendations v4.6

Page 83 of 151

8 SELECT BEST PATIENT SERIES
Select Best Patient Series involves reviewing all potential patient series which might satisfy the goals of an
antigen and determining the one or more revelant patient series which best fits the patient needs based on
several important factors.
The basic steps of this process are listed in table 8-1. Process steps 8.1 through 8.7 are repeated for each series
group to identify one prioritized patient series per series group. Process step 8.8 is then used to determing which
prioritized patient series are selected as a best patient series. In some cases, the prioritized patient series from
one series group may negate the need for the prioritized patient series from another equivalent series group.
However, in other cases, multiple prioritized patient series may be needed to fully protect the patient.
TABLE 8-1 SELECT BEST PATIENT SERIES PROCESS STEPS
Section

Activity

Goal

8.1

Pre-Filter Patient Series

The goal of this step is to determine which relevant patient series should be
excluded and which should be considered a scorable patient series.

8.2

Identify One Prioritized Patient Series

The goal of this step is to determine if one scorable patient series is superior to
the other scorable patient series for each series group.

8.3

Classify Scorable Patient Series

The goal of this step is to classify where the patient is in the overall path to
immunity and pass those scorable patient series on to the next step. Only those
scorable patient series with the most likely chance to be considered the best
are retained for scoring.

8.4

Complete Patient Series

The goal of this step is to apply the proper scoring business rules based on
results of the Classify Scorable Patient Series step. The scoring business rules
will determine the prioritized patient series. Scoring business rules are specific
to where the patient is in the overall path to immunity. The complete patient
series scoring business rules look at factors important when scorable patient
series are complete. Similarly, in-process patient series scoring business rules
and no valid doses scoring business rules look at factors important to their
respective situation. For any given Series Group, only one set of these scoring
business rules will be applied to each scorable patient series as determined by
Classify Scorable Patient Series.

8.5

In-Process Patient Series

The goal of this step is to apply the proper scoring business rules based on
results of the Classify Scorable Patient Series step. The scoring business rules
will determine the prioritized patient series. Scoring business rules are specific
to where the patient is in the overall path to immunity. The complete patient
series scoring business rules look at factors important when scorable patient
series are complete. Similarly, in-process patient series scoring business rules
and no valid doses scoring business rules look at factors important to their
respective situation. For any given Series Group, only one set of these scoring
business rules will be applied to each scorable patient series as determined by
the Classify Scorable Patient Series.

Logic Specification for ACIP Recommendations v4.6

Page 84 of 151

Section

Activity

Goal

8.6

No Valid Doses

The goal of this step is to apply the proper scoring business rules based on
results of the Classify Scorable Patient Series step. The scoring business rules
will determine the prioritized patient series. Scoring business rules are specific
to where the patient is in the overall path to immunity. The complete patient
series scoring business rules look at factors important when scorable patient
series are complete. Similarly, in-process patient series scoring business rules
and no valid doses scoring business rules look at factors important to their
respective situation. For any given Series Group, only one set of these scoring
business rules will be applied to each scorable patient series as determined by
the Classify Scorable Patient Series.

8.7

Select Prioritized Patient Series

The goal of this step is to evaluate the scored patient series and determine
which of the scorable patient series is the one and only prioritized patient series
for the series group.

8.8

Determine Best Patient Series

The goal of this step is to identify a final set of best patient series that apply to
the patient.

The process model below illustrates the major steps involved in selecting the best patient series.

FIGURE 8-1 SELECT BEST PATIENT SERIES PROCESS MODEL

Logic Specification for ACIP Recommendations v4.6

Page 85 of 151

The process model below illustrates for a Series Group the major steps involved in selecting the prioritized
patient series.

Logic Specification for ACIP Recommendations v4.6

Page 86 of 151

FIGURE 8-2 SELECT PRIORITIZED PATIENT SERIES PROCESS MODEL

8.1 PRE-FILTER PATIENT SERIES
Pre-filter patient series examines each of the patient series for a given Series Group to determine if any series
should be removed from consideration for best patient series. If a Series Group contains relevant patient series
of different priorities, only the set of highest priority patient series should be considered when determining the
best patient series for the Series Group.
TABLE 8-2 PRE-FILTER PATIENT SERIES BUSINESS RULES
Business Rule ID

Business Rule

SELECTB-24

A relevant patient series that is the basis of a patient series forecast must be considered a candidate scorable
patient series if one of the following is true:
• The patient series forecast does not have a patient series status of 'Contraindicated.'
• All the following are true:
o The patient series forecast has a patient series status of 'Contraindicated.'
o Each relevant patient series that is the basis of a patient series forecast that is made for
the same series group has a patient series status of 'Contraindicated'

SELECTSCORE-2

A relevant patient series must be considered a scorable patient series if one of the following is true:
• All the following are true for the relevant patient series:
o The relevant patient series tracks an antigen series with a series type of 'Risk.'
o The series priority of the antigen series tracked by the relevant patient series is the same
as or greater than the series priority of any relevant patient series that tracks an antigen
series that belongs to the same series group as the relevant patient series.
o It is a candidate scorable patient series.
• All the following are true for the relevant patient series:
o The relevant patient series tracks an antigen series with a series type of 'Standard.'
o The relevant patient series includes a target dose evaluating at least one vaccine dose
administered with an evaluation status of 'Valid'.
o The earliest vaccine dose administered with an evaluation status of 'Valid' associated
with the relevant patient series has a date administered before the maximum age to start
date.
o It is a candidate scorable patient series.
• All the following are true for the relevant patient series:
o The relevant patient series tracks an antigen series with a series type of 'Standard'
o The number of valid doses is 0 for each relevant patient series in the series group.
o There is no default patient series for the series group.
o It is a candidate scorable patient series.
• All the following are true for the relevant patient series:
o The relevant patient series tracks an antigen series with a series type of 'Evaluation
Only'
o The relevant patient series is a complete patient series.

8.2 IDENTIFY ONE PRIORITIZED PATIENT SERIES
Identify one prioritized patient series examines all of the patient series for a given Series Group to determine if
one of the patient series is superior to all other patient series and can be considered the prioritized patient series.
TABLE 8-3 IS THERE A SINGLE PRIORITIZED PATIENT SERIES IN A SERIES GROUP?
Logic Specification for ACIP Recommendations v4.6

Page 87 of 151

CONDITIONS

RULES

How many scorable patient series
are in the series group?

0

1

>1

>1

>1

How many default patient series are
in the series group?

1

-

-

-

1

How many complete patient series
are in the series group?

-

-

1

0

0

How many in-process patient series
are in the series group?

-

-

-

1

0

Yes. The single
default patient
series is the
prioritized patient
series for the
series group.

Yes. The single
scorable patient
series is the
prioritized patient
series for the
series group.

Yes. The single
complete patient
series is the
prioritized patient
series for the
series group.

Yes. The single
in-process patient
series is the
prioritized patient
series for the
series group.

Yes. The default
patient series is
the prioritized
patient series for
the series group.

OUTCOMES
Default: No. There is no single
prioritized patient series. More than
one scorable patient series has
potential. All scorable patient series
are examined to see which should be
scored and selected as the prioritized
patient series for the series group.

TABLE 8-4 IDENTIFY ONE PRIORITIZED PATIENT SERIES BUSINESS RULES
Business Rule ID

Business Rule

SELECTB-6

A scorable patient series must be considered a complete patient series if the patient series forecast made
from the scorable patient series has a patient series status of 'Complete'.

SELECTB-7

A relevant patient series must be considered a default patient series if the default series flag is 'Y' for the
antigen series.

SELECTB-16

A scorable patient series must be considered an in-process patient series if all the following are true:
• The scorable patient series includes at least one target dose with a target dose status of
'Satisfied.'
• The patient series forecast made from the scorable patient series has a patient series status of
'Not Complete'.

8.3 CLASSIFY SCORABLE PATIENT SERIES
Classify scorable patient series is an attempt to reduce the total number of patient series within a Series Group
to only those which have a chance to be selected as the prioritized patient series.
TABLE 8-5 WHICH SCORABLE PATIENT SERIES SHOULD BE SCORED?
CONDITIONS
Are there 2 or more
complete patient
series in the series
group?

RULES
Yes

Logic Specification for ACIP Recommendations v4.6

No

No

Page 88 of 151

CONDITIONS

RULES

Are there 2 or more
in-process patient
series and no
complete patient
series in the series
group?

-

Yes

No

Is the number of
valid doses = 0 for all
scorable patient
series in the series
group?

-

No

Yes

All complete patient series in the
series group should be scored.
Apply the complete patient series
scoring business rules to these
scorable patient series only. All
other patient series in the series
group are not scored and are
dropped from consideration.

All in-process patient series in the
series group should be scored.
Apply the in-process patient series
scoring business rules to these
scorable patient series only. All
other patient series in the series
group are not scored and are
dropped from consideration.

All scorable patient series in the
series group with the number of valid
doses = 0 should be scored. Apply
the no valid doses scoring business
rules to all scorable patient series in
the series group. All other patient
series in the series group are not
scored and are dropped from
consideration.

OUTCOMES

TABLE 8-6 CLASSIFY SCORABLE PATIENT SERIES BUSINESS RULES
Business Rule ID

Business Rule

SELECTB-6

A scorable patient series must be considered a complete patient series if the patient series forecast made
from the scorable patient series has a patient series status of 'Complete'.

SELECTB-16

A scorable patient series must be considered an in-process patient series if all the following are true:
• The scorable patient series includes at least one target dose with a target dose status of
'Satisfied.'
• The patient series forecast made from the scorable patient series has a patient series status of
'Not Complete'.

SELECTB-21

The number of valid doses for a scorable patient series must be calculated as the count of the target doses
included in the scorable patient series with a target dose status of 'Satisfied'.

8.4 COMPLETE PATIENT SERIES
Complete patient series provides the decision table for determining the number of points to assign to a complete
patient series based on a specified condition.
TABLE 8-7 HOW MANY POINTS ARE AWARDED TO A SCORABLE PATIENT SERIES THAT IS A COMPLETE
PATIENT SERIES?
Conditions
A scorable patient series has
the most valid doses.

If this condition is true for the If this condition is true for two or If this condition is not true for
scorable patient series
more scorable patient series
the scorable patient series
+1

Logic Specification for ACIP Recommendations v4.6

0

-1

Page 89 of 151

TABLE 8-8 COMPLETE PATIENT SERIES BUSINESS RULES
Business Rule ID

Business Rule

SELECTB-6

A scorable patient series must be considered a complete patient series if the patient series forecast made
from the scorable patient series has a patient series status of 'Complete'.

SELECTB-19

A scorable patient series has the most valid doses if the number of valid doses is the same as or greater
than the number of valid doses in all other scorable patient series.

8.5 IN-PROCESS PATIENT SERIES
In-process patient series provides the decision table for determining the number of points to assign to an inprocess patient series based on a specified condition.
TABLE 8-9 HOW MANY POINTS ARE AWARDED TO SCORABLE PATIENT SERIES THAT IS AN IN-PROCESS
PATIENT SERIES?
Conditions

If this condition is true for
the scorable patient series

If this condition is true for
two or more scorable
patient series

If this condition is not true
for the scorable patient
series

A scorable patient series is a product
patient series and has all valid doses.

+2

n/a

-2

A scorable patient series is
completable.

+3

n/a

-3

A scorable patient series has the
most valid doses.

+2

0

-2

A scorable patient series is closest to
completion.

+2

0

-2

A scorable patient series can finish
earliest.

+1

0

-1

TABLE 8-10 IN-PROCESS PATIENT SERIES BUSINESS RULES
Business Rule ID

Business Rule

SELECTB-2

A scorable patient series has all valid doses only if all evaluations based on the target doses that are part of
the scorable patient series have an evaluation status of 'Valid'.

SELECTB-3

A patient series must be considered completable if the forecast finish date is less than the maximum age
date of the last target dose.

SELECTB-5

A patient series must be the considered the closest to completion if the number of not satisfied target doses
is less than the number of not satisfied target doses in all other patient series.

SELECTB-11

A patient series can finish earliest if the patient series is completable and the forecast finish date is on or
before the forecast finish date in all other completable patient series.

SELECTB-12

The forecast finish date for a scorable patient series must be calculated as the earliest date of the patient
series forecast made from the scorable patient series plus the latest minimum interval from the remaining
target dose(s).

Logic Specification for ACIP Recommendations v4.6

Page 90 of 151

Business Rule ID

Business Rule

SELECTB-16

A scorable patient series must be considered an in-process patient series if all the following are true:
• The scorable patient series includes at least one target dose with a target dose status of
'Satisfied.'
• The patient series forecast made from the scorable patient series has a patient series status of
'Not Complete'.

SELECTB-19

A scorable patient series has the most valid doses if the number of valid doses is the same as or greater
than the number of valid doses in all other scorable patient series.

SELECTB-23

A patient series must be considered a product patient series if the product path flag is 'Y' for the select patient
series.

8.6 NO VALID DOSES
No valid doses provide the decision table for determining the number of points to assign to a scorable patient
series when there are no valid doses.
TABLE 8-11 HOW MANY POINTS ARE AWARDED TO A SCORABLE PATIENT SERIES THAT HAS NO VALID
DOSES?
Conditions

If this condition is true for
the scorable patient series

If this condition is true for two or If this condition is not true for
more scorable patient series
the scorable patient series

A scorable patient series can
start earliest.

+1

0

-1

A scorable patient series is
completable.

+1

n/a

-1

A scorable patient series is a
product patient series.

-1

n/a

+1

TABLE 8-12 NO VALID DOSES BUSINESS RULES
Business Rule ID

Business Rule

SELECTB-3

A patient series must be considered completable if the forecast finish date is less than the maximum age
date of the last target dose.

SELECTB-23

A patient series must be considered a product patient series if the product path flag is 'Y' for the select patient
series.

SELECTB-12

The forecast finish date for a scorable patient series must be calculated as the earliest date of the patient
series forecast made from the scorable patient series plus the latest minimum interval from the remaining
target dose(s).

SELECTB-14

A patient series must be considered start earliest if the start date is before the start date for all other patient
series with a start date.

8.7 SELECT PRIORITIZED PATIENT SERIES
Select prioritized patient series provides the business rules to be applied to the scored patient series which will
result in the prioritized patient series for the series group.
Logic Specification for ACIP Recommendations v4.6

Page 91 of 151

TABLE 8-13 SELECT PRIORITIZED PATIENT SERIES BUSINESS RULES
Business Rule ID

Business Rule

SELECTBEST-1

The scorable patient series score must be the sum of all points awarded to the scorable patient series.

SELECTBEST-2

The prioritized patient series must be one of the following:
• The scorable patient series with the highest scorable patient series score.
• The scorable patient series with the best ranked series preference if more than one scorable
patient series are tied for the highest scorable patient series score.

8.8 DETERMINE BEST PATIENT SERIES
Determine best patient series provides the decision table to be applied to the set of prioritized patient series, one
per Series Group, determined above. This step only happens after one prioritized patient series has been
selected for each Series Group for the antigen. After this process, one or more non-redundant best patient series
will remain. Each of these best patient series are necessary to fully protect the patient.
TABLE 8-14 IS THE PRIORITIZED PATIENT SERIES THE BEST PATIENT SERIES FOR THE SERIES GROUP?
CONDITIONS

RULES

Is the prioritized patient series a
complete patient series?

Yes

No

No

Is there a prioritized patient series that
is a complete patient series in an
equivalent series group?

-

No

No

Is the series type of the prioritized
patient series 'Evaluation Only'?

-

No

No

Is the series type of the prioritized
patient series 'Risk'?

-

Yes

No

Is there a prioritized patient series with
a series type of 'Risk' in an equivalent
series group?

-

-

No

OUTCOMES
Default: No. There is no best patient
series for the series group.

Yes. The prioritized patient
series is the best patient
series for the series group.

Logic Specification for ACIP Recommendations v4.6

Yes. The prioritized patient
series is the best patient
series for the series group.

Yes. The prioritized patient
series the best patient series
for the series group.

Page 92 of 151

9 IDENTIFY AND EVALUATE VACCINE GROUP
Identify and evaluate vaccine group combines patient series into a vaccine group-based forecast to provide a
common and consistent view for a forecast. In the evaluation, forecasting, and select patient series chapters, all
logic was specified for antigens. At this point it is important to define how those antigen-based evaluation and
forecasting results can be merged into vaccine group forecasts. For antigens which contain non-equivalent series
groups (e.g., multiple best patient series), it is important to only blend best patient series of the same series type
(e.g., risk with risk and standard with standard). Patients in this situation may end up with more than 1 vaccine
group forecast for a given vaccine group (e.g., a travel-based MMR forecast and an age-based MMR forecast).
Relationship to ACIP Recommendations
•

At present, MMR and DTaP/Tdap/Td vaccine groups are comprised of multiple antigens. MMR contains
the antigens Measles, Mumps, and Rubella. DTaP/Tdap/Td contains the antigens Diphtheria, Tetanus,
and Pertussis.

TABLE 9-1 IDENTIFY AND EVALUATE VACCINE GROUP PROCESS STEPS
Section

Activity

Goal

9.1

Apply General Vaccine Group Rules

The goal of the activity is to two-fold. The first is to apply general vaccine group
rules which apply to all vaccine groups. The second is to classify the vaccine
group type (Single Antigen or Multiple Antigen) for subsequent business rule
sections (9.2 or 9.3).

9.2

Single Antigen Vaccine Group

The goal of this activity is to apply the business rules necessary to generate a
vaccine group-based forecast in situations where only a single antigen is
associated with a vaccine group.

9.3

Multiple Antigen Vaccine Group

The goal of this activity is to apply the decision logic and business rules
necessary to generate a vaccine group-based forecast in situations where more
than one antigen is associated with a vaccine group.

The following figure provides an illustration of the identifying and evaluating vaccine group process.

FIGURE 9-1 IDENTIFY AND EVALUATE VACCINE GROUP PROCESS MODEL
Logic Specification for ACIP Recommendations v4.6

Page 93 of 151

9.1 APPLY GENERAL VACCINE GROUP RULES
Apply general vaccine group rules provides the business rules which are applied to both types of vaccine groups
(i.e., Single Antigen and Multiple Antigen). Finally, this table provides rules to classify the vaccine group type
(Single Antigen or Multiple Antigen) for subsequent business rule sections (9.2 or 9.3).
TABLE 9-2 GENERAL VACCINE GROUP BUSINESS RULES
Business Rule ID

Business Rule

FORECASTVG-1

A patient series forecast must be contained in a vaccine group forecast made for a vaccine group if all the
following are true:
• The patient series forecast is made from a patient series that is identified as a best patient series.
• The best patient series belongs to the series group for which the vaccine group forecast is being
made.
• The best patient series defines the regimen for an antigen classified by the vaccine group.

FORECASTVG-2

The adjusted recommended date of a vaccine group forecast must be the latest of the following dates:
• The earliest adjusted recommended date of all the patient series forecasts contained in the
vaccine group forecast.
• The earliest date of the vaccine group forecast.

FORECASTVG-3

The adjusted past due date of a vaccine group forecast must be the latest of the following dates:
• The earliest adjusted past due date of all the patient series forecasts contained in the vaccine
group forecast.
• The earliest date of the vaccine group forecast.

FORECASTVG-4

The latest date of a vaccine group forecast must be the earliest latest date of all the patient series
forecasts contained in the vaccine group forecast.

FORECASTVG-5

The unadjusted recommended date of a vaccine group forecast must be the earliest unadjusted
recommended date of all the patient series forecasts contained in the vaccine group forecast.

FORECASTVG-6

The unadjusted past due date of a vaccine group forecast must be the earliest unadjusted past due date of
all the patient series forecasts contained in the vaccine group forecast.

FORECASTVG-7

The forecast reasons explaining a vaccine group forecast must be the forecast reasons of all the patient
series forecasts contained in the vaccine group forecast.

FORECASTVG-8

An antigen must be considered a recommended antigen for a vaccine group forecast if all the following are
true:
• The antigen is given the regimen of a best patient series.
• The best patient series is the basis of a patient series forecast contained in the vaccine group
forecast.
• The best patient series has a patient series status of 'Not Complete'.

FORECASTVG-9

A series dose vaccine must be considered a recommended series dose vaccine for a vaccine group
forecast if the series dose vaccine is a recommended series dose vaccine for a patient series forecast
contained in the vaccine group forecast.

FORECASTDN-2

The forecast dose number for a vaccine group forecast must be one of the following:
• The minimum of the forecast dose numbers of the patient series forecasts contained in the
vaccine group forecast if the administer full vaccine group flag is 'Y' for the vaccine group that is
the basis of the vaccine group forecast.
• The maximum of the forecast dose numbers of the patient series forecasts contained in the
vaccine group forecast if the administer full vaccine group flag is 'N' for the vaccine group that is
the basis of the vaccine group forecast.

VACCINEGROUP-1

A vaccine group must be considered a single antigen vaccine group if it classifies exactly one antigen.

Logic Specification for ACIP Recommendations v4.6

Page 94 of 151

Business Rule ID

Business Rule

VACCINEGROUP-2

A vaccine group must be considered a multiple antigen vaccine group if it classifies more than one antigen.

9.2 SINGLE ANTIGEN VACCINE GROUP
The forecasting rules which need to be applied to a single antigen vaccine group are listed in the table below.
TABLE 9-3 SINGLE ANTIGEN VACCINE GROUP BUSINESS RULES
Business Rule ID

Business Rule

SINGLEANTVG-1

The vaccine group status of a vaccine group forecast made for a single antigen vaccine group must be the
patient series status of the patient series forecast contained in the vaccine group forecast.

SINGLEANTVG-2

The earliest date of a vaccine group forecast made for a single antigen vaccine group must be the earliest
date of all the patient series forecasts contained in the vaccine group forecast.

9.3 MULTIPLE ANTIGEN VACCINE GROUP
The forecasting decisions and rules which need to be applied to a multiple antigen vaccine group are listed
below.
TABLE 9-4 WHAT IS THE VACCINE GROUP STATUS OF A VACCINE GROUP FORECAST FOR A MULTIPLE
ANTIGENT VACCINE GROUP?
CONDITIONS

RULES

Is there a patient series forecast contained in the
vaccine group forecast with a patient series status of
'Contraindicated'?

Yes

No

No

No

No

No

Is there a patient series forecast contained in the
vaccine group forecast with a patient series status of
'Aged Out'?

-

Yes

No

No

No

No

Is there a patient series forecast contained in the
vaccine group forecast with a patient series status of
'Not Recommended'?

-

-

Yes

No

No

No

Is there a patient series forecast contained in the
vaccine group forecast with a patient series status of
'Not Complete'?

-

-

-

Yes

No

No

Do all patient series forecasts contained in the vaccine
group forecast have a patient series status of 'Immune'?

-

-

-

-

Yes

No

Do all patient series forecasts contained in the vaccine
group forecast have a patient series status of 'Complete'
or 'Immune'?

-

-

-

-

-

Yes

Not
Recommended

Not
Complete

OUTCOMES

Logic Specification for ACIP Recommendations v4.6

Contraindicated Aged
Out

Immune Complete

Page 95 of 151

TABLE 9-5 MULTIPLE ANTIGEN VACCINE GROUP BUSINESS RULES
Business Rule ID

Business Rule

MULTIANTVG-1

The earliest date of a vaccine group forecast for a multiple antigen vaccine group must be one of the
following:
• The later of the following dates if any patient series forecast contained in the vaccine group
forecast is a priority patient series forecast:
o The earliest date of all the patient series forecasts contained in the vaccine group
forecast.
o The latest date administered of all the vaccine doses administered containing a vaccine
classified by a vaccine type that belongs to the vaccine group.
• The latest earliest date of all the patient series forecasts contained in the vaccine group forecast if
there is no priority patient series forecast contained in the vaccine group forecast.

FORECASTPRIORITY-1 A patient series forecast must be considered a priority patient series forecast if all the following are true:
• The target dose forecasted by the patient series forecast includes at least one preferable interval.
• Each preferable interval for the target dose has an interval priority flag of 'Y'.

Logic Specification for ACIP Recommendations v4.6

Page 96 of 151

APPENDIX A: DOMAIN MODEL AND GLOSSARY
DOMAIN MODEL (CONCEPT MODEL, VOCABULARY) OVERVIEW
Purpose
The purpose of employing a domain model (i.e. concept model) is to:
•
•
•

Document agreed-upon terms and definitions for the project
Facilitate discussions of the terms and definitions among project participants and provide tools to capture
outcomes of these discussions
Establish a foundation and a reference source (common vocabulary) for other project materials

About Domain Model
A domain is an area of knowledge or activity characterized by a set of concepts and terminology understood by
the practitioners in the area. A domain model captures vocabulary—terms and definitions. It ensures that all
terminology and concepts that will appear in the project materials (e.g., business rules, specifications, and
process descriptions) are known and understood by the domain practitioners (agreed-upon definitions and
meaning).
A domain model includes:
•
•
•
•

A description for each domain models
Domain model diagram(s) that shows major business entities, their characteristics (attributes), and their
relationships (Figure A-1 through A-6)
Definitional rules for each domain model which establishes the necessity for a concept. (Table A-2
through A-6)
A glossary that provides the definitions of vocabulary terms represented on the domain model (Table A7)

Unlike a data model diagram that depicts storage of information or a workflow/process diagram that depicts the
sequence of steps in a process, a domain diagram is a high-level static representation of the main “things”
(entities) involved in the clinical decision support process, including a description of how these “things” (entities)
are related. It is important to note that the domain diagram is not a technical specification. Instead, the domain
diagram provides the foundation for other modeling diagrams and materials.
How to Read the Domain Model Diagrams
The following figure and glossary provide:
•
•

A legend for the symbols used the Domain Model diagrams
Definitions for what the symbols represent as well as definitions clarifying related terms.

Logic Specification for ACIP Recommendations v4.6

Page 97 of 151

FIGURE A-1 NEIGHBORHOOD

The glossary below provides some basic terms related to the methodology used to generate the Domain Model.
The terms in bold italics relate to the symbols on the diagram above.
TABLE A-1 DOMAIN MODEL GLOSSARY
Term

Definition

Binary Verb Concept

a verb concept that involves exactly two noun concepts

Business Rule

a rule that is practicable and that is under business jurisdiction

Category

a general concept whose meaning is more restrictive, but otherwise compliant with, another general
concept (the super-category)

Concept

a notion in a person’s mind that is a unit of knowledge created by a unique combination of definitional
criteria

Concept Model

a set of concepts structured according to the relations among them

Concept Model Diagram

a graphical representation of a concept model

General Concept

a noun concept that classifies potentially many things on the basis of common properties

Neighborhood

a section of a concept model diagram separated for convenience

Noun Concept

a concept that is the meaning of a noun or noun phrase

Property

a quality or trait belonging to a thing itself

Role

A noun concept that reflects how another noun concept is viewed in the context of a verb concept

Rule

a guide for conduct or action; one of a set of usually official regulations by which an activity (as a sport) is
governed; a standard on which a decision or judgment may be based [MWUD 1a, 1f and [criterion] 2]

Rule-based Term

a term for a concept for which some explicit definitional rule(s) is/are specified separately from the
concept’s definition

Super-Category

a general concept that is broader than its related category/ies

Synonym

a word (or phrase) having the same meaning as another word (or phrase)

Term

a designation for a general concept

U-nary Verb Concept

a verb concept that involves exactly one noun concept

Logic Specification for ACIP Recommendations v4.6

Page 98 of 151

Term

Definition

Verb Concept

the meaning of a verb phrase (including optional prepositions) along with one or more noun concepts in
specific relation to that verb phrase

DOMAIN MODEL DIAGRAMS
The domain diagram for the CDSi project is broken into five neighborhoods for enhanced readability and ease
of printing. Each neighborhood encapsulates a logical grouping of entities.
Patient Neighborhood
The patient neighborhood (Figure A-2) focuses on the patient and the patient’s history. The patient’s history is
composed of two distinct items of importance. The first is the set of patient observations which may not be directly
related to a previous immunization event. This includes observations about relevant medical, environmental,
occupational, and behavioral factors for the patient. The second is the immunization history which is composed
of vaccine doses administered and adverse reactions.

FIGURE A-2 CDSI DOMAIN DIAGRAM: PATIENT NEIGHBORHOOD

Table A-2 Patient Neighborhood Business Rules
Business Rule ID

Business Rule

DEFPATIENT-001

A vaccine dose administered must be received by exactly one patient.

DEFPATIENT-002

A vaccine dose administered must contain exactly one vaccine.

DEFPATIENT-003

A vaccine dose administered must be part of exactly one immunization history.

DEFPATIENT-004

An evidence of immunity must be documented for exactly one patient.

DEFPATIENT-005

An evidence of immunity must be part of exactly one patient history.

DEFPATIENT-006

A patient must have exactly one patient history.

Logic Specification for ACIP Recommendations v4.6

Page 99 of 151

Business Rule ID

Business Rule

DEFPATIENT-007

A patient history must be for exactly one patient.

DEFPATIENT-008

A patient observation must be part of exactly one patient history.

DEFPATIENT-009

An immunization history must be part of exactly one patient history.

DEFPATIENT-010

An adverse reaction must be part of exactly one immunization history.

DEFPATIENT-011

A vaccine dose administered must have all the following:
• date administered
• dose condition flag.

DEFPATIENT-012

A patient observation must have exactly one observation date.

DEFPATIENT-013

A patient history must include exactly one immunization history.

DEFPATIENT-014

The date administered of a previous vaccine dose administered must be on or before the date administered
of a current vaccine dose administered.

DEFPATIENT-015

A dose condition flag must be one of the following for a vaccine dose administered:
• 'Y'
• 'N'.

Schedule Neighborhood
A schedule is the highest-level entity encompassing a collection of recommendations and which is composed of
antigen series. The schedule neighborhood (Figure A-3) focuses on components that relate directly to the
schedule rather than to a specific antigen series or dose. These include:
•
•
•

Immunity considerations which may negate the need for vaccination of the patient
Contraindications which may alter the risk benefit analysis for a given vaccination, contraindications
may be either at the antigen or vaccine level
Vaccine conflicts which indicate adverse interactions between doses of vaccines

Logic Specification for ACIP Recommendations v4.6

Page 100 of 151

FIGURE A-3 CDSI DOMAIN DIAGRAM: SCHEDULE NEIGHBORHOOD

Table A-3 Schedule Neighborhood Business Rules
Business Rule ID

Business Rule

DEFSCHEDULE-001

A contraindication must have all the following:
• Contraindication text description
• Contraindication begin age
• Contraindication end age.

DEFSCHEDULE-002

A clinical guideline observation must have all the following:
• Observation code
• Observation title.

DEFSCHEDULE-003

A birth date immunity must have all the following:
• immunity birth date
• immunity country of birth
• immunity exclusion condition.

DEFSCHEDULE-004

An indication must have all the following:
• indication text description
• indication begin age
• indication end age.

DEFSCHEDULE-005

A clinical history immunity must have an immunity guideline.

DEFSCHEDULE-006

A schedule must include at least one target disease.

DEFSCHEDULE-007

A target disease must be part of at least one schedule.

Logic Specification for ACIP Recommendations v4.6

Page 101 of 151

Business Rule ID

Business Rule

DEFSCHEDULE-008

An immunity must be achieved for exactly one target disease.

DEFSCHEDULE-009

An antigen must protect against exactly one target disease.

DEFSCHEDULE-010

A target disease must be protected by exactly one antigen.

Antigen Series Neighborhood
A schedule is composed of antigen series. Each antigen series defines a path to immunity for an antigen. An
antigen series focuses on a specific antigen and not a specific vaccine or a vaccine group. Each antigen series
is composed of series dose(s). A series dose defines the recommendations of the ACIP through dose specific
entities. The series neighborhood (Figure A-4) focuses on what a vaccine is, how it is related to an Antigen and
a Vaccine Group, and how those three entities relate to a schedule.
A vaccine has several attributes which uniquely identify it and are important during evaluation and forecasting.
Each vaccine contains antigen and also belongs to a vaccine group. While not critically important at this stage,
it should be noted that a vaccine can contain more than one antigen and can belong to more than one vaccine
group. Combination vaccines – such as Hib-HepB – contain more than one antigen and belong to more than
one vaccine group.

Logic Specification for ACIP Recommendations v4.6

Page 102 of 151

FIGURE A-4 CDSI DOMAIN DIAGRAM: ANTIGEN SERIES NEIGHBORHOOD

Table A-4 Antigen Series Neighborhood Business Rules
Business Rule ID

Business Rule

DEFANTIGENSERIES001

A default series flag must be one of the following for an antigen series:
• 'Y'
• 'N'.

Logic Specification for ACIP Recommendations v4.6

Page 103 of 151

Business Rule ID

Business Rule

DEFANTIGENSERIES002

A product path flag must be one of the following for an antigen series:
• 'Y'
• 'N'.

DEFANTIGENSERIES003

A from immediate previous dose administered flag must be one of the following if there is an interval for a
series dose:
• 'Y'
• 'N'.

DEFANTIGENSERIES004

An interval priority flag must be one of the following if there is a preferable interval for a series dose:
• 'Y'
• 'N'

DEFANTIGENSERIES005

A recurring dose flag must be one of the following for a recurring dose:
• 'Y'
• 'N'.

DEFANTIGENSERIES006

A forecast vaccine type flag must be one of the following for a series dose vaccine:
• 'Y'
• 'N'.

DEFANTIGENSERIES007

An administer full vaccine group flag must be one of the following for a multiple antigen vaccine group:
• 'Y'
• 'N'.

DEFANTIGENSERIES008

A series dose may include more than one preferable interval only if the interval priority flag is the same for
all the preferable intervals.

DEFANTIGENSERIES009

An antigen series must belong to exactly one series group.

DEFANTIGENSERIES010

An antigen series may belong to a series group only if the antigen series defines a regimen for the same
antigen as the other antigen series that belong to the series group.

DEFANTIGENSERIES011

A series group code for a series group must be unique within the antigen that defines the regimen for all
the antigen series that belong to the series group.

Evaluation and Forecast Neighborhoods
The evaluation and forecast neighborhoods (Figure A-5 and A-6) are the result of merging the patient
neighborhood with the schedule and antigen series neighborhoods which apply the recommendations of ACIP.
That is, it is the result of evaluating vaccine doses administered against the ACIP recommendations and creating
the forecast for when the next vaccine dose should be administered according to the ACIP recommendations.
While the schedule, antigen series, and series doses from the series and schedule neighborhoods encompass
the recommendations of the ACIP. When the process of evaluation and forecasting occurs, it is important to
track the progress of the patient against the goals of the ACIP recommendations to know how close to series
completion the patient is. This concept is depicted as the patient series and target dose. They are the measuring
stick tracking the progress of the patient (and their history) against the recommendations of the ACIP. The target
dose is the “virtual dose” according to the ACIP. The vaccine dose administered is what patient actually received.
Each vaccine dose administered is evaluated against the target dose and assigned an evaluation status and
possible evaluation reason. The target dose is also used to create a forecast for the next time an immunization
is due.

Logic Specification for ACIP Recommendations v4.6

Page 104 of 151

FIGURE A-5 CDSI DOMAIN DIAGRAM: EVALUATION NEIGHBORHOOD

Table A-5 Evaluation Neighborhood Business Rules
Business Rule ID

Business Rule

DEFEVALUATION-001

A patient series must be satisfied by exactly one patient.

DEFEVALUATION-002

A patient series must track exactly one antigen series.

DEFEVALUATION-003

An antigen series must define the regimen for exactly one antigen.

DEFEVALUATION-004

An evaluation must have exactly one evaluation status.

DEFEVALUATION-005

A target dose must have exactly one target dose status.

DEFEVALUATION-006

A patient series must be comprised of at least one target dose.

DEFEVALUATION-007

A target dose must be part of exactly one patient series.

DEFEVALUATION-008

A target dose must track exactly one series dose.

DEFEVALUATION-009

A patient series may include a target dose only if all the following are true:
• The target dose tracks a series dose.
• The series dose is part of an antigen series.
• the antigen series is tracked by the patient series.

DEFEVALUATION-012

A series dose must be part of exactly one antigen series.

Logic Specification for ACIP Recommendations v4.6

Page 105 of 151

FIGURE A-6 CDSI DOMAIN DIAGRAM: FORECAST NEIGHBORHOOD

Table A-6 Forecast Neighborhood Business Rules
Business Rule ID

Business Rule

DEFFORECAST-004

A target dose may be forecasted by a patient series forecast only if the target dose is part of the patient
series that is the basis of the patient series forecast.

DEFFORECAST-005

A patient series forecast may be made for only one target dose.

DEFFORECAST-006

A target dose may be forecasted by only one patient series forecast.

DEFFORECAST-007

Each patient series must be the basis of exactly one patient series forecast.

DEFFORECAST-008

A patient series forecast must be made from exactly one patient series.

DEFFORECAST-010

A vaccine type may belong to a vaccine group only if the vaccine type contains an antigen that is classified
by the vaccine group.

DEFFORECAST-011

An antigen must be classified by exactly one vaccine group.

DEFFORECAST-012

A vaccine group forecast must be made for exactly one series group.

DEFFORECAST-013

Each patient series forecast made from a best patient series must be contained in exactly one vaccine group
forecast.

DEFFORECAST-015

A single antigen vaccine group must classify exactly one antigen.

Logic Specification for ACIP Recommendations v4.6

Page 106 of 151

Business Rule ID

Business Rule

DEFFORECAST-016

A vaccine group forecast made for a single antigen vaccine group must contain exactly one patient series
forecast.

DEFFORECAST-017

A series group may contain only one best patient series.

DEFFORECAST-018

A forecast vaccine type flag may be specified only for a preferable vaccine.

DEFFORECAST-019

A patient series forecast must be made for exactly one series group.

DEFFORECAST-020

A series group may include only one relevant patient series with a default series flag = 'Y'.

Glossary
The glossary provides the definitions of terms identified by the domain model.
TABLE A-7 GLOSSARY
Term

Definition

Absolute Minimum Age an age which may be earlier than the minimum age and allows for a vaccine dose administered to be
considered valid when administered abnormally early (e.g. grace period)
Absolute Minimum
Interval

an interval which maybe shorter than the minimum interval and allows for a vaccine dose administered to
be considered valid when administered abnormally early (e.g. grace period)

Active Patient
Observation

a patient observation that is applicable to a patient at the time of an evaluation or forecast

Administer Full Vaccine an indicator whether a multiple antigen vaccine group should have all antigens in the vaccine group
Group Flag
recommended to be administered at the same time
Administrative
Guidance

text conveying additional information pertaining to an antigen series, an indication or a contraindication

Adverse Reaction

a negative health consequence experienced by a patient related in time to administration of vaccine (s).
NOTE: 'In time' means that it happens in some reasonable time after the vaccination event. It might not be
attributable to a specific vaccine dose administered, especially in cases when the patient receives several
vaccines in one visit.

Age

the length of time from birth to a specified time

Aged Out

A patient series status that indicates the patient exceeded the maximum age prior to completing the patient
series

Allowable Interval

an interval that is outside of the preferable interval, but still counts towards immunity

Allowable Vaccine

a series dose vaccine which is not currently recommended by ACIP for a series dose within an antigen
series, but still contributes to completing the antigen series

Allowable Vaccine Type a list of vaccines that are allowed to be administered to a patient if a preferable vaccine is not available
Antigen

a foreign (non-self) substance found in the body that produces an immune response

Antigen
Contraindication

a contraindication which applies to all current formulations of vaccine for a given antigen (e.g. all
formulations of hepatitis a vaccine are contraindicated for a patient with a hypersensitivity to alum)

Antigen Series

one possible path to achieve presumed immunity against a target disease

Antigen Supporting
Data

supporting data for a specific antigen

Assessment Date

the date for which a forecast is determined

Logic Specification for ACIP Recommendations v4.6

Page 107 of 151

Term

Definition

Association Begin Age

the earliest age a vaccine type is used for an antigen

Association End Age

the latest age a vaccine type is used for an antigen

Best Patient Series

a patient series determined to be an optimal choice for a patient

Birth Date Immunity

an immunity that may provide protection if a patient was born before an established immunity birth date
within a country of birth

Cessation Date

the ending date after which a logical component instance is no longer appropriate to use

Clinical Guideline
Observation

an observation defined by an organization (e.g., ACIP) that impacts a patient's immunization
recommendations

Clinical History
Immunity

an immunity that may provide protection based on patient history

Complete

a patient series status that indicates the patient has met all of the ACIP recommendations for the patient
series

Conditional Skip

a situation where, based on a patient's immunization history or age, the patient may not need a particular
dose of vaccine.

Conditional Skip Begin
Age

For Conditions of Type Vaccine Count by Age, the Begin Age defines the beginning point of the age range
to be considered.

Conditional Skip
Condition

a fact about a patient which may impact a patient's need for a particular dose of vaccine.

Conditional Skip
Condition ID

a numeric identifier for a condition within a set

Conditional Skip
Condition Logic

When a set consists of more than 1 condition, the Condition Logic determines if all conditions must be met
or just a single one in order for the set to be met.

Conditional Skip
Condition Logic - AND

When the Condition Logic is 'AND', all conditions in the set must be met in order for the set to be met.

Conditional Skip
Condition Logic - OR

When the Condition Logic is 'OR', only a single condition in the set must be met for the set to be met.

Conditional Skip
Context

The circumstances in which conditional skip rules should be applied during the Evaluation and Forecasting
process

Conditional Skip
Description

a textual description of the intent of the condition

Conditional Skip Dose
Count

For Condition of Types of Vaccine Count by Age or Vaccine Count by Date, the Dose Count indicates the
critical number of doses for the Condition. The Dose Count works together with Dose Type and Dose
Count Logic to fully define the Condition.

Conditional Skip Dose
Count Logic

For Condition of Types of Vaccine Count by Age or Vaccine Count by Date, the Dose Count Logic
indicates for the Condition whether the patient's dose count must be greater than, less than or equal to the
Dose Count. The Dose Count Logic works together with Dose Count and Dose Type to fully define the
Condition.

Conditional Skip Dose
Type

For Condition of Types of Vaccine Count by Age or Vaccine Count by Date, the Dose Type indicates for
the Condition whether or not counted doses must be valid doses for the patient series or not. The Dose
Type works together with Dose Count and Dose Count Logic to fully define the Condition.

Conditional Skip End
Age

For Conditions of Type Vaccine Count by Age, the End Age defines the ending point of the age range to
be considered.

Conditional Skip End
Date

For Conditions of Type Vaccine Count by Date, the End Date defines the ending point of the date range to
be considered.

Logic Specification for ACIP Recommendations v4.6

Page 108 of 151

Term

Definition

Conditional Skip
Interval

For Conditions of Type of Interval, the Interval defines the minimum space of time since the last satisfied
target dose.

Conditional Skip Series For Conditions of Type of Completed Series, indicates for the condition which series group needs to
Group
contain a completed series for the condition to be met
Conditional Skip Set

A set is one or more conditions which need to be considered together when determining if a patient can
skip a particular dose of vaccine.

Conditional Skip Set ID a numeric identifier for a set of conditions that may lead to the skipping of a series dose
Conditional Skip Set
Logic

When The Conditional Skip section contains more than 1 set, The Set Logic determines if all sets must be
met or just a single one in order for the dose to be skipped.

Conditional Skip Set
Logic - AND

When the Set Logic is 'AND', all Sets must be met in order for the Dose to be skipped

Conditional Skip Set
Logic - OR

When the Set Logic is 'OR', only a single Set must be met for the Set for the Dose to be skipped.

Conditional Skip Start
Date

For Conditions of Type Vaccine Count by Date, the Start Date defines the beginning point of the date
range to be considered.

Conditional Skip Type

The Type specifies the nature of the condition

Conditional Skip Type - If the patient's age at the time of dose administration or forecast is equal to or greater than the Begin Age,
Age
then the condition is met.
Conditional Skip Type - If the patient has completed a patient series in the specified Series Group, then the condition is met.
Completed Series
Conditional Skip Type - If the interval from the administered date of the last satisfied target dose equals or exceeds the Interval,
Interval
then the condition is met.
Conditional Skip Type – If the patient meets the dose count requirement based on the age range then the condition is met. The
Vaccine Count by Age Dose Count Logic determines if the patient administered dose count should be greater than, less than or
equal to the Dose Count (either valid or total based on the value of Dose Type). The upper age range
boundary will be either a discrete age (specified in End Age) or the age of the patient at the time of dose
administration or forecast (if End Age is n/a). If the Vaccine Types (CVX List) parameter is populated, then
an administered dose must be of one of the specified CVX codes in order to be counted. If the parameter
is not populated, then any vaccine valid for the antigen is permitted.
Conditional Skip Type – If the patient meets the dose count requirement based on the date range then the condition is met. The
Vaccine Count by Date Dose Count Logic determines if the patient administered dose count should be greater than, less than or
equal to the Dose Count (either valid or total based on the value of Dose Type). If the Vaccine Types (CVX
List) parameter is populated, then an administered dose must be of one of the specified CVX codes in
order to be counted. If the parameter is not populated, then any vaccine valid for the antigen is permitted.
Conditional Skip
Vaccine Type

the specific types of vaccine dose administered.

Conflict Begin Interval

an interval which identifies the start of a vaccine conflict

Conflict End Interval

an interval which identifies the end of a vaccine conflict

Conflicting Vaccine
Type

the vaccine type of a vaccine that causes a vaccine type conflict if it is administered at too close an interval
to a different vaccine type

Contraindicated

a patient series status that indicates no further vaccines should be administered at this time for the patient
series

Contraindicated Patient a patient series for which there are one or more contraindications that apply to a patient
Series

Logic Specification for ACIP Recommendations v4.6

Page 109 of 151

Term

Definition

Contraindication

a clinical guideline observation describing a condition in a patient that greatly increases the chance of a
serious adverse reaction and renders a vaccination inadvisable for the patient

Contraindication Begin the earliest age that a contraindication applies to
Age
Contraindication End
Age

the latest age that a contraindication applies to

Contraindication Text
Description

a recommended action for a clinical guideline observation where there is a contraindication

Country of Birth

the birth country where an individual was born

Current Target Dose

a target dose being evaluated to determine whether it has been satisfied by a current vaccine dose
administered

Current Vaccine Dose
Administered

a vaccine dose administered being evaluated to determine whether or not it is valid

CVX Code

a numerical identifier used to identify a vaccine type

Date Administered

the date of the vaccine dose administered

Date of Birth

the date of the patient's birth

Default Patient Series

An antigen series which best describes the standard recommendations of the ACIP
Defined by the rule:
A relevant patient series must be considered a default patient series if the default series flag is 'Y' for the
antigen series.

Default Series Flag

an indicator that an antigen series is the one that best describes the standard recommendations of the
ACIP

Dose Condition Flag

an indicator that a dose administered to a patient is considered substandard

Dose Count

the number of vaccine doses administered

Dose Number

the ordinal number of a series dose in an antigen series

Earliest Date

the earliest point in time at which the next target dose could be given
Defined by the rule:
The earliest date of a patient series forecast made from a relevant patient series must be the candidate
earliest date.

Earliest Recommended the preferred age a vaccine should be administered
Age
Earliest Recommended the lower bound within a range for a preferable interval at which point a patient is recommended to receive
Interval
their next target dose
Effective Date

the starting date at which point a logical component instance is appropriate to use

Equivalent Series
Group

a series group which provides protection equivalent to an antigen series

Evaluation

the result of the process of applying recommendations for a given series dose. It is the outcome of the
evaluation process that determines whether a vaccine dose administered is valid.

Evaluation Only Series

an antigen series which outlines recommendations which do not need to be forecasted for completion (e.g.
non-U.S recommendations, historical US-specific series)

Evaluation Reason

a reason why a vaccine dose administered is or is not valid

Logic Specification for ACIP Recommendations v4.6

Page 110 of 151

Term

Definition

Evaluation Status

the state of a vaccine dose administered with respect to an assessment of its validity against a target dose

Evidence of Immunity

the proof or written documentation that indicates a patient may have immunity

Extraneous

an evaluation status that indicates the vaccine dose administered was not administered according to ACIP
recommendations, but the dose does not need to be repeated (including maximum age and extra doses)

Forecast

the outcome of determining a patient’s next recommended action based on a set of immunization rules and
the patient’s particular situation

Forecast Dose Number

the ordinal number of the next target dose in a forecast based on the evaluation of a patient’s
immunization history
Defined by the rule:
The forecast dose number for a patient series forecast must be calculated as one of the following:
• The count of all target doses plus 1 where all the following are true:
o The target dose is part of the relevant patient series.
o The target dose has a target dose status of 'Satisfied'
o There is no seasonal recommendation start date for the series dose that is tracked by
the target dose.
• The count of all target doses plus 1 where all the following are true:
o The target dose is part of the relevant patient series.
o The target dose has a target dose status of 'Satisfied'
o There is a seasonal recommendation start date for the series dose that is tracked by the
target dose.
o The date administered of the vaccine dose administered evaluated by the target dose is
on or after the seasonal recommendation start date.

Forecast Reason

a reason why a target dose is or is not recommended to be administered

Forecast Vaccine Type
Flag

an indicator that a specific vaccine type or vaccine product type should be recommended for a series dose
vaccine

From Immediate
Previous Dose
Administered Flag

an indicator that an interval is applied from the date administered of the previous vaccine dose
administered within an antigen series

From Most Recent
(CVX List)

see From Most Recent Vaccine Type

From Most Recent
Vaccine Type

a vaccine type for which an interval is determined from the date administered of the most recent
occurrence of that vaccine type

From Relevant
Observation Code

a clinical guideline observation from which the interval is determined

From Target Dose
Number in Series

the dose number within an antigen series used in calculating an interval

Gender

socially constructed roles, behaviors, activities, and attributes that a given society considers appropriate for
boys and men or girls and women

Immune

a patient series status that indicates the patient has evidence of immunity indicating no further vaccines
are needed for the patient series

Immunity

a condition of being able to resist a target disease

Immunity Birth Date

the date that suggests when a patient may have protection from a specific disease

Immunity Country of
Birth

the country where a patient must have been born in order for a birth date immunity to apply

Logic Specification for ACIP Recommendations v4.6

Page 111 of 151

Term

Definition

Immunity Exclusion
Condition

a patient factor which precludes a patient from being considered immune without vaccination

Immunity Guideline

a statement defined by an organization (e.g., ACIP) that can be used to help determine whether clinical
history immunity is applicable

Immunization

the process of being made immune or resistant to an infectious disease typically by the administration of a
vaccine

Immunization History

a collection of information detailing vaccination events for a patient

Impacted Vaccine Dose a vaccine dose administered that is impacted by a vaccine conflict
Administered
Defined by the rule:
A current vaccine dose administered must be considered an impacted vaccine dose administered if all the
following are true for the date administered of the current vaccine dose administered:
• It is on or after the conflict begin interval date.
• It is before the conflict end interval date.
Impacted Vaccine Type the vaccine type of a vaccine that may be ineffective if it is administered at too close an interval to a
different vaccine type
Inadvertent
Administration

a vaccine dose administered where an inadvertent vaccine was administered

Inadvertent Vaccine

a series dose vaccine which is currently prohibited by ACIP for a series dose within an antigen series, and
which does not contribute to completing the antigen series

Indication

a clinical guideline observation signifying the need for an antigen series because of an increased risk of a
target disease

Indication Begin Age

the earliest age that an indication applies to

Indication End Age

the latest age that an indication applies to

Indication Text
Description

a recommended action for a clinical guideline observation where there is an contraindication

Interval

a period of time between instances, typically between vaccine doses administered

Interval Priority Flag

an indicator of whether the earliest date of a multiple antigen vaccine group forecast must be accelerated
to recommend earlier vaccination

Latest Date

the latest point in time at which the next target dose should be given
Defined by the rules:
The latest date of a patient series forecast must be one of the following:
• The maximum age date minus 1 day if there is a maximum age date.
• Blank if there is no maximum age date.

Latest Recommended
Age

the age a vaccine must be administered before the patient is considered overdue

Latest Recommended
Interval

the upper bound within a range for a preferable interval after which a patient is considered overdue for
their next target dose

Logical Component

a set of related logical component elements that contribute to the supporting data (e.g. Age, Preferable
Interval, Allowable Interval and Conditional Skip)

Logical Component
Element

a single concept contained as part of a Logical Component (e.g. elements of the Age logical component
include Absolute Minimum Age, Minimum Age and Earliest Recommended Age)

Logic Specification for ACIP Recommendations v4.6

Page 112 of 151

Term

Definition

Logical Component
Instance

a set of specific values for the Logical Component Elements in a Logical Component

Lot Number Expiration
Date

the date after which the vaccine is no longer considered potent

Manufacturer

an organization that produces a vaccine product type

Maximum Age

the latest age a vaccine may be administered

Maximum Age To Start

the latest age an antigen series may be started

Minimum Age

the earliest age a vaccine may be administered

Minimum Age To Start

the earliest age an antigen series may be started

Minimum Conflict End
Interval

an interval which identifies the absolute earliest end of a vaccine conflict

Minimum Interval

the shortest interval between two vaccine doses administered

Multiple Antigen
Vaccine Group

a vaccine group containing more than one antigen designed to protect against more than one target
disease (e.g. MMR, DTaP/Tdap/Td)
Defined by the rule:
A vaccine group must be considered a multiple antigen vaccine group if it classifies more than one antigen.

MVX Code

an identifier established and maintained by the CDC that describes a manufacturer

Next Target Dose

a target dose that comes after the current target dose in a patient series

Next Vaccine Dose
Administered

a vaccine dose administered that occurred after a current vaccine dose administered

Not Complete

a patient series status that indicates the patient has not yet met all of the ACIP recommendations for the
patient series

Not Recommended

a patient series status that indicates the patient's immunization history provides sufficient protection
against a target disease and there's no recommended action at this time

Not Satisfied

a target dose status that indicates no vaccine dose administered has met the goals of the target dose

Not Valid

an evaluation status that indicates the vaccine dose administered was not administered according to ACIP
recommendations and must be repeated at an appropriate time in the future

Observation

a notation of a medical, environmental, behavioral, or occupational situation

Observation Code

a unique identifier for a clinical guideline observation

Observation Date

the date which a clinician determined the patient observation occurred or will occur

Observation Title

a name for a clinical guideline observation

Past Due Date

the date a patient should be considered overdue for the next target dose

Patient

an individual who is the actual or potential recipient of a vaccine dose administered

Patient Gender

the patient's gender

Patient History

a narrative or record of current and/or past events and circumstances that are or may be relevant to a
patient's current state of health

Patient Observation

an observation specific to a patient

Patient Series

an antigen series based on a patient's actual progress towards completing ACIP recommendations

Patient Series Forecast a forecast for a patient series

Logic Specification for ACIP Recommendations v4.6

Page 113 of 151

Term

Definition

Patient Series Status

the state of a patient series with respect to a patient satisfying the goals for the patient series

Preferable Interval

an interval defined by ACIP best practices

Preferable Vaccine

a series dose vaccine which is currently recommended by ACIP for a series dose within an antigen series
and that contributes to completing the antigen series

Previous Target Dose

a target dose that comes before the current target dose in a patient series

Previous Vaccine Dose a vaccine dose administered that occurred prior to or on the same day as a current vaccine dose
Administered
administered
Prioritized Patient
Series

a scorable patient series within a series group that has been selected for further consideration as a best
patient series
Defined by the rule:
The prioritized patient series must be one of the following:
• The scorable patient series with the highest scorable patient series score.
• The scorable patient series with the best ranked series preference if more than one scorable
patient series are tied for the highest scorable patient series score.

Product Path Flag

an indicator that an antigen series specifically targets a product, vaccine type, and/or trade name

Reason

a rationale or justification for an outcome

Recommended Date

the date at which the next target dose should be given

Recurring Dose

a dose that is to be repeated

Recurring Dose Flag

an indicator that a target dose is a recurring dose

Relevant Patient Series a patient series that has been selected based on the appropriateness for a patient
Required Gender

the gender that is recommended for an antigen series

Risk Series

an antigen series which outlines immunization recommendations based on underlying indications a patient
may have

Satisfied

a target dose status that indicates a vaccine dose administered has met the goals of the target dose

Schedule

a collection of guidelines defined by an organization (e.g. ACIP) recommending under what circumstances
someone should or should not receive a vaccine

Schedule Supporting
Data

supporting data which span antigens including:

Logic Specification for ACIP Recommendations v4.6

Page 114 of 151

Term

Definition

Scorable Patient Series a relevant patient series that has been selected for further consideration as a potential prioritized patient
series
Defined by the rule:
A relevant patient series must be considered a scorable patient series if one of the following is true:
• All the following are true for the relevant patient series:
o The relevant patient series tracks an antigen series with a series type of 'Risk'
o The series priority of the antigen series tracked by the relevant patient series is the same
as or greater than the series priority of any relevant patient series that tracks an antigen
series that belongs to the same series group as the relevant patient series.
o It is a candidate scorable patient series.
• All the following are true for the relevant patient series:
o The relevant patient series tracks an antigen series with a series type of 'Standard'
o The relevant patient series includes a target dose evaluating at least one vaccine dose
administered with an evaluation status of 'Valid'.
o The earliest vaccine dose administered with an evaluation status of 'Valid' associated
with the relevant patient series has a date administered before the maximum age to start
date.
o It is a candidate scorable patient series.
• All the following are true for the relevant patient series:
o The relevant patient series tracks an antigen series with a series type of 'Standard'
o The number of valid doses is 0 for each relevant patient series in the series group.
o There is no default patient series for the series group.
o It is a candidate scorable patient series.
• All the following are true for the relevant patient series:
o The relevant patient series tracks an antigen series with a series type of 'Evaluation
Only'
o The relevant patient series is a complete patient series.
Seasonal
Recommendation

a recommendation which is indicated by a seasonal start date and a seasonal end date in conjunction with
the patient's age

Seasonal
Recommendation End
Date

the last day a seasonal vaccine should be recommended

Seasonal
Recommendation Start
Date

the first day a seasonal vaccine should be recommended

Select Patient Series

a set of properties used in determining one or more best patient series

Series Dose

an individual dose within an antigen series

Series Dose Vaccine

a vaccine type or a vaccine product type that can be used for a series dose based on adherence to the
ACIP recommendations

Series Group

a classification of one or more antigen series based on the ACIP recommendations for achieving immunity

Series Group Code

a unique identifier for a series group

Series Group Name

a meaningful label for a series group

Series Name

a meaningful identifier for an antigen series

Series Preference

a ranking given to antigen series within a series group

Series Priority

a ranking given to antigen series within a single series group. The series priority is considered when
selecting relevant patient series to evaluate as a potential best patient series

Series Type

a categorization of a type of antigen series

Logic Specification for ACIP Recommendations v4.6

Page 115 of 151

Term

Definition

Sex

one’s biological status as either male or female, and is associated primarily with physical attributes such as
chromosomes, hormone prevalence, and external and internal anatomy

Single Antigen Vaccine a vaccine group containing one antigen designed to protect against one target disease (e.g., Hib, HepB,
Group
Polio)
Defined by the rule:
A vaccine group must be considered a single antigen vaccine group if it classifies exactly one antigen.
Skipped

a target dose status that indicates no vaccine dose administered has met the goals of the target dose. Due
to the patient's age and/or interval from a previous dose, the target dose does not need to be satisfied.

Standard Series

an antigen series which outlines routine immunization recommendations

Sub-standard

an evaluation status that indicates the vaccine dose administered has a known dose condition (e.g.,
expired, sub-potent, and recall) which requires the dose to be repeated at an appropriate time in the future

Supporting Data

a structured representation of ACIP recommendations

Target Disease

a disease where a vaccine can be administered to a patient to reduce the risk of contracting the disease by
working with the body's natural defenses to help it develop an immunity to the disease

Target Dose

a patient-specific dose required to satisfy a recommendation of the ACIP

Target Dose Number

the ordinal number of a target dose in a patient series

Target Dose Status

the state of a vaccine dose administered with respect to the vaccine dose administered meeting the goals
of the target dose against which it is being evaluated

Trade Name

the manufacturer's proprietary name for a vaccine type

Vaccination

the use of vaccines to produce immunity to a disease

Vaccine

a dose of substance administered during a vaccination event

Vaccine Conflict

a condition that occurs when a vaccine type is administered at too close of an interval with another
substance such as a vaccine type causing a reduction in the effectiveness of a vaccine

Vaccine
Contraindication

a contraindication which is specific to a particular vaccine (e.g. a prefilled syringe with a latex plunger
would trigger a vaccine contraindication for patients with a latex allergy but other formulations of vaccine
for the same antigen may be safe to give)

Vaccine Dose
Administered

a medical occurrence of administering one Vaccine to a Patient

Vaccine Group

a classification of antigens that describes broad categories of target diseases

Vaccine Group
Forecast

a forecast for a vaccine group

Vaccine Group Status

the state of a vaccine group forecast with respect to meeting the goals of the vaccine group for which the
vaccine group forecast is being made

Vaccine Product Type

a classification that describes the manufacturer, and presentation of a vaccine type

Vaccine Type

a classification of vaccines that describes the target disease(s) to which it provides immunity

Vaccine Type Antigen
Association

a vaccine type that is used for an antigen

Vaccine Type Begin
Age

the earliest age a series dose vaccine is applicable

Vaccine Type Conflict

a vaccine conflict between two vaccine types

Logic Specification for ACIP Recommendations v4.6

Page 116 of 151

Term

Definition

Vaccine Type
Description

a description of a vaccine type

Vaccine Type End Age

the latest age a series dose vaccine is applicable

Valid

An evaluation status that indicates the vaccine dose administered was administered according to ACIP
recommendations

Volume

the amount of space a substance takes up

Logic Specification for ACIP Recommendations v4.6

Page 117 of 151

APPENDIX B: ACRONYMS AND ABBREVIATIONS
The table below provides the meanings of acronyms and abbreviations stated within the document.
TABLE B-1 ACRONYMS AND ABBREVIATIONS
Term

Meaning

ACIP

Advisory Committee on Immunization Practices

CDC

Centers for Disease Control and Prevention

CDS

Clinical Decision Support

CDSi

Clinical Decision Support for Immunization

DHHS

U.S. Department of Health and Human Services

DT

Diphtheria and tetanus toxoids adsorbed (children)

DTaP

Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed

EHR

Electronic Health Record

FDA

Federal Drug Administration

Flu

Influenza

HECB

Health Education and Communication Branch

HepA

Hepatitis A vaccine

HepB

Hepatitis B vaccine

Hib

Haemophilus influenza type b conjugate vaccine

HIE

Health Information Exchange

HIS

Health Information System

HIV

Human Immunodeficiency Virus

HPV

Human papillomavirus vaccine

IDAB

Informatics and Data Analytics Branch

IIS

Immunization Information System

JE

Japanese Encephalitis vaccine

MCV

Meningococcal conjugate vaccine

MMR

Measles, Mumps, and Rubella vaccine

MMRV

Measles, Mumps, Rubella, and Varicella vaccine

MMWR

Morbidity and Mortality Weekly Report

NCIRD

National Center for Infectious Diseases

Mpox & Smallpox

Orthopoxvirus vaccine

PCV

Pneumococcal conjugate vaccine

PPSV

Pneumococcal polysaccharide vaccine

Polio

Poliomyelitis vaccine

Rota

Rotavirus vaccine

Logic Specification for ACIP Recommendations v4.6

Page 118 of 151

Term

Meaning

RSV

Respiratory Syncytial Virus vaccine

SME

Subject Matter Expert

Td

Tetanus and diphtheria toxoids adsorbed (adult)

Tdap

Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed

TBE

Tick-borne Encephalitis vaccine

VZ

Varicella vaccine

YF

Yellow Fever vaccine

Logic Specification for ACIP Recommendations v4.6

Page 119 of 151

APPENDIX C: RETIRED ITEMS
The table below provides a list of terms, rules and tables used in previous versions of the document but which
are no longer in use.
TABLE C-1 RETIRED ITEMS
Version

Item

Name

Motivation

4.4

Business
Rule

ALLOWABLE-1

This rule is no longer used.

4.4

Business
Rule

ALLOWABLE-2

This rule is no longer used.

4.4

Business
Rule

CALCDTINT-7

This rule is no longer used.

4.4

Business
Rule

CALCDTLIVE-1

This rule is no longer used.

4.4

Business
Rule

CALCDTLIVE-2

This rule is no longer used.

4.4

Business
Rule

CALCDTLIVE-3

This rule is no longer used.

4.4

Business
Rule

CALCDTLIVE-4

This rule is no longer used.

4.4

Business
Rule

CONFLICT-1

This rule is no longer used.

4.4

Business
Rule

CONFLICT-2

This rule is already covered under the CONFLICT-1 business rule.

4.4

Business
Rule

EVALINADVERT-1

This rule is no longer used.

4.4

Business
Rule

EVALINT-1

This rule is no longer used.

4.4

Business
Rule

EVALINT-2

This rule is no longer used.

4.4

Business
Rule

MULTIANTVG-2

This rule is being replaced with new rule FORECASTVG-2.

4.4

Business
Rule

MULTIANTVG-3

This rule is being replaced with new rule FORECASTVG-3.

4.4

Business
Rule

MULTIANTVG-4

This rule is being replaced with new rule FORECASTVG-4.

4.4

Business
Rule

MULTIANTVG-5

This rule is being replaced with new rule FORECASTVG-5.

4.4

Business
Rule

MULTIANTVG-6

This rule is being replaced with new rule FORECASTVG-6.

4.4

Business
Rule

MULTIANTVG-7

This rule is being replaced with new rule FORECASTVG-7.

4.4

Business
Rule

MULTIANTVG-8

This rule is being replaced with new rule FORECASTVG-8.

Logic Specification for ACIP Recommendations v4.6

Page 120 of 151

Version

Item

Name

Motivation

4.4

Business
Rule

MULTIANTVG-9

This rule is being replaced with new rule FORECASTVG-9.

4.4

Business
Rule

PREFERABLE-1

This rule is no longer used.

4.4

Business
Rule

PREFERABLE-2

This rule is no longer used.

4.4

Business
Rule

SINGLEANTVG-10

This rule is being replaced with new rule FORECASTVG-9.

4.4

Business
Rule

SINGLEANTVG-3

This rule is being replaced with new rule FORECASTVG-2.

4.4

Business
Rule

SINGLEANTVG-4

This rule is being replaced with new rule FORECASTVG-3.

4.4

Business
Rule

SINGLEANTVG-5

This rule is being replaced with new rule FORECASTVG-4.

4.4

Business
Rule

SINGLEANTVG-6

This rule is being replaced with new rule FORECASTVG-5.

4.4

Business
Rule

SINGLEANTVG-7

This rule is being replaced with new rule FORECASTVG-6.

4.4

Business
Rule

SINGLEANTVG-8

This rule is being replaced with new rule FORECASTVG-7.

4.4

Business
Rule

SINGLEANTVG-9

This rule is being replaced with new rule FORECASTVG-8.

4.4

Business
Rule

VALIDATEREC-1

This rule is no longer used.

4.4

Decision
Table

Could the Two Vaccine
Doses Administered be
in Conflict?

This decision table was replaced by new rules CALCDTCONFLICT-1 & 2.

4.4

Decision
Table

Is the Current Vaccine
Dose Administered in
Conflict With a Previous
Vaccine Dose
Administered?

This decision table was replaced by new rule CONFLICT-3.

4.4

Decision
Table

Should the Current
Vaccine Dose
Administered be
Evaluated for a Live
Virus Conflict?

This decision table was replaced with new rule CONFLICT-3.

4.4

Decision
Table

What is the Vaccine
Group Type?

The decision table was replaced by new rules VACCINEGROUP-1 & 2.

4.4

Term

Antigens Needed

This term is no longer used.

4.4

Term

Conflicting vaccine dose
administered

This term is no longer used.

4.4

Term

Current Vaccine Type

This term is no longer used.

4.4

Term

Live Virus Vaccine

This term is no longer used.

4.4

Term

Previous Vaccine Type

This term is no longer used.

Logic Specification for ACIP Recommendations v4.6

Page 121 of 151

Version

Item

Name

Motivation

4.4

Term

Total Count of Valid
Doses

This term is no longer used as of v2.1.

4.2

Business
Rule

SELECTB-1

This rule is no longer needed and therefore was retired in version 4.2.

4.2

Business
Rule

SELECTB-8

This rule is no longer needed and therefore was retired in version 4.2.

4.1

Term

Observation Description

Term was replaced by Indication Text Description and Contraindication Text
Description which are used in Supporting Data.

4.1

Term

Relevant Environmental
Observation

The term is not being used.

4.1

Term

Vaccination
Administrative Guidance

Retired term due to update to rule FORECASTGUIDANCE-1 which no longer
references the term.

4.0

Business
Rule

SELECTSCORE-1

Rule was retired and condensed into one rule in SELECTSCORE-2.

4.0

Term

Organization

Term is not used anywhere.

4.0

Term

Relevant Behavioral
Observation

The term is not being used.

4.0

Term

Relevant Medical
Observation

The term is not being used.

4.0

Term

Schedule Name

Term is not used anywhere.

3.0

Business
Rule

SELECTB-10

This rule is no longer needed and therefore was retired in version 3.0.

3.0

Business
Rule

SELECTB-15

This rule is no longer needed as gender consideration was moved to the create
relevant series section.

3.0

Business
Rule

SELECTB-22

The Rule was retired when the term “candidate patient series” was replaced by
“scorable patient series”.

3.0

Business
Rule

SELECTB-4

The Rule was retired when the term “candidate patient series” was replaced by
“scorable patient series”.

3.0

Business
Rule

SELECTB-9

This rule is not used use anywhere in the Logic Spec per the Domain Model
Analysis.

3.0

Decision
Table

Is the Patient's Gender
One of the Required
Genders?

The decision table was retired when the gender logic was incorporated into the
selection of relevant patient series.

3.0

Term

Candidate Patient Series The term was retired when replaced by "scorable patient series" when the
evolution of patient series was rethought.

3.0

Term

CVX List

Has no clear definition and is only a descriptor of Supporting Data elements

3.0

Term

Date Administered of
First Satisfied Target
Dose

Is only a conglomeration of individual terms

3.0

Term

Exceeded Maximum Age This term is no longer needed and therefore was retired in version 3.0.
To Start

3.0

Term

First Dose Begin Age

Not used in version 3.0. It should have been removed/retired in version 2.1.

3.0

Term

First Dose End Age

Not used in version 3.0. It should have been removed/retired in version 2.1.

Logic Specification for ACIP Recommendations v4.6

Page 122 of 151

Version

Item

Name

Motivation

3.0

Term

Gender-Specific Patient
Series

This rule is no longer needed as gender consideration was moved to the create
relevant series section.

3.0

Term

Medical History

Replaced in version 3.0 by Patient History.

3.0

Term

Preferable Vaccine Trade The term was retired because Trade Name is an attribute of Vaccine of which
Name
there are two flavors, preferable and allowable. See the term Trade Name for a
definition.

3.0

Term

Preferable Vaccine
Volume

The term was retired because Volume is an attribute of Vaccine of which there
are two flavors, preferable and allowable. See the term Volume for a definition.

3.0

Term

Select Best Patient
Series

Replaced with Select Patient Series in V3.0

3.0

Term

Vaccine Type Begin Age
Date

This is a duplicate of Preferable Vaccine Type Begin Age Date

3.0

Term

Vaccine Type End Age
Date

This is a duplicate of Preferable Vaccine Type End Age Date.

2.1

Business
Rule

CALCDTCOND-1

The rule was no longer needed in the Logic Specification due to the newly
added conditional skip logic.

2.1

Business
Rule

CALCDTCOND-2

The rule was no longer needed in the Logic Specification due to the newly
added conditional skip logic.

2.1

Business
Rule

CALCDTSKIP-1

The rule was no longer needed in the Logic Specification due to the newly
added conditional skip logic.

2.1

Business
Rule

CALCDTSKIP-2

The rule was no longer needed in the Logic Specification due to the newly
added conditional skip logic.

2.1

Business
Rule

CALCDTSUB-1

The rule was no longer needed in the Logic Specification due to the newly
added conditional skip logic. It was replaced with CALCDTSKIP-3 rule.

2.1

Business
Rule

CALCDTSUB-2

The rule was no longer needed in the Logic Specification due to the newly
added conditional skip logic. It was replaced with CALCDTSKIP-4 rule.

2.1

Business
Rule

CONDNEED-1

The rule was no longer needed in the Logic Specification due to the newly
added conditional skip logic.

2.1

Business
Rule

CONDNEED-2

The rule was no longer needed in the Logic Specification due to the newly
added conditional skip logic.

2.1

Business
Rule

Number of Doses
Remaining

The rule was no longer needed in the Logic Specification due to the newly
added conditional skip logic.

2.1

Business
Rule

SELECTBEST-3

The rule was incorporated into SELECTBEST-2.

2.1

Business
Rule

SUBDOSE-1

The rule was no longer needed in the Logic Specification due to the newly
added conditional skip logic.

2.1

Business
Rule

SUBDOSE-2

The rule was no longer needed in the Logic Specification due to the newly
added conditional skip logic.

2.1

Decision
Table

Can Target Doses Be
The decision table was retired in favor of new conditional skip logic.
Substituted? (Evaluation)

2.1

Decision
Table

Can Target Doses Be
Substituted? (Forecast)

The decision table was retired in favor of new conditional skip logic.

2.1

Decision
Table

Is the Condition Met?

This decision table was retired in favor of new Conditional Skip logic.

Logic Specification for ACIP Recommendations v4.6

Page 123 of 151

Version

Item

Name

Motivation

2.1

Decision
Table

Is the Target Dose
Conditionally Needed?

This decision table was retired in favor of new Conditional Skip logic.

2.1

Term

Conditional Begin Age

The term was replaced with the Conditional Skip term.

2.1

Term

Conditional Begin Age
Date

The term was replaced with the Conditional Skip term.

2.1

Term

Conditional End Age

The term was replaced with the Conditional Skip Begin Age term.

2.1

Term

Conditional End Age
Date

The term was replaced with the Conditional Skip term.

2.1

Term

Conditional End Date

The term was replaced with the Conditional Skip Condition term.

2.1

Term

Conditional Need

The term was replaced with Conditional Skip Type- Vaccine Count by Age term.

2.1

Term

Conditional Need Dose
Count

The term was replaced with the Conditional Skip Dose Count term.

2.1

Term

Conditional Need
Vaccine Count

The term was replaced with the Conditional Skip term.

2.1

Term

Conditional Need
Vaccine Type

The term was replaced with the Conditional Skip term.

2.1

Term

Conditional Set

The term was replaced with the Conditional Skip Type-Vaccine Count by Date
term.

2.1

Term

Conditional Start Date

The term was replaced with Conditional Skip Vaccine Types (CVX List)
supporting data concept.

2.1

Term

Conditionally Needed
Administrations

The term was replaced with Number of Conditional Doses Administered rule.

2.1

Term

First Dose Begin Age
Date

The term was replaced with Conditional Skip.

2.1

Term

First Dose End Age Date The term was replaced with Conditional Skip.

2.1

Term

Forecast Status

The term was retired because it is not used anywhere (except on Domain
model for versions 1.3) in the Logic Specification.

2.1

Term

Number of Doses
Remaining

The term was replaced with Conditional skip.

2.1

Term

Number of Target Doses
to Substitute

The term was replaced with Conditional Skip.

2.1

Term

Skip Target Dose

The term was replaced with the Conditional Skip.

2.1

Term

Substitute Dose

This term was replaced with Conditional Skip.

2.1

Term

Substituted

This term was replaced with Conditional Skip.

2.1

Term

Target Doses with a
Target Dose Status
“Satisfied”

This term was replaced with Conditional Skip.

2.1

Term

Trigger Age

The term was replaced with Conditional Skip.

2.1

Term

Trigger Age Date

The term was replaced with Conditional Skip.

2.1

Term

Trigger Doses
Administered

The term was replaced with Conditional Skip.

2.1

Term

Trigger Interval

The term was replaced with Conditional Skip.

Logic Specification for ACIP Recommendations v4.6

Page 124 of 151

Version

Item

Name

Motivation

2.1

Term

Trigger Interval Date

The term was replaced with Conditional Skip.

2.1

Term

Trigger Target Dose

The term was replaced with Conditional Skip.

2.1

Term

Unnecessary

1.7

Term

Conflict End Date

The term was replaced with Conflict End Interval Date term.

1.5

Business
Rule

SATISFIEDVG-1

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Business
Rule

SATISFIEDVG-2

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Business
Rule

SATISFIEDVG-3

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Business
Rule

SATISFIEDVG-4

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Business
Rule

UNSATPARTVG-1

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Business
Rule

UNSATPARTVG-2

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Business
Rule

UNSATPARTVG-3

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Business
Rule

UNSATPARTVG-4

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Business
Rule

UNSATPARTVG-5

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Business
Rule

UNSATPARTVG-6

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Business
Rule

UNSATPARTVG-7

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Business
Rule

UNSATPARTVG-8

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Business
Rule

UNSATPARTVG-9

The rule was retired due to restructuring of Chapter 7 in v1.5.

1.5

Decision
Table

What is the Type and
Condition of the Vaccine
Group?

The decision table was retired and replaced by 'What is the Vaccine Group
Type?'

1.5

Decision
Table

What Is the Vaccine
Group Forecast?

The decision table was retired and replaced by 'What is the Vaccine Group
Status?'

1.5

Term

Satisfied Patient Series

The tern was retired due to redesign of chapter 7 in v1.5

1.5

Term

Satisfied Vaccine Group

The term was retired due to redesign of chapter 7 in v1.5

Term

Preferred Candidate
Patient Series

Term is not being used.

Logic Specification for ACIP Recommendations v4.6

Page 125 of 151

Logic Specification for ACIP Recommendations v4.6

Page 126 of 151

APPENDIX D: ACKNOWLEDGEMENTS
Subject Matter Experts
•

Bill Adams, MD, Boston University School of Medicine
Dr. William Adams is an epidemiologist, medical informatician, and practicing pediatrician at
Boston Medical Center (BMC). He is Director of BU-CTSI Clinical Research Informatics, Director of
Child Health Informatics, and Professor of Pediatrics at Boston University School of Medicine. His
research focuses on developing and evaluating information technology (IT)-based solutions for
improving the quality of health and healthcare for children. His focuses include immunization
registries, the child health EHR, patient-centered IT and clinical data warehousing for quality
improvement and research. He is a member of the Massachusetts Immunization Information
System (MIIS) technical and programmatic teams. He is a founding member of the American
Academy of Pediatrics (AAP) Partnership for Policy Implementation (PPI), a group of child health
informaticians committed to improving AAP guideline quality including computability. He also
serves as advisor to the AAP Center for Child Health Informatics and is a member of the AAP Steering
Committee for the Quality Innovation Network.

•

Greg Anderson, Connexin Software

•

Judy Anderson, Hewlett Packard (HP)
Judy Anderson has nearly 8 years of hands-on immunization registry experience that includes direct
interaction with the Georgia registry users, in-depth knowledge of the immunization schedules,
requirement analysis, and test case development. Past projects have included data exchange and
inventory management/reporting enhancements, in addition to a supporting role on the current
VTrckS implementation for the Georgia registry. One of her strengths, as a member of the HP
Immunization Evaluator Workgroup, is to interpret CDC/ACIP recommendations into logical
solutions that can be implemented across the WIR-based registries. She is a graduate of Loyola
University of Chicago with a Bachelor of Arts degree in Communication Arts/Mass Media.

•

Regina Austin, HLN Consulting
Regina Austin has over 20 years of healthcare-related experience and expertise in analysis,
requirement elicitation, writing, testing, and training in her current position as Senior Analyst and
Project Specialist with HLN Consulting. Her focus in recent years has been assisting public health
clients with the development and deployment of customized, cutting-edge software meeting the
latest standards in healthcare IT. She is current the lead business analyst on several major HLN
immunization-related projects. Regina attends and participates in key industry conferences, most
recently as a facilitator of HL7 2.5.1 and clinical decision support round-table discussions at the
2012 and 2013 AIRA conferences. Regina is also a member of American Immunization Registry
Association’s (AIRA) Standards and Interoperability Steering Committee (SISC). Among her recent

Logic Specification for ACIP Recommendations v4.6

Page 127 of 151

publications is a white paper in the HIMSS Journal of Healthcare Information Management on open
source clinical decision support for immunizations.
•

Freddie Barber, RN, BA, MSHCA, Scientific Technology Company (STC)
Freddie Barber became a Registered Nurse in 1983. She started her nursing career as a critical care
nurse spending 20 years at various levels in the acute care setting in monitored units. In 1997 she
received her BA in Sociology and Anthropology and her MS in Health Care Administration in 2003.
In 2011 Freddie completed a Certificate in Informatics in Public Health from Johns Hopkins
Bloomberg School of Public Health. Freddie began working in Public Health as a Vaccines for
Children Representative in Arkansas and then as the Vaccines for Children Coordinator. She is
currently a Data Transfer Coordinator/Public Health Advisor for Scientific Technologies
Corporation working with State IIS on interfacing with EHRs.

•

Janis Betten, Oregon Immunization System (OIS)
Janis has worked in Oregon with the development of immunization forecasting logic and testing for
use with clinical evaluation programs and school student information system immunization
modules since the early 1990’s. Her other professional interests include all activities involved with
Oregon school immunization law—a passion for over 30 years.

•

Gerry Bragg, MBA, Altarum Institute / Michigan Care Improvement Registry (MCIR)
Gerry Bragg has over 20 years of experience in systems analysis and programming and for the past
15 years, has supported the Michigan Care Improvement Registry (MCIR) as a Senior Systems
Developer. He has supported the MCIR system in a variety of capacities, including the development
of patient de-duplication/match-merge processes and clinical decision support/immunization
forecasting algorithms. Mr. Bragg also specializes in database/SQL performance, scalability, tuning,
refactoring, design, technical planning, and configuration management. The system currently
supports more than 25,000 users. Mr. Bragg holds an MBA in Management Information Systems
from the University of Minnesota in Minneapolis, Minnesota, and a BA in Accounting from Hillsdale
College in Hillsdale, Michigan.

•

Kahil Branton, Advanced Strategies
Kahil Branton has had an 18+ year career in the Information Technology industry, with experience
in business requirements analysis, JDA facilitation, systems architecture, software development,
and user interface design. Kahil has facilitated groups through the development of business object
models (aka. conceptual data models), architectural designs and business process models. Kahil also
has extensive experience in event, location and socio-political modeling. As a Senior Consultant with
Advanced Strategies, Inc., Kahil teaches courses on business analysis and consults with government
and private sector organizations. He has facilitated numerous sessions for public health and
healthcare organizations, including: The CDC, AIRA, and Hospital Corporation of America. Kahil has
both a Master’s and Bachelor’s degree in Computer Science and Engineering from Massachusetts
Institute of Technology.

Logic Specification for ACIP Recommendations v4.6

Page 128 of 151

•

Nathan Bunker, Dandelion Software & Research, LLC
Nathan Bunker is a software developer and public health consultant for public and private agencies;
focusing specifically on immunization software and data exchange. His work has given him
experience with key immunization registry functions, including: immunization
recommendation/forecast, HL7 interfacing, data quality analysis, vaccination matching, patient
matching, and vaccine barcoding.

•

John Canning, Physicians Computer Company (PCC)

•

Daryl Chertcoff, BSE, HLN Consulting, LLC
Mr. Chertcoff has been providing information technology consulting services and delivering
electronic healthcare systems to public health agencies and their partners for the past 12 years. He
has worked with a wide range of technologies throughout his career, is an ongoing student of Health
Information Technology standards, and believes strongly in participating in volunteer efforts to
further the adoption of Health IT nationwide. Mr. Chertcoff offers each new business process
analysis or development effort a combination of project management and technical leadership skills
to get the job done. He enjoys collaborating with partners and considers each new challenge an
opportunity to make sense of the problem in a practical manner, by drawing on experience from
past projects as well as from involvement in standards groups and technology forums.

•

Joan Christison-Lagay, Connecticut Immunization Registry and Tracking System (CIRTS)
Joan Christison-Lagay, a former Peace Corps volunteer, is a graduate of Smith College and holds
master’s degrees from both Brown University and the UNC. She began her public health career for
the City of Hartford, CT in 1980 working on projects to reduce the incidence of low birth weight
infants. In 1993 she was named the director of the first immunization registry in New England, now
known as the CT Immunization Registry and Tracking System (CIRTS). She currently contracts with
CT DPH, MA DPH and Community Health Centers, CT on issues relating to immunization assessment
and training.

•

Rebecca Coyle, MS Ed, American Immunization Registry Association (AIRA)

•

Rachel Cunningham, MPH, Texas Children’s Hospital
Rachel M. Cunningham, MPH, is the immunization registry and educational specialist at Texas
Children’s Hospital in the Immunization Project. Rachel is the primary author of VaccinePreventable Disease: The Forgotten Story of which more than 130,000 copies have been distributed.
Rachel also worked with Nathan Bunker and other Immunization Project staff to develop the TCH
Immunization Forecaster and TCH Forecast Tester. The TCH Immunization Forecaster is used
through Texas Children’s Hospital as well as its private pediatric network, Texas Children’s
Pediatrics (TCP), which has 48 practices throughout the greater Houston area. The TCH
Immunization Forecaster is also currently being utilized by Indian Health Services and the Virginia

Logic Specification for ACIP Recommendations v4.6

Page 129 of 151

Department of Health while the TCH Forecast Tester is being utilized by multiple organizations
across the U.S. Rachel has been at Texas Children’s since 2007. She earned her Bachelor of Science
degree from Oral Roberts University and has a master’s in public health from The University of
Texas Health Science Center at Houston.
•

Gail DeCosta, Advanced Strategies
Gail DeCosta has had a 30+ year career in the Information Technology industry, with experience in
business requirements analysis, JDA facilitation, software development, and project management.
She has facilitated groups through the documentation of current business processes and the
transformation to a desired future state of “To-Be” business process models. Additionally, Gail also
has extensive experience in event, location, socio-political, and business object/data modeling and
project management. Gail is employed by Advanced Strategies, Inc. and both teaches courses on
business analysis and consults with government and private sector organizations. She has
facilitated numerous sessions for public health and health care organizations, including: The CDC,
AIRA, MN Department of Health, Hospital Corporation of America and the National Cancer Institute.
Gail holds a Bachelor of Arts degree in Psychology from Brown University and a Master’s degree in
Education from Georgia State University.

•

Mark Dente, MD, General Electric (GE) Healthcare
Dr. Dente’s informatics career spans over 19 years, focusing on new approaches to increase patient
safety and creating new methods to implement evidence-based medicine. As Chief Medical Officer
for GE Healthcare IT, his responsibilities include: Leading the organization’s clinical and Informatics
strategy; representing GE on government, health ministries, and advocacy committees; evaluating
and executing on strategic corporate, industry and research objectives as well as supporting GE
Healthcare IT’s regulatory needs.

•

Kristen Forney, MPH, New York Citywide Immunization Registry (CIR)
Kristen Forney is a public health professional who has led a variety of health IT projects for the
Citywide Immunization Registry at the New York City Department of Health and Mental
Hygiene. She has participated in the Immunization Calculation Engine (ICE) project as the lead
analyst for New York City. As lead analyst for NYC, Kristen co-facilitated the subject matter expert
workgroup responsible for developing and documenting the rules and test cases used to implement
the ICE algorithm.

•

Anita Geevarughese, MD, New York Citywide Immunization Registry (CIR)
Dr. Anita Geevarughese serves as the Adult Immunization Medical Specialist for the Bureau of
Immunization at the New York City (NYC) Department of Health and Mental Hygiene. In this role,
Dr. Geevarughese works on a variety of programmatic and policy initiatives to support
immunizations in NYC, including improvement of healthcare personnel influenza vaccination
coverage, development of school-located influenza vaccination programs and utilization of
electronic health record data to create feedback reports for adult providers on practice-level
influenza and pneumococcal vaccination coverage. Dr. Geevarughese assists in the development of

Logic Specification for ACIP Recommendations v4.6

Page 130 of 151

both public and provider communications and offers provider education on a number of topics
related to adult immunization. She current serves on the executive committee for the National
Adult Immunization Coordinators Partnership and has previously served as the principal NYC
contact for a CDC-sponsored pilot to field test the National Quality Forum measure on standardized
reporting of healthcare personnel influenza vaccination.
•

Shaun Grannis, MD, MS, FAAFP, Regenstrief Institute / Indiana University
Dr. Shaun Grannis is a Research Scientist at Regenstrief Institute, Inc. and Assistant Professor of
Family Medicine at the Indiana University School of Medicine. He received an Aerospace
Engineering degree from the Massachusetts Institute of Technology, and underwent post-doctoral
training in Medical Informatics and Clinical Research at Regenstrief Institute. He joined Indiana
University in 2001 and collaborates closely with national and international public health
stakeholders to advance the technical infrastructure and data-sharing capabilities. He is a member
of World Health Organization (WHO) Collaborating Center for the Design, Application, and Research
of Medical Information Systems, where he provides consultancy on issues related to health
information system identity management and implementing automated patient record matching
strategies.
Dr. Grannis completed an analysis of an automated regional electronic laboratory reporting system
that revealed substantial increases in the capture rates for diseases of public health significance
when compared to manual, paper-based procedures. He is project director for an initiative
integrating data flows from over 120 hospitals across the state of Indiana for use in public health
disease surveillance. For the last 5 years this system has received real-time data from hospitals
amounting to more than 2 million transactions per year, and has detected public health outbreaks
of gastrointestinal illness, carbon monoxide poisoning, and other events of interest to public health.
Most recently this system was leveraged to monitor H1N1 influenza disease burden across the state
of Indiana. As co-chair of the U.S. Health Information Technology Standards Panel (HITSP)
Population Health technical work group, Dr. Grannis helped lead development of technical
Interoperability Specifications for nationally recognized public health IT use cases.
Dr. Grannis also serves as the Director of the Indiana Center of Excellence in Public Health
Informatics, which recognizes that public health practice is driven by a wide variety of data types,
data sources, and data management techniques.

•

Christine Marr Gray, MPH, CHES, Virginia Immunization Information System (VIIS)
Christine Gray has been working with the Virginia Immunization Information System (VIIS) since
March 2009. Currently as the VIIS Business Plan and Data Quality Manager, Ms. Gray develops and
evaluates data quality standards for registry data; coordinating and executing VIIS application
testing, proposed changes and system enhancements, immunization scheduling. Prior to this
position, Ms. Gray was the VIIS Consultant for the South Central region of Virginia. Primarily she
trained interested providers and other health care workers to use the registry, and acted as a liaison
to the rest of the VIIS staff. Ms. Gray received her Master in Public Health from The George
Washington University in 2009 and is a Certified Health Education Specialist. She graduated from
Virginia Tech in 2004 with a Bachelor’s of Science in Economics. Before her tenure at the Virginia

Logic Specification for ACIP Recommendations v4.6

Page 131 of 151

Department of Health, Ms. Gray worked for five years with the National Turkey Federation (NTF)
improving worker safety and decreasing food borne illness.
•

Amy Groom, MPH, Indian Health Service (IHS)
Amy Groom is a Public Health Advisor with the Centers for Disease Control and Prevention, assigned
to work with the Indian Health Service’s Division of Epidemiology and Disease Prevention. She has
served as the National IHS Immunization Program manager since 2001. In this capacity,she works
with IHS and tribal immunization programs across the country to develop immunization policy,
implement immunization programs, and monitor immunization coverage. In addition, she is the
lead for the development of the IHS clinical decision support software for immunizations, and
provides training to end-users on the use of the sofwtare. She is the ex-officio representative for IHS
on both the Advisory Committee on Immunization Practices and the National Vaccine Advisory
Committee. She holds a Masters in Public Health from Boston University.

•

Ruth Gubernick, MPH, HLN Consulting, LLC
Ruth Gubernick is an independent consultant. For over 15 years, she has been part of a consulting
team with HLN, LLC which has performed needs assessments regarding immunization registries in
WA, UT, KY, NH and VT. She was a subject matter expert (SME) for registry planning in MN and LA
and registry evaluation and enhanced development in CA, RI, OH, New York City and Philadelphia.
Ruth has been a participant, as a SME, on the American Immunization Registry Association (AIRA)’s
Modeling Immunization Registry Operations Workgroup (MIROW). Ruth works with the Pediatric
Council on Research and Education (PCORE), the Foundation of the American Academy of
Pediatrics, NJ Chapter (AAPNJ), as a Program Specialist facilitating quality improvement efforts with
pediatric medical home teams and practice-based systems change. She is also working with the
National AAP’s Quality Improvement Innovation Network (QuIIN) as a Quality Improvement
Advisor.

•

Chip Hart, Physician’s Computer Company (PCC)
Chip Hart is the Director of PCC's Pediatric Solutions and author of the blog "Confessions of a
Pediatric Practice Consultant" (chipsblog.pcc.com). Chip's two decades of pediatric practice
management expertise have been focused on the support and development of independent
pediatric practices. Chip spends nearly all of his time working in and with private practices around
the country. He has worked as a consultant for the American Academy of Pediatrics (AAP) and the
AAP Section on Administration and Practice Management (SOAPM). Chip leads educational
seminars and consults for pediatric professionals nationwide for organizations like the AAP, state
chapter AAP programs, the MGMA, and various physician and hospital organizations around the
country. Chip was a member of the CCHIT Child Health Work Group and the CDC Clinical Decision
Support working group. Chip contributes articles on practice management and health care
information technology for Pediatric Coding Alert, the AAP's SOAPM Newsletter, and Medical Group
Management Association.

•

Mari Hilleman, Hewlett Packard (HP)

Logic Specification for ACIP Recommendations v4.6

Page 132 of 151

Mari Hilleman is a business analyst with Hewlett Packard and has been focused on statewide
immunization information systems for 11 years. Mari has worked with five different State
immunization programs to define requirements and test plans for the development of
enhancements to their Immunization Information Systems. Currently Mari is supporting the Idaho
Immunization Reminder Information System in the implementation and testing of the Wisconsin
Immunization Evaluator module used for forecasting and evaluation of Idaho’s ACIP schedule as
well as school and childcare eligibility.
•

Robert Hopkins, Jr., MD, FACP, FAAP, American College of Physicians (ACP)
Dr. Hopkins is Professor of Internal Medicine and Pediatrics and director of the division of the
Division of General Internal Medicine at the University of Arkansas for Medical Sciences. He has
active teaching and faculty practices in Internal Medicine and Pediatrics at UAMS and also directs
the Combined Internal Medicine-Pediatrics residency at UAMS. He is recognized nationally as an
expert in adult immunization, clinical practice guidelines review and development, medical
education and quality improvement and has published well over 100 articles on these topics. He is
the immediate past governor of the Arkansas Chapter of the American College of Physicians and has
served on numerous national ACP committees in addition to his roles at the University of Arkansas
for Medical Sciences. Currently, he serves on the Adult Immunization Technical Advisory
Committee and the ACP Performance Measurement Committee and the Arkansas Department of
Health Vaccine Medical Advisory Committee.

•

Paul Hunter, MD, American Academy of Family Physicians (AAFP)
As Associate Medical Director of the City of Milwaukee Health Department (MHD), Dr. Paul Hunter
focuses on clinical aspects of local public health, especially immunizations, sexually transmitted
diseases, tuberculosis, and obesity. He writes the medical orders that MHD nurses use to vaccinate
Milwaukeeans. He represents MHD on the Wisconsin Council on Immunization Practices and on the
Immunization Work Group of the National Association of County and City Health Officials. He helped
develop Immunize Milwaukee! (IM!), a coalition of stakeholders from health systems, health
departments, schools, neighborhood centers, health insurers, and others, which focuses on raising
vaccination rates of all residents of Metro-Milwaukee. As an Assistant Professor of Family Medicine
at the University of Wisconsin School of Medicine and Public Health, he teaches medical and public
health students about practical aspects of implementing community health interventions. Dr.
Hunter practiced family medicine for 19 years in underserved neighborhoods in Milwaukee and
Rockford.

•

Janel Jorgenson, Utah Statewide Immunization Information System (USIIS)
Janel Jorgenson is a graduate of the University of Utah with a degree in Health Education &
Promotion. She has an interest in children’s health issues and has been with the Utah Department
of Health Immunization Program since 2000. Janel is currently the Provider Relations Coordinator
where she provides supervision, support, training, and education for both the Utah VFC Program
and the Utah Statewide Immunization Information System (USIIS).

Logic Specification for ACIP Recommendations v4.6

Page 133 of 151

•

Erin Kennedy, DVM, MPH, Centers for Disease Control and Prevention (CDC)
Dr. Erin Kennedy is a Medical Officer in the Immunization Services Division, National Center for
Immunization and Respiratory Diseases at the Centers for Disease Control. Dr. Kennedy has a DVM
and Masters in Anatomy and Neurobiology from Colorado State University and an MPH in
Epidemiology from Emory University. Dr. Kennedy first joined the CDC as a fellow on the Rabies
Team and then became an Epidemic Intelligence Service Officer in 2008 where she worked
primarily on 2009 H1N1 pandemic influenza surveillance. Her career in public health has included
research and policy on vaccine preventable diseases, pandemic preparedness, and improving
coverage for recommended adult vaccines.

•

Brady Kerr, RN, Texas Children’s Hospital
Brady Kerr is a graduate of the University of Utah with a bachelor’s degree in Nursing. He is
currently working as the Health Education Nurse for the Immunization Project at Texas Children’s
Hospital. An important part of his role in the Immunization Project is working to maintain, improve
and promote the immunization forecaster for Texas Children’s Hospital. Previous roles have
included caring for geriatric patients as a Home Health RN Case Manager and working as an
Immunization Nurse for the Salt Lake County Health Department.

•

Pinar Keskinocak, PhD, Georgia Institute of Technology School of Industrial and Systems
Engineering
Pinar Keskinocak is the Joseph C. Mello Professor in the School of Industrial and Systems
Engineering and the co-founder and co-director of the Center for Humanitarian Logistics at the
Georgia Institute of Technology. She also serves as the Associate Director for Research at the Health
Systems Institute at Georgia Tech. Her research focuses on applications of operations research and
management science with societal impact (particularly health and humanitarian applications),
supply chain management, pricing and revenue management, and logistics/transportation. She has
worked on projects in several industries including automotive, semiconductor, paper
manufacturing, printing, healthcare, hotels, and airlines. Her research has been published in
journals such as Operations Research, Management Science, Manufacturing & Service Operations
Management, Production and Operations Management, IIE Transactions, Naval Research Logistics,
and Interfaces.

•

Alean Kirnak, Software Partners (SWP), LLC

•

Chandra Klein, Envision Technology
Chandra Klein works with Envision Technology Partners, Inc. as a Subject Matter Expert. She has
developed test cases for the forecast feature of the WebIZ immunization registry. Chandra has been
a public health nurse for over 10 years. She has worked in many areas of public health including
Tuberculosis Case Management, Perinatal Hep B Case Management, and Immunizations. Most
recently she was the Immunization Program Supervisor for the Larimer County Health Department
in Fort Collins, Colorado.

Logic Specification for ACIP Recommendations v4.6

Page 134 of 151

•

Nichole Lambrecht, Envision Technology Partners, Inc.
Nichole Lambrecht is a Senior Project Manager with Envision Technology Partners, Inc. and has
been with the company for two years. Envision Technology Partners, Inc. has developed the
immunization information system (IIS) called WebIZ in which several state and city governments
utilize. In Nichole’s current role, she works with state and city governments to develop and manage
their WebIZ application, as well as provides training and system quality assurance. Nichole
previously worked with the Kansas Immunization Registry where she served a total of five years in
all aspects of the project, including user support and Project Manager. Nichole has participated in
several national workgroups with the Centers of Disease Control (CDC) and American Immunization
Registry (AIRA) and she has served as a subject matter expert regarding aspects of IIS functionality
and best practices. During this project she helped test and develop the test case toolkit.

•

Carl Lauter, MD, FACP, American College of Physicians (ACP)
Dr. Carl Lauter, currently the Governor of the Michigan Chapter, American College of Physicians,
graduated from Wayne State University and Wayne State University School of Medicine. He
completed his residency in internal medicine followed by a NIH fellowship in infectious diseases
and subsequently a fellowship in allergy and immunology. He is board certified in all three
specialties. He was on the full time faculty of Wayne State University School of Medicine from 1973
– 1980 and has been at William Beaumont Hospital, Royal Oak, Michigan, since that time. In the
past, Dr. Lauter was an internal medicine residency director in two different programs and Chief,
Department of Medicine at William Beaumont Hospital for ten years. He is Professor of Medicine at
Oakland University School of Medicine and Section Head of Allergy and Immunology, as well as
Clinical Professor of Medicine at Wayne State University. Dr. Lauter is an editorial reviewer for
several peer reviewed journals. He is a contributor to the medical literature. At the national level
he sits on the Immunization Technical Advisory Committee of the American College of Physicians
and the Primary Immunodeficiency Committee and the Altered Immune Response Committee of the
American Academy of Allergy, Asthma and Immunology. His clinical and teaching interests involve
immunology, immunodeficiency and adverse and allergic reactions to vaccinations.

•

Susan Lett, MD, MPH, Massachusetts Department of Health
Dr. Susan Lett has been the medical director of the Massachusetts Immunization Program for over
25 years and has played a key role in the development of the Massachusetts Immunization
Information System (MIIS). For the past 5 years, she has co-lead with Dr. Bill Adams, the MIIS
immunization decision support team. The MIIS uses a web-service based immunization forecasting
module (IFM) which is supported by Drs. Lett and Adams, and their technical team. The IFM
includes forecasting rules for children and adults and also supports advanced decision support
related to clinical features such as contraindications, immunities, and special indications. All MIIS
IFM rules are based on ACIP recommendations. The team has also developed an extensive set of test
cases designed to provide comprehensive, automated testing of rules. Dr. Lett is also an internist
who has served as a voting member on the Advisory Committee for Immunization Practices
(ACIP). She is currently active on 4 ACIP working groups: Adult Schedule, Harmonized (Childhood)

Logic Specification for ACIP Recommendations v4.6

Page 135 of 151

Schedule, General Recommendations on Immunization and Influenza. Susan also helped to review
phase1 of the Logic Specification for ACIP Recommendations.
•

Tom Maerz, Wisconsin immunization Registry (WIR)
Tom Maerz is an Applications Developer, Computer Electronics Builder and Network Specialist by
trade. He’s worked with Health Care records and integration with Electronic Medical Record (EMR)
systems since 1979 and Vital Records de-duplication of information since 1990. In addition, his
experience includes working with Health Care providers, HMO’s, Schools and EMR vendors
regarding an Immunization Registry for the State of Wisconsin since 1995.

•

Judy Merritt, Scientific Technologies Corporation (STC)
Judy Merritt is the Clinical Decision Support Specialist and Senior Developer for Scientific
Technologies Corporation focusing on interfaces between immunization forecasting services and
health applications. She has over 17 years’ experience with design, development, implementation
and support of immunization systems in public health. She also served as the Immunization
Registry Coordinator for one of the first state immunization registry systems in the nation
implemented as an early CDC immunization registry pilot project.

•

Ninad Mishra, MD, MS, CDC Public Health Informatics and Technology Program Office (PHITPO)

•

Saad Omer, MBBS, MPH, PhD, Emory University Schools of Public Health & Medicine & Emory
Vaccine Center
Dr. Saad Omer is an Assistant Professor of Global Health, Epidemiology, and Pediatrics at Emory
University, Schools of Public Health & Medicine and an affiliate faculty of the Emory Vaccine Center.
He has worked on studies in the United States, Guatemala, Ethiopia, India, Pakistan, Uganda and
South Africa. Dr. Omer has conducted several studies to evaluate the roles of schools, parents, health
care providers, and state-level legislation in relation to immunization coverage and disease
incidence. Dr. Omer’s research portfolio includes clinical trials to estimate efficacy and/or
immunogenicity of influenza, polio, measles and pneumococcal vaccines; studies on the impact of
spatial clustering of vaccine refusers; and clinical trials to evaluate drug regimens to reduce motherto-child transmission of HIV in Africa. Dr. Omer is the principal investigator for the Georgia site of
the Vaccine Safety Datalink -based at Kaiser Permanente, Georgia. He is also the principal
investigator of a cohort study in Georgia (United States) for evaluating the impact of influenza
vaccine receipt in pregnancy and fetal/birth outcomes. He was awarded the Maurice Hilleman
Early-stage Investigator award in vaccinology by the National Foundation of Infectious Diseases.

•

Vikki Papadouka, PhD, MPH, New York Citywide Immunization Registry (CIR)
Vikki Papadouka worked for the New York City Immunization Registry in NYC’s Department of
Health and Mental Hygiene since 1997, and has been the director of research and evaluation since
2003. Her work includes designing systems and protocols to ensure data quality for the IIS, working
with internal and external agencies in collaborative research projects that use CIR data, working

Logic Specification for ACIP Recommendations v4.6

Page 136 of 151

with clinical experts to translate immunization schedule rules into algorithms, and working with
vendors to improve registry operations and data capture.
•

Priya Rajamani, MBBS, PhD, MPH, Minnesota Immunization Information Connection (MIIC)
Sripriya Rajamani is a physician with medical training from India. She holds a public health and
doctoral degree in Health Informatics from the University of Minnesota. She is actively involved
with the Minnesota e-Health Initiative and staffing its Standards and Interoperability workgroup
for the last five years. She is currently with the Minnesota Immunization Registry (MIIC) program
as part of the EHR-IIS Interoperability grant. One of the deliverables of the MN grant is the upgrade
of vaccine forecasting. She got interested in clinical decision support and volunteered for the
Process, Communications and Sustainability panel of CDC Clinical Decision Support (CDS) team.

•

Shadkashara “Shad” Rajashekarappa, General Electric (GE) Healthcare

•

Kim Salisbury-Keith, MBA, KIDSNET, Rhode Island Department of Health
Kim Salisbury-Keith has worked in Public Health for over 25 years. She has an undergraduate
degree from the University of North Carolina at Chapel Hill and an MBA from the University of Rhode
Island. Kim has worked in a variety of public health programs including WIC, Lead poisoning
prevention, and Newborn screening. She has served as Rhode Island’s Immunization Program
Manager and is currently the Development Manager for KIDSNET, RI’s integrated childhood
information system. Kim was a founding member of the American Immunization Registry
Association (AIRA) and has served as an officer and board member for that organization. She has
also served on a variety of CDC and AIRA work groups and panels including two MIROW initiatives.

•

Bobby Sanchez, New Mexico Statewide Immunization Information System (NMSIIS)

•

Rob Savage, Northrop Grumman Corporation
Rob Savage has been involved in the Immunization Information Systems arena since 1989, playing
a number of roles including system architect, developer, business analyst and technical writer.
While working on the development of the Wisconsin Immunization Registry (WIR), he was the
architect of the CDS engine evaluating immunization history and forecasting next doses due. He has
been involved in HL7 standards development since 2005. He represented the American
Immunization Registry Association for a number of years. He continues to be involved as a Northrup
Grumman contractor to the Immunization Information Systems Support Branch at CDC. He is the
author of the Version 2.5.1 Implementation Guide for Immunization Messaging. In this role he
provided consultation to NIST for their development of Meaningful Use Certification. Rob is a cochair of the Public Health and Emergency Response workgroup and participates in a number of
other work groups. Based on his experience in public health and immunization messaging, he has
presented tutorials and seminars on the role of HL7 in supporting public health and on
implementing Version 2.5.1 immunization messaging.

•

Mark Sawyer, MD, American Immunization Registry Association (AIRA)

Logic Specification for ACIP Recommendations v4.6

Page 137 of 151

Dr. Sawyer is a Professor of Clinical Pediatrics and a Pediatric Infectious Disease specialist at the
UCSD School of Medicine and Rady Children’s Hospital San Diego. He is the medical director of the
UCSD San Diego Immunization Partnership, a contract with the San Diego County Agency for Health
and Human Services to improve immunization delivery in San Diego. He is also the Past-President
of the California Immunization Coalition and a member of the CDC Advisory Committee on
Immunization Practices (ACIP).
•

Eric Schuh, Hewlett Packard (HP) / Oregon Immunization Program (OIP)
Eric Schuh is a business analyst with Hewlett Packard and has been focused on statewide
immunization information systems for 11 years. During this time Eric has provided support for the
Georgia Registry of Immunization Transactions and Services (GRITS) and is currently working with
the Oregon ALERT Immunization Information System. While working on the Georgia and Oregon
projects, Eric played a key role in the design, testing, and implementation of multiple upgrades to
the immunization evaluation and forecasting tool utilized by the states. Eric is an active member of
the WIR-based Immunization Evaluator Workgroup and the WIR Consortium. Eric was also a
member of the Phase I Clinical Decision Support for Immunizations Expert Panel for childhood
vaccinations.

•

Richard Shiffman, MD, MCIS, Yale University School of Medicine

•

Rosalyn Singleton, MD, MPH, Alaska Native Tribal Health Consortium (ANTHC)
Dr. Rosalyn Singleton received her medical degree from Northwestern University Medical School,
Chicago in 1982, and completed a Pediatric residency at Children’s Memorial Hospital, Chicago, and
a MPH from Loma Linda University. During 1984-88 Dr. Singleton worked in a small Navajo hospital
in Chinle, Arizona as a pediatrician. Since 1988 Dr. Singleton has worked as a part-time pediatrician
at Alaska Native Medical Center, an Immunization Consultant for Alaska Native Tribal Health
Consortium and a visiting research associate with Arctic Investigations Program – Centers for
Disease Control and Prevention (CDC). Her research grants and publications have been in the areas
of RSV, Hib, and Pneumococcal disease and chronic respiratory disease.

•

Shane Speciale, Avanza Systems, Inc.
Shane Speciale is the President of Avanza Systems, Inc., an immunization registry product
manufacturer. Shane has been personally involved in the planning, design, development,
implementation, and/or support of more than 20 immunization registries at the local, state, and
federal (DOD) levels over the past 19 years and has intimate knowledge of and experience with
immunization-related recommendations and clinical decision support. Shane was also a member
of the Clinical Decision Support for Immunizations Expert Panel for childhood vaccinations in 2011
and 2012.

•

Rosemary Spence, RN, Colorado Immunization Information System (CIIS)
Rosemary Spence is a public health nurse consultant with the Colorado Immunization Section. She
has been a nurse consultant in the Section for 14 years. Previous roles have included managing

Logic Specification for ACIP Recommendations v4.6

Page 138 of 151

Colorado’s Vaccines for Children Program. She currently serves as the nurse consultant for the
Colorado Immunization Information System (CIIS) and provides clinical guidance for updating the
registry’s vaccine forecasting algorithm. Rosemary was the immunization coordinator and child
health nursing manager at the Weld County Department of Public Health and Environment in
Greeley, CO prior to working at the Colorado Department of Public Health and Environment.
•

Amanda Timmons, Oregon Immunization Program (OIP) / ALERT Immunization Information
System
Amanda Timmons has worked with computerized forecasting algorithms for the past twelve years;
first in Oregon’s home-grown mmunization registry, Oregon Immunization ALERT and more
recently, with Oregon’s new implementation of WIR. Amanda’s other professional interests include
providing technical support to immunization providers, conducting ongoing training and learning
whatever new skills will be required in the ever-changing world of immunization.

•

Narasimha Velagaleti, Epic Systems Corporation

•

Bryan Volpp, MD, Veterans Health Administration
Dr. Bryan Volpp is an Infectious Diseases Physician at the VA Northern California Healthcare System
and the Chief Health Informatics Officer for the regional office. Dr. Volpp attended Duke University
Medical School and did his residency and fellowship training at the University of Iowa. Dr. Volpp
has been involved with the implementation of the VA EHR and the decision support tools in the VA
EHR since 1994. Dr. Volpp has served on the VA/DOD National Clinical Practice Guideline Council
and has built, tested and supported most of the existing National VA clinical reminders and all of the
regional reminders which include reminders for many immunizations.

•

Kent Ware, Ohio Statewide Immunization Information System (SIIS)
Kent Ware was privileged to lead a great team in Ohio for 26 years through many program areas
including VFC, outbreak management, Strategic National Stockpile, Pandemic Influenza and the IIS
program. Managing and directing these programs have been simultaneously humbling and
rewarding, for the tasks were often daunting. Mr. Ware is now VP of Health Integration at Esah
Health Integration Services. Working with the CDS team continues to strengthen his perspective
that there are many talented individuals applying their skills for the betterment of public health.

•

Stuart Weinberg, MD, FAAP, Vanderbilt University School of Medicine
Stuart Weinberg’s involvement with immunization registries began in 1992 with his participation
as an informatics consultant in an "All Kids Count" Planning Grant. Dr. Weinberg also served as CoChair of the Pennsylvania Statewide Immunization Information System (SIIS) Task Force from
1994-1997. His recent activities at Vanderbilt have included developing two-way functionalities
between Vanderbilt's electronic medical record and Tennessee's immunization registry, and
piloting immunization assessment and forecasting through web services. In 2012, Dr. Weinberg was
the recipient of Tennessee's first Childhood Immunization Champion Award from the Centers for
Disease Control and Prevention (CDC).

Logic Specification for ACIP Recommendations v4.6

Page 139 of 151

•

Gary Wheeler, Hewlett Packard (HP)

Communication and Education Branch (CEB) Liaison
• Andrew Kroger, Center for Disease Control and Prevention (CDC)
Current CDSi Project Team
• Stuart Myerburg, JD, Centers for Disease Control and Prevention (CDC)
• Eric Larson, Peraton
• Patricia Speights, MPH, Peraton
• Hana Tesfamichael, Peraton

Logic Specification for ACIP Recommendations v4.6

Page 140 of 151

APPENDIX E: REFERENCES
1. CDC. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United
States. MMWR 2005;54(No. RR-16). Available at http://www.cdc.gov/mmwr/PDF/rr/rr5416.pdf
2. CDC. Addition of Severe Combined Immunodeficiency as a Contraindication for Administration of Rotavirus
Vaccine.
MMWR
2010;
59(No.
22).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5922a3.htm?s_cid=mm5922a3_e%0d%0a
3. CDC. FDA Approval of Expanded Age Indication for a Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular
Pertussis
Vaccine.
MMWR
2011;
60(No.
37).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6037a3.htm?s_cid=mm6037a3_e%0d%0a
4. CDC. FDA Approval of Expanded Age Indication for a Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular
Pertussis
Vaccine.
MMWR
2009;
58(No.
14).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5814a5.htm
5. CDC. FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated
HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR
2010; 59(No. 20). Available at http://www.cdc.gov/mmwr/PDF/wk/mm5920.pdf
6. CDC. FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and
Guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010; 59(No. 20). Available at
http://www.cdc.gov/mmwr/PDF/wk/mm5920.pdf
7. CDC. General Recommendations on Immunizations. MMWR 2011;60(No. RR-2). Available at
http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf
8. CDC. Haemophilus b Conjugate Vaccines for Prevention of Haemophilus influenzae Type b Disease Among Infants
and Children Two Months of Age and Older. MMWR 1991;40(No. RR-01). Available at
http://www.cdc.gov/mmwr/preview/mmwrhtml/00041736.htm
9. CDC. Interim Recommendations for the Use of Haemophilus influenzae Type b (hib) Conjugate Vaccines Related
to the Recall of Certain Lots of Hib-Containing Vaccines (PedvaxHIB® and Comvax®). MMWR 2007; 56(No. 50).
Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5650a4.htm
10. CDC. Licensure of 13-Valent Pneumococcal Conjugate Vaccine for Adults Aged 50 Years and Older. MMWR 2012;
61(No. 21). Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6121a3.htm
11. CDC. Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among
Children --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010; 59(No. 09). Available at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5909a2.htm
12. CDC. Licensure of a Haemophilus influenzae Type b (Hib) Vaccine (Hiberix) and Updated Recommendations for
Use
fo
Hib
Vaccine.
MMWR
2009;58(No.
36).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a5.htm?s_cid=mm5836a5_e
13. CDC. Licensure of a Meningococcal Conjugate Vaccine (Menveo) and Guidance for Use --- Advisory Committee
on
Immunization
Practices
(ACIP),
2010.
MMWR
2010;
59(No.
09).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5909a5.htm
14. CDC. Licensure of a Meningococcal Conjugate Vaccine for Children Aged 2 Through 10 Years and Updated
Booster Dose Guidance for Adolescents and Other Persons at Increased Risk for Meningococcal Disease --Advisory Committee on Immunization Practices (ACIP), 2011. MMWR 2011; 60(No. 30). Available at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6030a3.htm?s_cid=mm6030a3_e%0d%0a
15. CDC. Measles, Mumps, and Rubella - Vaccine Use and Strategies for Elimination of Measles, Rubella, and
Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on
Immunization
Practices
(ACIP).
MMWR
1998;
47(No.
RR-8).
Available
at
http://www.cdc.gov/mmwr/PDF/rr/rr4708.pdf
16. CDC. Notice to Readers: Alternate Two-Dose Hepatitis B Vaccination Schedule for Adolescents Aged 11-15 Years.
MMWR 2000;49(No. 12). Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4912a5.htm
17. CDC. Notice to Readers: FDA Approval for a Combined Hepatitis A and B Vaccine. MMWR 2001;50(No. 37).
Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5037a4.htm

Logic Specification for ACIP Recommendations v4.6

Page 141 of 151

18. CDC. Notice to Readers: FDA Approval of an Alternate Dosing Schedule for a Combined Hepatitis A and B Vaccine
(Twinrix®).
MMWR
2007;56(No.
40).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5640a5.htm?s_cid=mm5640a5_e
19. CDC. Notice to Readers: FDA Approval of Havrix® (Hepatitis A Vaccine, Inactivated) for Persons Aged 1 - 18 Years.
MMWR
2005;54(No.
48).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5448a4.htm?s_cid=mm5448a4_e
20. CDC. Notice to Readers: FDA Approval of VAQTA® (Hepatitis A Vaccine, Inactivated) for Children Aged >1 Year.
MMWR 2005;54(No. 40). Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5440a7.htm
21. CDC. Notice to Readers: FDA Licensure of Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed,
Hepatitis B (Recombinant), and Poliovirus Vaccine Combined, (PEDIARIX™) for Use in Infants. MMWR
2003;52(No. 10). Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5210a8.htm
22. CDC. Notice to Readers: Licensure of a Combined Live Attenuated Measles, Mumps, Rubella, and Varicella
Vaccine.
MMWR
2005;
54(No.
47).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5447a4.htm?s_cid=mm5447a4_e
23. CDC. Notice to Readers: Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP)
for
the
Control
and
Elimination
of
Mumps.
MMWR
2006;
55(No.
22).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5522a4.htm?s_cid=mm5522a4_e
24. CDC. Notice to Readers: Revised Recommendations of the Advisory Committee on Immunization Practices to
Vaccinate All Persons Aged 11--18 Years with Meningococcal Conjugate Vaccine. MMWR 2007; 56(No. 31).
Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5631a3.htm?s_cid=mm5631a3_e
25. CDC. Pertussis Vaccination: Use of Acellular Pertussis Vaccines Among Infants and Young Children. MMWR
1997;46(No. RR-7). Available at http://www.cdc.gov/mmwr/PDF/rr/rr4607.pdf
26. CDC. Poliomyelitis Prevention in the United States. MMWR 2000; 49(No. RR-5). Available at
http://www.cdc.gov/mmwr/PDF/rr/rr4905.pdf
27. CDC. Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, Reduced
Diphtheria Toxoid and Acellular Pertussis Vaccines. MMWR 2006; 55(No. RR-3). Available at
http://www.cdc.gov/mmwr/PDF/rr/rr5503.pdf
28. CDC. Prevention and Control of Influenza with Vaccines Recommendations of the Advisory Committee on
Immunization
Practices
(ACIP),
2010.
MMWR
2010;
59(No.
RR-08).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5908a1.htm
29. CDC. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on
Immunization Practices (ACIP) - United States, 2012-13 Influenza Season. MMWR 2012; 61(No. 32). Available at
http://www.cdc.gov/mmwr/pdf/wk/mm6132.pdf
30. CDC. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on
Immunization
Practices
(ACIP),
2011.
MMWR
2011;
60(No.
33).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6033a3.htm
31. CDC. Prevention and Control of Meningococcal Disease. MMWR 2005; 54(No. RR-7). Available at
http://www.cdc.gov/mmwr/PDF/rr/rr5407.pdf
32. CDC. Prevention and Control of Seasonal Influenza with Vaccines Recommendations of the Advisory Committee
on
Immunization
Practices
(ACIP),
2009.
MMWR
2009;
58(No.
RR-8).
Available
at
http://www.cdc.gov/mmwr/pdf/rr/rr5808.pdf
33. CDC. Prevention of Hepatitis A Through Active or Passive Immunization. MMWR 2006;55(No. RR-7). Available at
http://www.cdc.gov/mmwr/PDF/rr/rr5507.pdf
34. CDC. Prevention of Pneumococcal Disease Among Infants and Children — Use of 13-Valent Pneumococcal
Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine. MMWR 2010; 59(No. RR-11). Available
at http://www.cdc.gov/mmwr/pdf/rr/rr5911.pdf
35. CDC. Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization
Practices
(ACIP).
MMWR
1997;
46(No.
RR-08).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/00047135.htm
36. CDC. Prevention of Rotavirus Gastroenteritis Among Infants and Children. MMWR 2009; 58(No. RR-2). Available
at http://www.cdc.gov/mmwr/PDF/rr/rr5802.pdf
37. CDC. Prevention of Varicella. MMWR 2007; 56(No. RR-4). Available at http://www.cdc.gov/mmwr/pdf/rr/rr5604.pdf
Logic Specification for ACIP Recommendations v4.6

Page 142 of 151

38. CDC. Quadrivalent Human Papillomavirus Vaccine. MMWR 2007; 56(No. RR-2). Available at
http://www.cdc.gov/mmwr/PDF/rr/rr5602.pdf
39. CDC. Recommendation of the ACIP for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D)
Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease. MMWR 2011;
60(No.
40).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6040a4.htm?s_cid=mm6040a4_e%0d%0a
40. CDC. Recommendations for Use of Haemophilus b Conjugate Vaccines and a Combined Diphtheria, Tetanus,
Pertussis,
and
Haemophilus
b
Vaccine.
MMWR
1993;42(No.
RR-13).
Available
at
http://www.cdc.gov/mmwr/PDF/rr/rr4213.pdf
41. CDC. Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males - Advisory Committee
on
Immunization
Practices
(ACIP),
2011.
MMWR
2011;
60(No.
50).
Available
at
http://www.cdc.gov/mmwr/pdf/wk/mm6050.pdf
42. CDC. Recommended Immunization Schedules for Persons Aged 0 through 18 years - United States, 2011. MMWR
2011;60(No. 5). Available at http://www.cdc.gov/mmwr/pdf/wk/mm6005.pdf
43. CDC. Recommended Immunization Schedules for Persons Aged 0 through 18 years - United States, 2012. MMWR
2012;61(No. 5). Available at http://www.cdc.gov/mmwr/pdf/wk/mm6105.pdf
44. CDC. Report from the Advisory Committee on Immunization Practices (ACIP): Decision Not to Recommend Routine
Vaccination of All Children Aged 2--10 Years with Quadrivalent Meningococcal Conjugate Vaccine (MCV4). MMWR
2008; 57(No. 17). Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5717a4.htm
45. CDC. Update: Recommendations from the Advisory Committee on Immunization Practices (ACIP) Regarding
Administration
of
Combination
MMRV
Vaccine.
MMWR
2008;
57(No.
10).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5710a3.htm?s_cid=mm5710a3_e
46. CDC. Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Use of 7Valent Pneumococcal Conjugate Vaccine (PCV7) in Children Aged 24--59 Months Who Are Not Completely
Vaccinated.
MMWR
2008;
57(No.
13).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5713a4.htm?s_cid=mm5713a4_e
47. CDC. Updated Recommendations for Use of Haemophilus influenzae Type b (Hib) Vaccine: Reinstatement of the
Booster
Dose
at
Ages
12-15
Months.
MMWR
2009;
58(No.
24).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5824a5.htm?s_cid=mm5824a15e
48. CDC. Updated Recommendations for Use of Meningococcal Conjugate Vaccines --- Advisory Committee on
Immunization
Practices
(ACIP),
2010.
MMWR
2011;
60(No.
03).
Available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm
49. CDC. Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis
(Tdap) Vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR 2011; 60(No. 01). Available
at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6001a4.htm
50. CDC. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Routine
Poliovirus Vaccination. MMWR 2009; 58(No. 30). Available at http://www.cdc.gov/mmwr/PDF/wk/mm5830.pdf
51. CDC. Use of Combination Measles, Mumps, Rubella and Varicella Vaccine. MMWR 2010; 59(No. RR-3). Available
at http://www.cdc.gov/mmwr/pdf/rr/rr5903.pdf
52. CDC. Use of Diphtheria Toxoid-Tetanus Toxoid-Acellular Pertussis Vaccine as a Five-Dose Series. MMWR
2000;49(No. RR-13). Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4913a1.htm
53. CDC. U.S. Vaccine Abbreviations---Advisory Committee on Immunization Practices (ACIP), 2012. Available at
http://www.cdc.gov/vaccines/acip/committee/guidance/vac-abbrev.pdf

Logic Specification for ACIP Recommendations v4.6

Page 143 of 151

APPENDIX F: SUPPLEMENTAL MATERIAL

Logic Specification for ACIP Recommendations v4.6

Page 144 of 151

APPENDIX G: DOCUMENT MANAGEMENT
Date

Changed By

Comments

8/31/12

Draft distributed to Expert Panel and Reviewers
Final Draft distributed to CDC leadership

0.2

Initial publication

1.0

11/07/13

E. Larson

01/09/14

E. Larson

03/20/14

E. Larson

Updated Executive Summary (1.3 and 1.4)
Updated to meet section 508 requirements
Fixed minor errors in Acknowledgements Appendix
Select Best Patient Series language clarifications
o Sections 6.1, 6.2, 6.3, 6.5, and 6.6
Select Best Patient Series Decision Table correction
o Section 6.3
Updated Date Calculation Intervals to define intervals to only be from Valid or
Not Valid doses. Substandard doses do not need an interval.
o Section 3.4
Assessment date was added to the domain model and a typo was corrected in
the definition of the term assessment date
o Appendix A
Evaluation and Forecasting for Skipping Doses were updated to incorporate a
Trigger Interval in addition to the existing Trigger Age to address issues found
while testing polio, guidance from EIPB, and the harmonized schedule.
o Sections 3.4, 4.2, 5.1, Appendix A
Updated business rule numbers to an improved identification scheme for
referencing business rules and improved ability to insert newly needed business
rules in the future.
o Sections 3.4, 5.4, 6.7, 7.3, 7.4, 7.6
Minor wording updates in various business rules to improve clarity and ability to
implement
o Section 3.4
Updates to properly select the catch-up schedule when children start late by
age. A new concept (Maximum Age To Start) was defined in the appendix and
added to the select best patient series logic.
o Sections 6.1, 6.5, Appendix A
Added new appendix to address multiple paths to immunity concept as
supplemental material and references to the new appendix in various sections.
o Sections 2.1, 2.8, Appendix E
Updates to Forecast sections regarding Conditional Need. The logic remained
the same as previously but moved Conditional Need into its own section (New
section 5.3) and added a specific target dose status for improved clarity on the
use of conditional need.
o Changes to Sections 3.2, 5, 5.3 (New), 5.4 (previously 5.3)
Document editorial consistency improvements
o Entire document
Evaluation and Forecasting for Skipping Doses were updated to incorporate a
Trigger Target Dose to address issues found while testing Tdap/Td, guidance
from EIPB, and the harmonized schedule.
o Sections 4.2, 5.1, Appendix A
Identify and Evaluate Vaccine Group (Chapter 7) was refactored to apply a
cleaner process model, decision tree, and business rules based on Tdap/Td and
MMR testing and research.
o Chapter 7
Updated inconsistencies found in Supplemental Material graphics.
o Appendix E

1.1

01/09/13
09/19/13

L. McKenzie,
E. Larson
L. McKenzie,
E. Larson
L. McKenzie,
E. Larson
L. McKenzie,
J. Wain
J. Wain
E. Larson

Version
#
0.1

10/05/12
10/29/12
11/14/12

Logic Specification for ACIP Recommendations v4.6

1.2
1.3

1.4

1.5

1.6

Page 145 of 151

Date

Changed By

08/14/14

E. Larson

12/16/14

E. Larson

05/11/15

P. Speights,
E. Larson

12/22/15

C. Newman,
P. Speights,
E. Larson

Comments

Version
#

Added Business Rule to Calculate Dates to ensure consistent application of
date calculations
o Section 3.4 – See CALCDT-6 Business Rule
Updated definition of Maximum Age to Start
o Section 6.1
Added/improved diagrams and process models
o chapters 4, 5, 6, 7, 8 and appendices
Updated attribute tables to cross-reference with date calculation business rules
o chapters 4 and 5
Added a new Patient Series Status and associated usage of new “Aged Out”
status.
o Section 3.2 and chapters 5 and 6
Improved decision table and business rule language to fully utilize vocabulary.
o Chapters 5 and 6
Assigned Patient Series Status to outcomes section of decision table.
o Section 5.4
New Evaluation section was added to accommodate clarifications from EIPB on
Hep A intervals after a not valid dose.
o Section 4.6 was created (Allowable Interval).
o Other updates due to this were in the chapter 4 process model,
section 4.11, and Appendix A.
Added support for maximum doses by age (i.e.: 6 doses by 7 years in DTaP
o Section 5.1 and Appendix A
Added Zoster to the Vaccine Groups in Table 1-1
Added Age base Adult Recommendations to the Additional Items in scope
include.
Added Not Recommended status and definition in Table 3-3
Updated Table 3.5 to include business rule CALCDTINT-8, CALCDTCOND-1,
and CALCDTCOND-2
Added From Most Recent explanation under the Relationship to ACIP
Recommendation in Section 4.5
Added Figure 4-10 From Most Recent timeline in section 4.5
Added Supporting data “From Most Recent” to table 4-11
Updated the Activity and Goal in Table 5-1 to incorporate sections 5.4
Updated the processing model in Figure 5-1 to add section 5.4
Added the new Immunity section in section 5.4
Updated Table 5-7 to add supporting data for Begin and End Age Date.
Updated Table 5-14 to add Not recommended status info.
Added the term Minimum Age to Start Date and Definition in table 6.2
Updated Table 7-3 to add business rule SINGLEANTVG-10
Updated Table 7-4 to add business rule MULTIANTVG-9
Updated the Figure 8-2
Updated the Domain models Figure A-1, Figure A-2, and Figure A-3
Added new terms and definitions to the Table A-1 Glossary section. Included
are Conditional begin age, Birth Date Immunity, Clinical History Immunity,
Country of Birth, Conditional End Age, Exclusion Condition, Forecast Vaccine
Type, From Most Recent, Immunity Date, Immunity Guideline, Minimum Age to
Start, and Recommended Vaccine,
Updated the fourth paragraph in Background and Goals 1.1.
Updated text in section 2.4.
Updated text in the first paragraph of section 3.1.
Removed Substituted from Target Dose Statuses Table 3.2
Updated Supporting Data text in 3.3
Updated Logical Component Date Rules in Table 3-5
Added Table 3-8 What Exercises Should I do today in section 3.5.
Updated Evaluation Process Steps in Table 4-1
Updated Evaluation Process Model in Figure 4-1

Logic Specification for ACIP Recommendations v4.6

1.7

1.8
2.0

2.1

Page 146 of 151

Date

Changed By

6/20/16

C. Newman,
P. Speights,
E. Larson

02/22/19

C. Newman,
P. Speights,
E. Larson

Comments

Version
#

Removed Skip Target Dose section and replaced with Evaluate Conditional Skip
in section 4.2.
Removed Substitute Target dose section
Updated Evaluate Interval in Section 4.4.
Updated Live Virus Conflict Business Rules in Table 4-23 of section 4.6
Updated Forecast Dates and Reasons Process steps in Table 5-1.
Updated Forecast Dates and Reason Process Model in Figure 5-1.
Replaced Skip Target dose with Evaluate Conditional Skip in section 5.1.
Removed Substitute Target Dose section.
Updated text in Determine Evidence of Immunity section 5.2.
Updated decision table 5-3: “Does the patient have evidence of immunity?”
Updated Generate Forecast Date and Recommended Vaccine Business rules in
Table 5-7.
Updated Select Best Patient Series Vocabulary/Definition in Table 6-2.
Updated Select Best Patient Series Business Rules in Table 6-8.
Updated Organize Immunization History Process Model in Figure 8-2.
Updated the CDSI Domain Diagram: Patient Neighborhood in Figure A-1.
Updated the CDSI Domain Diagram: Vaccine and Schedule Neighborhood in
Figure A-2.
Updated the CDSI Domain Diagram: Evaluation and Forecasting Neighborhood
in Figure A-3.
Updated the Glossary in Table A-1.
Added PPSV to the Acronym’s and Abbreviations in Appendix B.
Expanded scope to include coded contraindications and series based on patient
risk
Updated description of CDSi resources in Section 1.4
Moved Processing Model description from Chapter 8 to Chapter 4
Updated Patient Series descriptions to include Relevant, Scorable, Prioritized
and Best Patient Series
Enhanced Create Patient Series discussion in the Processing Model
Inserted a new Create Relevant Patient Series chapter (Chapter 5)
Inserted a new Evaluate for Inadvertent Vaccine section (Section 6.3)
Updated references to Interval to Preferable Interval to distinguish from
Allowable Interval
Updated From Most Recent interval type accommodate a list of CVX codes in
Section 6.5
Added a new interval type of From Relevant Observation in Section 6.5
Moved Evaluate Gender logic from Chapter 6 to Chapter 5
Inserted a new Determine Contraindications section (Section 7.3)
Updated Select Patient Series Business Rules (Table 8-2)
Inserted a new Pre-Filter Patient Series section (Section 8.2)
Enhanced Patient Series selection in Chapter 8 to include Series Groups
Split the Vaccine and Schedule neighborhood into separate Schedule and
Series neighborhoods in Appendix A
Updated Table A-1 Glossary
Created new Appendix to contain the new Retired Items table
Added support for Historical Recommendation Supporting Data
Added support for conditional skip context to control when skipping occurs (e.g.,
only in evaluation, only in forecast, both evaluation and forecast)
Updated the location of the business rules in Chapter 8
Updated the description of the Supporting Data
Updated processing model in section 4.6 (Identify and Evaluation Vaccine
Group)
Added section 7.6 for validating recommendations
Updated Decision Table 6-8
Updated CALCDTSKIP-5

Logic Specification for ACIP Recommendations v4.6

3.0

4.0

Page 147 of 151

Date

06/02/20

06/29/21

Changed By

P. Speights,
E. Larson

P. Speights,
E. Larson

Comments

Version
#

Consolidated SELECTSCORE-1 and SELECTSCORE-2 into one rule to
eliminate unnecessary referencing. This also resulted in the retirement of a term
(Exceeded Maximum age to start).
Substantive Improvements
The following rules and decision tales were improved based on implementer
feedback and will result in improved consistency/accuracy.
• FORECASTDT-1: Added additional date for calculating the earliest date
• MULTIANTVG-1: Better logic for selecting logical dates for forecasting
• MULTIANTVG-8: Better logic for selecting antigens needed
• SELECTBEST-2: Better logic to define how to break a tie
• SELECTSCORE-2: The previous version was ambiguous with regards to
starting age requirements and was incorrectly excluding series which should
not have been excluded.
• Evaluate Age and Evaluate Preferable Interval Decision Tables were refined
to allow grace period to be used following an invalid dose if it has been at
least 1 year.
Additional Improvements
The following improvements will improve the overall consistency of the Logic
Specification, but should not change any rules, decisions, or processing. The
domain model is was redrawn using a new tool which gives it a new look. A new
section was added in Appendix A entitled “How to read the Domain Model
Diagram”. As part of this process improvements were made to the domain
model, terminology, and definitions. These improved terms were then used
within the logic specification rules and decision tables.
The following rules and decision tales were improved based on implementer
feedback and will result in improved consistency/accuracy.
• CALCDTLIVE-2: Added additional rule text for doses not yet evaluated.
• CALCDTLOTEXP-1 Added new logic for lot expiration dates when only
month and year known.
• MULTIANTVG-8: Reverted to version 4.0 business rule.
• SELECTSCORE-2: Added additional logic for Contraindicated series and
Evaluation Only series
• SELECTB-24: Created new rule for use in SELECTSCORE-2 related to
contraindicated series
• Table 8-8: “How Many Points Are Awarded to a Complete Patient Series?”
When 2 or More Scorable Patient Series are Complete, the scoring table
was simplified (now a single condition). This was to address issues in
selecting the proper series in 65+ patients receiving PPSV followed by PCV.
This can also happen in other antigens and will change previous evaluation
status from “extraneous” to “valid” in cases where a patient now fits into a
better series with the most valid doses. Evaluating these doses as “Valid”
vs. “Extraneous” is preferable since ACIP recognizes those administration
patterns (e.g., HepB 4-dose vs. HepB 3-dose).
• Table 7-9: “Should the Patient Receive Another Target Dose?” was updated
to change the flu outcome to “Not Recommended” when the seasonal end
date is past.
• Table 6-4: “Conditional Skip Attributes” was updated to include an
“Assumed Value if Empty” values for CALDTSKIP-3 and CALCDTSKIP-4.
• Table 5-4: “Is the Series Relevant for the Patient?” was updated to add
Evaluation Only Series text to the second condition.
• Updated the Glossary in Table A-1
• “Evaluation Only” series were created as a new series type. This will enable
support for Non-FDA authorized COVID-19 vaccines that are authorized by
WHO and can count towards U.S. vaccination. The impact on the logic can
be found in Chapters 5 (Table 5-4) and 8 (SELECTSCORE-2).

Logic Specification for ACIP Recommendations v4.6

4.1

4.2

Page 148 of 151

Date

Changed By

Comments
•

Version
#

Select Patient Series Process Model (beginning of chapter 8) was updated
to improve clarity regarding the last step in the process (Determine Best
Patient Series).

09/10/21

P. Speights,
E. Larson

The following decision table was improved based on implementer feedback and
will result in improved consistency/accuracy.
• Table 8-14: “Is the Series a Best Patient Series? was updated to improve
selection of the best patient series by adding a new rule for “Evaluation
Only” series.

4.3

01/11/24

P. Speights,
E. Larson

Overarching Updates Impacting All Chapters
•
Improved relationship between the Domain Model and the usage of the
domain model terms in rules and decision tables throughout the Logic
Specification
o This includes better use of Antigen Series, Relevant Patient Series,
Scorable Patient Series, Prioritized Patient Series, and Best Patient
Series. Numerous references to “series” have been updated to be
more specific to which type of series. See Chapter 4 for a graphic of
these terms (Figure 4.2).
•
Simplified some decision tables with a “Default Outcome”. The default
outcome is used when no conditions are met. This reduces the number of
columns in decision tables.
•
Created consistent terminology always ending in “Flag” for terms which can
only have a value of Yes or No (or n/a).
o Note: these have not been applied to supporting data yet. That will
happen in version 5.0.

4.4

Chapter 3 Logic Specification Concepts
•
Rule improvements (for clarity) throughout. None had a functional change
in the outcome.
•
A few were retired (see Appendix C) due to lack of use and the Live Virus
rework in Chapter 6.
Chapter 4 Processing Model
•
Processing Models and other graphics were updated to align with other
chapters.
Chapter 5 Create Relevant Patient Series
•
Rule and decision table improvements (for clarity) throughout. None that
had a functional change in the outcome.
Chapter 6 Evaluate Vaccine Dose Administered
•
Rule and decision table improvements (for clarity) throughout. None that
had a functional change in the outcome.
•
Section 6.7 (Evaluation Vaccine Conflict) was completely revamped to be
less process driven and more business rule driven.
•
Section 6.7 also moved from “Live Virus Conflict” to “Vaccine Conflict” to
support more conflicts than just live virus.
•
New terms Conflicting Vaccine Type and Impacted Vaccine Type have
been created. These replace the previously used live virus conflict terms
Previous Vaccine Type and Current Vaccine Type. Please see the
Implementer Note in Section 6.7 regarding the Logic Specification terms
and Supporting Data terms for more information.
Chapter 7 Forecast Dates and Reasons
•
Rule and decision table improvements (for clarity) throughout. The next
bullets describe the biggest changes.
Logic Specification for ACIP Recommendations v4.6

Page 149 of 151

Date

Changed By

Comments
•
•

•

Version
#

Section 7.3 (Determine Contraindications) expanded the decision table to
be more explicitly tied to the domain model by adding references to
Adverse Events along with Active Patient Observations.
Section 7.6.2 (Validate Forecasted Dates Business Rules) was removed.
This logic is now in section 7.4 (Determine Forecast Need) with the
creation of FORECASTDTCAN-1 and included in the Decision Table. This
new term is also used in section 7.5 (Generate Forecast Dates). This
should not result in a functional change.
Introduction of the new rule (FORECASTDN-1) to standardize the forecast
dose number calculation across the community. This is also referenced in
Chapter 9.

Chapter 8 Select Best Patient Series
•
Rule and decision table improvements (for clarity) throughout. The next
bullets describe the biggest changes.
•
SELECTSCORE-2 introduced a new condition for situations when no
series in a Standard series group is identified as a default series.
•
The decision table in Section 8.2 (Identify One Prioritized Patient Series)
was refactored to simplify the conditions column so each condition is a
distinct question with a count of series for an answer. The functional
outcome should be identical to the previous decision table in version 4.3.
Chapter 9 Identify and Evaluate Vaccine Group
•
Refactored this chapter to generalize many rules which could be applied to
both Single Antigen and Multiple Antigen series. This should not result in a
functional change.
•
Introduction of new rule (FORECASTDN-2) to standardize the forecast
dose number calculation across the community.

02/23/24

P. Speights,
E. Larson

Appendix A Domain Model and Glossary
•
Several improvements throughout all neighborhoods which are now
integrated into the rules and decision tables throughout the logic
specification.
•
Split the Evaluation and Forecast Neighborhood into two neighborhoods.
One for Evaluation and one for Forecast for readability purposes.
•
Introduced Definitional Rules to help describe the relationship between two
terms on a domain model. These help set expectations (e.g., A vaccine
dose administered must be received by exactly one patient)
The following changes were made to Chapter 6: Evaluate Vaccine Dose
Administered.

4.5

Section 6.2 (Evaluate Conditional Skip)
Expanded conditional skip to support a new type of skip in preparation for the fall
2024 RSV season when some kids will be in their second season and vaccinated
in their first season. This change expands vaccine counting to now support the
following types of skips:
• Vaccine Count by Date (existing skip)
• Vaccine Count by Age (existing skip)
• Vaccine Count by Date and Age (new skip)
The change to support this expansion is a minor adjustment to CONDSKIP-1 and
default behavior when supporting data fields are populated with n/a.
CONDSKIP-1
• The old rule expected the date administered to be between two ages OR
two dates, but never both. This expansion changes the “OR” to an “AND”
Logic Specification for ACIP Recommendations v4.6

Page 150 of 151

Date

Changed By

Comments

Version
#

condition so that the date administered must be between two ages AND
two dates. Other business rule methodology updates were also applied
to improve readability, but those do not have an impact on the rule.
Default Behavior
• When only date is used (i.e., the existing “Vaccine Count by Date”), the
calculated begin age date and end age date are defaulted (see attribute
table 6-4) to 01/01/1900 and 12/31/2999 so that all doses will be between
those dates ensuring that half of the AND condition is met. The start and
end dates will be the controlling factor in this skip.
• When only age is used (i.e., the existing “Vaccine Count by Age”), the
start date and end date are defaulted (see attribute table 6-4) to
01/01/1900 and 12/31/2999 so that all doses will be between those dates
ensuring that half of the AND condition is met. The begin age and end
age will be the controlling factor in this skip.
• When both date and age are used (i.e., the new “Vaccine Count by Date
and Age”), both date and age conditions will be defined. Defaults will only
be used on open ended dates or ages (e.g., no end age). The date
administered must fit between the defined start date and end date as well
as the begin age and end age.

Section 6.4 (Evaluate Age)
•

•

The decision table (Table 6-15) was simplified. The final two conditions
were removed to support simplified evaluation guidance from clinical
SMEs. The grace period can now be used following an invalid dose
provided the grace period is allowed to be used for the dose in general.
This results in two conditions (rows) and two outcomes (columns) being
removed.

Section 6.5 (Evaluate Preferable Interval)
•

•
12/13/24

P. Speights,
E. Larson

The decision table (Table 6-18) was simplified. The final two conditions
were removed to support simplified evaluation guidance from clinical
SMEs. The grace period can now be used following an invalid dose
provided the grace period is allowed to be used for the dose in general.
This results in two conditions (rows) and two outcomes (columns) being
removed.

Section 4.4 (Evaluate and Forecast All Relevant Patient Series
•

4.6

Figure 4-6 (Evaluate Immunization History Process Model) was updated to
swap the order of two decision points. By checking if the target dose is a
recurring dose first, it allows for any target dose to be a recurring dose.
Previously, only the last target dose in a series could be a recurring dose.
The step-by-step description below figure 4-6 was also updated to reflect
the changes in the process model. This change will be immediately helpful
for 2024-2025 COVID-19 recommendations.

Logic Specification for ACIP Recommendations v4.6

Page 151 of 151

